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A B S T R A C T  
Dengue virus (DENV) infections are a significant public health burden in tropical and sub-tropical 
regions of the world. Infections are caused by four different but antigenically related viruses which 
result in four DENV serotypes. The multifaceted nature of DENV pathogenesis hinders the 
sensitivity of assays designed for the diagnosis of infection. Different markers can be optimally 
detected at different stages of infection. Of particular clinical importance is the identification of 
acute viremia during the febrile phase of infection which is pivotal for management of infection. 
Non-structural protein 1 (NS1) has been identified as a good early surrogate marker of infection 
with possible applications in epidemiological surveillance and the development of blood screening 
assays. This contribution is towards using serotype-specificity to achieve specific and more 
sensitive diagnostic detection of DENV NS1. 
The general aim of this work is to isolate immune-reagents that can be used to develop an assay 
with improved sensitivity of DENV NS1 detection in a diagnostic setting. In this work, we sought 
to isolate serotype-specific antibodies that discern discreet antigenic differences in NS1 from each 
DENV serotype. Additionally, we also sought to isolate a pairing antibody that recognises NS1 
from all four DENV serotypes (pan-reactive) for tandem capture of the DENV NS1. To achieve 
this, three naive, immunoglobulin gene libraries (a VH domain, a scFv and a Fab library) were 
interrogated for binders to recombinant NS1 antigen from all four DENV serotypes using phage 
display technology and various biopanning approaches.  
From biopanning experiments, four antibody fragments specific to NS1 from each DENV serotype 
as well as a panel of pan-reactive antibody fragments were isolated. The isolated antibody 
fragments were reformatted into fully assembled IgG1 antibodies for characterisation. In a 
sandwich ELISA, none of the pan-reactive antibodies were able to bind DENV NS1 in tandem with 
the serotype-specific antibodies. All four of the serotype-specific antibodies however, recognised 
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their serotype-respective recombinant and native DENV NS1. The serotype-specific 
immunoglobulins showed equilibrium dissociation constants that ranged from µM to nM. Used as 
capture reagents in a sandwich ELISA with a commercial pan-reactive antibody as the detection 
probe, three of the antibodies (9H2 anti DENV-1 NS1, 7G11 anti DENV-3 NS1 and 6A5 anti 
DENV-4 NS1) were able to achieve clinically relevant limits of DENV NS1 detection. 4C11, an 
antibody against DENV-2 NS1 had the poorest performance and was subjected to affinity 
maturation through targeted mutagenesis of VH CDR3. A new variant A4, showed marginal 2-fold 
improvement in performance when incorporated into a limit of detection ELISA with the 
commercial pan-reactive antibody.  
Our data suggests that the four serotype-specific antibodies, including the new variant, would be 
useful for inclusion in a sandwich ELISA that uses NS1 to serotype DENV infections. To develop a 
complete DENV NS1 serotyping assay however, the serotype-specific antibodies will need to be 
used in a new iteration of a biopanning campaign to isolate an appropriate pan-reactive pairing 
partner. 
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Chapter 1  
A GENERAL INTRODUCTION TO  
ANTIBODIES  
PHAGE DISPLAY  
AND DENGUE VIRUS DIAGNOSIS 
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1.1 HUMORAL IMMUNE RESPONSE 
Adaptive immunity is a branch of the immune system that involves two different classes of 
lymphocytes known as T and B cells.  T cells are involved in cell-mediated responses and are not 
the focus of this current work. B cells on the other hand can be recruited for the elimination of 
foreign molecules in humoral responses which involve secretion of antibodies also referred to as 
immunoglobulins. Immunoglobulins A, D, E, G and M shown in Figure 1.1 are made of light and 
heavy chains. Light chains are of either κ or λ isotypes while the heavy chains α, δ, ε, γ and μ are 
what determine the antibody class. Antibodies consist of units which includes the antigen binding 
fragment (Fab) molecule, made up of VL-VH and CL-CH1 domains as well as a class-specific Fc 
(fragment crystallizable) region made up of CH2 and CH3 domains or CH2, CH3 and CH4 in the case 
of IgE and IgM. The antibody molecule is stabilized by inter-chain and intra-chain disulphide 
bridges.  
The variable regions on the Fab fragment are involved in antigen recognition. An antigen is “any 
entity—a cell, a macromolecular assembly, or a molecule—that may be bound by either a B-cell 
receptor or an antibody molecule” (87) while the specific region on the antigen that is bound is 
called a B-cell epitope or an antigenic determinant. The ability to bind antigen is determined by 
specific amino acid residues on the antibody (paratopes) and their complementarity to the B-cell 
epitope. These regions of hyper-variability known as complementarity determining regions (CDRs) 
are found within the variable light and variable heavy chains. The light chain loci is spread over two 
gene segments (Variable-Joining) while the heavy chain loci is spread over three gene segments 
(Variable-Diversity-Joining) (71, 79). 
The Fc regions determine the effector function of the antibody. On binding to the B-cell epitope, the 
antibody-mediated response directed by the Fc region of the recruited antibody can result in 
inactivation of the pathogen by perturbing their ability to attach to host cells (65), marking of 
pathogens for destruction by recruiting phagocytic cells (108), cell-mediated cytotoxicity (92), 
complement activation (73) and mast cell binding (41). The majority (80%) of the immune response 
is dominated by IgG. Its sub-classes IgG1, IgG2, IgG3 and IgG4 are so named based on the order of 
their relative concentrations in serum. The main effector functions that are characteristic of IgG 
(except IgG4) are antibody-dependent cellular cytotoxicity (ADCC), complement activation and 
antigen opsonization for subsequent phagocytic uptake (43, 69, 107). Despite the dominance of IgG 
in circulation, other classes of antibodies can be recruited upon insult and these are 
antigen/pathogen dependent (46).  
 3 
 
 
Figure 1.1 Structural representation of antibody classes (91). Shown are monomeric IgD, 
IgE and IgG as well as dimeric IgA and pentameric IgM. Antibody multimers are linked 
by J chains which promote polymerisation.  
During an antigenic challenge, a genetically varied polyclonal response to different B-cell epitopes 
is mounted. Germinal centres (high cell density regions in secondary lymphoid organs) are the 
epicentre of clonal expansion and secondary diversification of immunoglobulin genes (42). Iterative 
rounds of selection and hypermutation facilitate selection of antibodies based on their affinity for 
the target antigen. The challenge widens an individual’s immune repertoire by exposure of immune-
competent B-cells to the antigen, leading to a maximally finite number of antibodies (1012) being 
able to recognize an infinite number of antigens with varied specificities and associated affinities 
(60, 84). In most cases the effector function results in elimination of the foreign molecule and 
classically results in immunological memory.  
Antibody responses shape the foundations of vaccination, antibody therapeutics and antibody 
diagnostics. Strategies that prevent infections are highly valued for improvement of public health. 
Vaccination relies on immunogenicity of pathogens. Immunogenicity of a molecule refers to its 
ability to evoke a potentially protective immune response. This aspect can be taken advantage of by 
artificially sensitize the immune system to an attenuated pathogen and thus generate memory B-
cells. Priming of the immune system allows for swift clearance of the pathogen on a subsequent 
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encounter. Antibodies can be used to identify regions of the pathogen that contribute to 
immunogenicity and have these regions alone used as subunit vaccines. In the absence of an 
effective preventative strategy, therapeutic options are often explored as an infection management 
strategy. Monoclonal antibodies (mAbs) are regarded as a potential panacea for different disease 
states in the 21st century. The ability of a particular antibody to induce a therapeutic effect, firstly by 
its targeted antigen binding which is then followed by an appropriate effector function is highly 
valued. It is for this reason that antibodies against varying targets ranging from receptors to 
cytokines for management of chronic diseases such as cancer and inflammatory diseases dominate 
the biopharmaceutical market (17). The ability of antibodies to specifically bind target antigens also 
makes them desirable as diagnostic reagents. The use of immunoassays to analyze biomolecules for 
diagnostic purposes has grown immensely. Antibodies are improving diagnostic sensitivity and 
specificity by dedicating more focus on engineering highly refined antibody properties (12).  To be 
able to carry out any of the aforementioned applications, a source of the antibodies is required.  
Antibodies have historically been sourced from antisera. Serum contains circulating antibodies, the 
specificities of which can be shaped by an antigen used for immunization. The antigen-induced 
antibodies can then be harvested for use in different applications. The limitation in the amount of 
antibody that can be harvested and the invariable polyclonal nature of the serum is apparent. Due to 
these disadvantages, a progression to sourcing antibodies from hybridomas was developed. This 
involves somatic fusion of antigen-activated splenic B-cells and myeloma cells (62). Alternately, 
the Epstein-Barr Virus can be used to immortalize antigen-specific human B lymphocytes (104). 
Continuous culture of the polyclonal B-cells is followed by antigen-specific selection. The selection 
process allows for an antibody of a single idiotype (monoclonal) and with desired properties to be 
maintained in culture.  Both antiserum and hybridomas however, heavily rely on antigen-driven 
production of B-cells and antibodies in immunized laboratory animals. Hurdles such as difficulty in 
expressing the target antigen to use in immunization and the need to perform immunization each 
time that antibodies are required for a particular target have necessitated the need to employ other 
techniques to source antibodies. Combinatorial immune repertoire libraries sourced from peripheral 
blood mononuclear cells (PBMCs) have gained popularity in recent times. The immune libraries are 
displayed as antibody fragments on different platforms, such as bacteriophage (phage), yeast, E. 
coli, ribosomes and mammalian cells. Phage display is deemed the more ancestral molecular 
display technology compared to others such as yeast and ribosomal display. The phage display 
technology has been shown to be robust and has had immense success. This body of work focuses 
on phage display of antibody fragment libraries. 
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1.2 PHAGE DISPLAY TECHNOLOGY 
Phage display technology links genotype with phenotype to screen and identify protein-ligand 
interactions. There are variations of phage display systems that exist. Detailed here are generic 
concepts that relate to a gIIIp phage display system that was used in this current work. 
Phage display facilitates display of foreign polypeptides on the surface of a phage particle by 
splicing the genes encoding an array of polypeptides into a gene that encodes a phage coat structural 
protein (81, 85). The coat protein functions to anchor the displayed polypeptide via a peptide linker. 
The resultant fusion protein is engineered to affect neither the structure and assembly of the phage 
particle, nor the structure and function of the tethered polypeptide (13, 19). The phage particles 
encoding and displaying the polpeptides are used to identify specific ligands in screening assays 
referred to as biopanning. 
Phage are a varied group of viruses that infect prokaryotic cells (13). Phage display applications 
typically employ the use of filamentous phage. Filamentous phage have a circular, single stranded 
DNA genome that is surrounded by a cylindrical protein coat Figure 1.2. The genome encodes 11 
genes, five of which are responsible for the expression of structural coat proteins. The coat is 
mainly made up of 2 700 molecules of pVIII, the major coat protein that covers the length of the 
phage particle. The orientation of the genome is such that a capped 78 nucleotide hairpin structure 
that makes up the packaging signal, is on one end which also has five copies of pVII and pIX 
proteins (6, 80).  The other end of the particle is capped by another pair of coat proteins pIII and 
pVI both of which also have five copies.  
 
Figure 1.2 Structural architecture and dimensions of filamentous phage (76). The 
schematic shows cylindrically shaped bacteriophage and the different coat proteins that it 
has on its surface. In parentheses are the copy numbers of each coat protein. 
In 1985, Smith (95) showed that foreign DNA stretches can be integrated into the genome of 
bacteriophage. Each of the coat proteins has been used for display of polypeptides (33, 58, 70). The 
 6 
 
first display system published by Smith involved in-frame cloning DNA segments within the amino 
and carboxy terminal ends of the gene which codes for the minor protein pIII (gIIIp) of the 
bacteriophage. The result was the expression of a fusion protein which displayed the foreign protein 
tethered to the pIII coat. This landmark method allowed for the development of different variations 
of in vitro selection methods. In 1991 Hoogenboom demonstrated the ability to integrate more than 
one subunit within the gene III of bacteriophage (57). This advancement allowed the display of Fab 
on the distal pIII, generating an in vitro selection library of the immune repertoire. This technology 
took advantage of the domain architecture of antibodies allowing tethering of antibody fragments 
on the coat of filamentous bacteriophage. The modular design of immunoglobulins allows the 
deletion of individual domains of immunoglobulins to allow the use of ‘fragments’ in antigen 
driven selection. 
The construction of a combinatorial phage display library involves cloning of recombinant antibody 
genes from B-cell cDNA of antigen immunized or antigen naive individuals into phagemid vectors. 
Phagemid vectors have a phage derived origin of replication (intergenic region) as well as their own 
plasmid origin of replication.The reverse transcribed B-cell mRNA is PCR amplified with 
germline-specific primers for variable regions. The variable fragment (Fv) region of antibodies as 
previously mentioned is responsible for antigen binding. This means that the Fc portion of 
antibodies can be excluded in display technologies. Smaller fragments lend themselves well to 
phage display as they can be produced in bacterial host systems without compromising protein 
folding. A fragment format is chosen for variable gene restriction cloning into the phagemid vector. 
The VH and VL domains are amplified and artificially shuffled in single chain variable fragments 
(scFv) and Fab formats to create added antibody repertoire diversity. scFv are the product of linked 
recombinant genes that encode VH and VL domains brought together with a short linker peptide 
such as 3 x (Glycine-Glycine-Glycine-Glycine-Serine). Construction of the Fab molecule involves 
two component polypeptides as it is made up of VL-VH and CL-CH1 domain interactions. The 
variable regions are cloned into a vector that already includes the constant domains. Each heavy and 
light chain can be designed to have its own ribosomal binding site allowing each chain to be 
independently translated for display on the surface of filamentous phage. The minimal VH domains 
of human antibodies (dAb) are sufficient for antigen recognition and therefore can also be singly 
amplified and cloned into a phagemid vector. 
Phage display libraries are used for selection of binders to target ligands. The selection protocol for 
an antibody library displayed on phage involves biopanning for antigen binders. A schematic of the 
typical process is shown in Figure 1.3. Often the antigen is immobilized on a surface, following 
which the library is then exposed to the antigen-coated surface. Different types of surfaces such as 
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nitrocellulose, polystyrene, magnetic beads and column matrices can be used. The displayed 
antibody fragments interact with the presented antigen during biopanning, functioning as probes to 
essentially self-select when exposed to an antigen to which they have binding specificity. Non-
specific binders are washed away followed by elution of specific binders. The specific binders then 
need to be amplified in bacteria. Phage display takes advantage of the bacteriophage replication 
cycle to enrich selected binders. The N-terminal of pIII forms knob-like structures illustrated in 
Figure 1.2. pIII not displaying tethered polypeptide binds to the F-pilus for infection of bacteria. 
Adsorption of pIII to the bacterial host cell F-pilus is followed by delivery of the single stranded 
phage DNA into the bacterial cytoplasm. The phagemid vector includes an origin of replication that 
has both a cis-acting sequence for replication and also an optimal cis-acting signal sequence for 
packaging single stranded DNA into nascent viral filaments. The gIIIp while allowing for foreign 
antibody fragements to be displayed on the virion surface, the hybrid protein by itself cannot 
support phage assembly. Virus assembly requires helper phage in a process called phage rescue. 
Phagemids carry a filamentous phage origin of replication which is inactive until a bacterial cell is 
infected with helper phage. Trans-acting sequences on helper phage provide the supplementary 
genes required for phage assembly. Helper phage are also filamentous phage that rely on the 
expression of the F-pilus on bacteria for infectivity. Additionally, helper phage carry a selectable 
marker different to the phagemid, have gene sequences that code for production of coat proteins, 
have gene sequences that code for virus assembly and importantly have a defunct packaging signal 
(109). This results in the preferential assembly of phage particles with phagemid DNA when both 
phagemid and helper phage infect the same bacterium. The amplified phage population of binders is 
then subjected to more iterations of panning to enrich for specific binders. 
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Figure 1.3 General overview of biopanning a phage library displaying antibody fragments. 
The target antigen is either adsorbed onto a solid surface or immobilized to a desired 
matrix. The phage-displayed antibody fragment library is then exposed to the antigen 
select for binders. Weak binders and non-binders are discarded during washing steps. pH 
shift elution is used to recover the target-specific binders which are rescued and amplified 
by infecting E. coli with the target-specific phage and helper phage. Bacterial replication 
allows replication of the phage which can be used in iterative rounds of biopanning. The 
biopanning protocol is repeated until sufficient enrichment is achieved. Individual phage 
are screened in a monoclonal ELISA to determine target-specificity. Positive binders from 
the screening are sequenced and characterized as phage-displayed antibody fragments, 
soluble antibody fragments of reformatted fully assembled antibodies. 
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1.3 AN OVERVIEW OF DENGUE VIRUS INFECTIONS  
Infection with dengue virus (DENV) is an increasingly significant health problem that puts nearly 
3.5 billion people in the tropics and sub-tropics at risk each year. 2010 population data and 
cartographic methods estimated the global dengue infection rate at 390 million infections annually, 
96 million of which were symptomatic (9). The World Health Organization cites this viral disease 
as one which is pandemic-prone due to a 30-fold increase in incidence of dengue in the last 50 
years. The global distribution of dengue has spread over the years and epidemics have been reported 
in many countries including Brazil, Columbia, Cuba, Peru, Venezuela, Lao People’s Democratic 
Republic, Vietnam, Malaysia, Thailand and Vietnam (97). The spread of DENV has been attributed 
to factors such as urbanization which has led to the geographic spread of the principal mosquito 
vectors Aedes aegypti and Aedes albopictus, increased host densities caused by swelling 
populations within the same limited living areas, increased ease and frequency of global travel 
which allows establishment of transmission cycles in non-endemic regions, and the rescinding of 
vector control programs (7, 29). The lack of an approved dengue virus vaccine or a dengue virus 
specific therapeutic, both of which are the focus of many research efforts, means that there is a 
heavy reliance on the management of the dengue disease burden. Consequently, there are concerted 
efforts towards improvements in diagnostic acumen, vector control, public health measures and 
disease surveillance. The necessity for improved diagnostic acumen is exemplified by the 
DENFRAME project, a consortium of researchers from Asia, Europe and Latin America working 
towards reliable and rapid diagnosis including integration of progressive tools such as biosensor 
technology. 
Dengue virus along with other insect-transmitted viruses such as West Nile virus (WNV), yellow 
fever virus (YFV), Japanese encephalitis virus (JEV) and tick-borne encephalitis virus (TBEV) 
belong to the flavivirus genus (5, 51, 97). Two or more flaviviruses often co-circulate in regions of 
hyper-endemicity such as parts of Asia where both DENV and JEV are commonly found (52).  
Dengue virus has four antigenically and phylogenetically distinct serotypes which can also co-
circulate within the same regions (56). Within these four serotypes are further genotypic subtypes. 
The dengue virus serotypes have varied infectivity and virulence (28, 106). DENV infections evoke 
both an innate and an adaptive immune response. The humoral immune system response is involved 
in two ways; (i) Antibodies target major glycoproteins produced by the virus (ii) Antibodies can 
mediate infection of target cells and aid viral replication through a phenomenon called antibody 
dependent enhancement (ADE) in secondary DENV infections. In ADE, non-neutralising 
antibodies produced during primary infections are thought to form immune complexes with the 
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virus, inadvertently aiding virus attachment to the Fc-γ receptor which allows mediated infection of 
host cells (53, 86, 88, 97).  
Dengue virus infections are generally self-limiting and result in a benign dengue fever (DF) which 
may be asymptomatic or lead to a wide spectrum of mild disease syndromes that share clinical 
characteristics with many other febrile illnesses (83). Serious infections such as Dengue 
Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS) however, are characterized by 
plasma leakage as a result of vascular permeability and haemostatic dysfunction (47, 52, 54). The 
development of DHF and DSS has been attributed to various factors such as host genetics, 
involvement of T-cells in immune response, and a second heterotypic infection subsequent to an 
initial priming infection (ADE) (32, 50, 55).  It is the possibility of progression to serious disease 
and possible mortality in the absence of timely supportive treatment that highlights the need for 
improved diagnostic acumen. Mitigation of mortality governs current protocols for hospitalization 
of all individuals infected with dengue viruses (102). In 2005, the mean cost of a hospitalized 
DENV infection case in international dollars (I$) was I$ 1394 (98). This is a significant cost that 
brings into play the fact that beyond just improved diagnosis of infection, diagnostic assays in the 
future need to be prognostic of severe disease so as manage disease associated costs. 
1.4 DENV STRUCTURE AND REPLICATION 
DENV is a 50 nm spherical virus made up of a nucleocapsid core that encapsulates the DENV 
genome within a capsid coat. A host-derived viral envelope made up a lipid bilayer covers the 
nucleocapsid. 180 copies of envelope and membrane proteins are embedded in the viral envelope 
and are displayed in an icosahedral pattern on the virus surface. The embedded proteins offer both a 
protective function and mediation of virus entry into host cells. A schematic of the DENV structure 
is shown in Figure 1.4.   
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Figure 1.4 Schematic representation of the dengue virus structure (113). Shown, is the 
icosahedral-like symmetry of envelope (E) and membrane (M) proteins on the surface of 
spherical DENV. Mature virions display M proteins while immature virions display a 
membrane protein precursor (prM). Within the protective outer protein coat are the capsid 
proteins which encapsulate the virus genome. 
The dengue virus has a tropism for dendritic cells, blood monocytes and tissue macrophages (22, 
110). Infection is mediated by dendritic cells on the skin surface as these cells are used for 
replication of the viral genome and proteins so the newly synthesized dengue viruses can go on to 
infect other host cells. The dengue virus has an incubation period of about two weeks before the 
presence of virus in blood and the presentation of symptoms (100). Upon a blood meal by a DENV 
vector, the virus attaches and is internalized by Langerhans cells through endocytosis. Fusion with 
endosomal membranes allows for acid-dependent cytoplasmic release of the virus genome (Figure 
1.5) (75). DENV is a single-stranded, positive sense, RNA virus of 11 kb. The 5’ end of the viral 
genome is made up of an untranslated region (UTR) of about 100 bp, while the 3’ UTR is about 450 
bp. Between the UTR ends is an open reading frame that encodes a single polypeptide of about 
3400 amino acids. The amino acids code for 3 structural proteins - capsid, membrane and envelope 
- and 7 non-structural (NS) proteins - NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (20). These 
proteins are produced following post-translational cleavage by viral and host proteins and all have 
various roles in the pathogenicity of DENV (101). These proteins are pivotal for replication at the 
surface of the endoplasmic reticulum (ER) where double stranded RNA is synthesized from the 
transcription of single stranded RNA provided be the virus genome. The structural proteins are 
included in the assembly of extracellular mature virus particles which also occurs in the ER.  
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Following assembly, the virions bud from the ER, are transported to the Golgi apparatus and then 
leave the host cell through the secretory pathway. 
 
Even though the non-structural proteins are expressed within the infected host cell, they are not part 
of the virion and as such, their use as diagnostic antigens is attractive.  The role of the non-structural 
proteins is in virus replication. Six of the seven non-structural proteins are incorporated into a 
scaffolded replication complex formed by NS2A, NS2B, NS3, NS4A, NS4B and NS5 on the 
cytoplasmic face of the ER (1). NS1 however is not part of the replication complex. NS1 is found 
within the ER lumen and associates with the replication complex through NS4B and possibly NS4A 
(77).  Following different signals and post-translational modifications, some proportions of NS1 
gets trafficked through the ER to the Golgi and then get secreted into circulation. The secretory 
characteristic of NS1 in measurable amounts makes it a good surrogate marker of infection and 
therefore an attractive diagnostic target (77, 111). Furthermore, the amount of DENV NS1 in 
circulation has also been found to be positively correlated with development of severe disease (66). 
 
 
Figure 1.5 Representation of the RNA genome of DENV (48). 5’ and 3’ untranslated 
regions flank the single polypeptide that codes for dengue virus. 
1.5 IMMUNE MODULATIONS IN DENV INFECTIONS 
Dengue virus infections evoke complex innate and adaptive immune responses. The outcomes of 
the infection are governed by the interplay between the speed of viral replication, the spread of 
infection, the response to infection and pushback from immune evasion tactics employed by the 
virus.    
Initial viral replication occurs in the Langerhans cells which are infected upon a blood meal by the 
viral vector. In their defense, the infected Langerhans cells initially produce interferons. This is a 
non-specific, innate response to infection that is encoded in the germline. Interferons – types I (α 
and β) and II (γ) result in a generalized antiviral state to minimize the effects of infection by 
inhibiting translation /replication of viral RNA and activating phagocytic cells respectively (27). 
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Furthermore the innate immune system responds by activating complement. Complement activation 
is important in; restraint of viral infectivity by mechanisms which lyse viral envelopes, recruitment 
and activation of phagocytic cells, promotion of viral clearance, and facilitation of antigen 
presentation to induce adaptive immune responses by B-cell and T-cell receptors.  
Some of the infected dendritic cells drain to the lymph nodes in an attempt to sequester and clear 
the pathogen. This unfortunately leads to the spread of the virus as the lymphatic system aids 
dissemination of the virus and new rounds of viral replication occur which in turn increase viremia. 
High titre viremia which is Fc-γ receptor mediated occurs during the febrile period. 
The engagement of the adaptive immune system involves B-cell antigen receptors – antibodies – 
which are produced to; neutralize the viral particles by direct receptor binding, complement 
mediated lysis of the infected cells or antibody-dependent cytotoxicity. The main targets of the 
antibodies are multiple domains of the E-protein, pre-membrane protein and NS1. The NS1 
response in particular is associated with ADCC and complement-mediated cytolysis (36, 44). In this 
flurry of responses, cytotoxic T cells are also recruited to kill the infected cells in response to the 
proteins synthesized by the viral particles. T-cells, like B-cells express clonally distributed antigen-
specific receptors that are generated by the same V-(D)-J gene rearrangement strategies. Peptides 
are displayed on surfaces of the host cells and these are recognized by the Major Histocompatibility 
Complex (MHC) which associates with the infected cells. This association flags the infected cells 
for killing by T-cell receptors (TCR) which make pivotal interactions with both the MHC and the 
proteins displayed on the infected cells. The TCR unlike the soluble B-cell receptor 
(immunoglobulin) is not secreted, its activation results in the proliferation and release of 
inflammatory cytokines which heavily influence the direction, magnitude and outcome of effector 
functions (23). The cytokine storm in particular, is responsible for the resultant fever which can last 
up to 10 days. Acute symptoms such as rashes, headache, retro-orbital pain, leucopenia and myalgia 
are also experienced during high viral titres. When the cumulative responses are excessive, vascular 
permeability and coagulation abnormalities cause severe disease (DHF/DSS) through mechanisms 
that are not fully elucidated.  
Dengue viruses utilize evasion tactics such as error prone RNA polymerases that generate variants 
of the viruses that are less recognizable by B and T cell receptors (27). These inhibit some of the 
immune responses but the combined innate and adaptive responses clear the self-limiting infection. 
The primary infection results in lifelong immunity to the infective DENV serotype and transient 
immunity to the other three serotypes. This means that asymptomatic reinfections with homotypic 
serotypes of DENV are common in the presence of neutralizing antibodies. The response to 
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secondary infections with heterotypic serotypes of DENV is not as straight forward as the response 
to primary infections. Previous, cross-reactive responses that are only partially neutralizing in 
heterotypic DENV challenge facilitate faster viral replication and faster spread of the virus by 
mediating infection and replication in Fc-γ receptor bearing cells and therefore increase the chances 
of development of DHF/DSS.  
The immunological storm that occurs during infection is important for the resolution of infection 
but also poses significant challenges to DENV diagnosis. To mitigate morbidity and mortality 
associated with DENV infections, acute phase diagnosis needs to differentiate DENV from other 
febrile disorders such as malaria, typhoid fever, scrub typhus, influenza and leptospirosis. Timely 
diagnosis in the absence sufficient of clear clinical signs can aid effective clinical approaches.  
1.6 DIAGNOSIS OF DENGUE VIRUS INFECTIONS 
Current protocols for the diagnosis of dengue infections include; serological detection of IgM and 
IgG responses to the major antigenic determining regions of the envelope protein, virus isolation by 
culture followed by detection with immune-fluorescence, nucleic acid amplification of the DENV 
genome or detection of viral antigenic polypeptides such as DENV NS1 (40, 50, 100).  
Diagnosis based on serology is used for diagnosis of dengue virus infections in endemic countries 
such as Singapore. The ratio between IgM and IgG responses is used to indicate either a primary or 
secondary infection. Furthermore, IgM and IgG responses are measured on two separate occasions 
(paired sample) from each individual to show an increase in antibody titre that is expected with 
progression of infection. The disadvantages of this method is that paired samples cannot always be 
obtained, there is a lag phase in detection of IgG and IgM antibodies and some patients fail to 
seroconvert (90). Additionally, there can be low specificity associated with IgM/IgG assays as the E 
protein epitopes that are targeted by the antibodies are found on other flaviviruses.  
Dengue virus culture is highly specific and indicative of the presence of virus. Virus detection in 
circulation is optimal for approximately two to seven days after the onset of illness and corresponds 
to the period of fever (94). The attainment of a virus culture result is unfortunately slow making this 
diagnostic method of little value in terms of early patient management (100).   
Nucleic acid amplification of the viral genome particularly of capsid and prM genes is highly 
sensitive in the acute phases of infection which have an associated high viral titre (24). In most 
instances this method uses reverse transcription-polymerase chain reaction (RT-PCR) to amplify 
and detect the viral genes followed by a secondary semi-nested PCR amplification to identify the 
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infective serotype. Unfortunately amplification processes are prone to contamination leading to 
false positives (82). The amplification protocols can also be complex requiring costly machinery in 
often resource-poor settings where much of the dengue virus burden is felt.  
Detection of DENV NS1 an antigen produced by DENV has become increasingly popular. 
Indonesia, another DENV endemic country and also the largest archipelago country inhabited by 
around 240 million people has clinicians increasingly using commercial NS1 antigen detection 
assays as the tool of choice to confirm DENV infection (4). DENV NS1 is detected from the onset 
of fever, up to approximately 12 days post the presentation of symptoms (111). This method of 
diagnosis is quick but does not provide any information on the infective serotype. Additionally, this 
method suffers from sensitivity issues particularly in secondary infections which are the bulk of 
infections seen in endemic countries. 
Detection of DENV NS1 can be carried out using multiplex polymerase chain reaction (PCR). 
SYBR green real-time PCR is preceded by viral RNA extraction and reverse transcription of the 
NS1 gene. The cycling steps of the PCR use serotype-specific primers to amplify the NS1 gene 
resulting in measurable signals to identify the infective DENV serotype.   
NS1 detection can also be carried out using antibodies in assay formats such as ELISA or by using 
rapid diagnostic test (RDT) kits that employ immunochromatographic techniques. In a sandwich 
ELISA, at least two antibodies that bind mutually exclusive sites are used to capture and detect the 
antigen. Immunochromatographic assays such as lateral flow devices utilize the same concept 
where membrane-immobilized antibodies and a reporter antibody conjugated to a coloured 
microsphere provide a test result. Because both assays are antibody based, conceptually, the 
sensitivity of the assays will rely on the availability of the epitopes that are recognized by the 
antibodies and the antibody affinity for those epitopes in the test matrix. The specificities and 
sensitivities of the DENV NS1 detection assay would need to be evaluated in local settings to assess 
their utility for varied populations.  In a recent comparison of a DENV NS1 detection ELISA and a 
DENV NS1 detection lateral flow test in Belo Horizonte, Brazil, the lateral flow devices were found 
to be marginally (not significantly) more sensitive than the ELISA (38). The RDT kits are 
advantageous in their ability to be taken into the field and their reduced assay time to obtaining a 
result but in scenarios where there are DENV epidemics, ELISA allows for high-throughput testing 
at low cost. 
Of the methods that have been mentioned, multiplexed PCR is the most sensitive method to detect 
DENV NS1 very early during infection (14, 61). The multiplex PCR as previously stated requires 
strict control measures to minimize cross-contamination of samples and expensive equipment that is 
 16 
 
generally reserved for specialized laboratories. In routine laboratory testing, patient serum is 
assayed for the presence of NS1 antigen using sandwich ELISA and RDTs. While the specificity of 
these routine testing assays can be very high, the sensitivity can be affected by the infective 
serotype (37, 74, 93) and secondary infections with heterotypic serotypes of DENV.   
The diagnosis of acute primary and secondary dengue virus infection cannot be achieved at required 
levels of sensitivity with a single marker of DENV infection (40) as each method of detection is 
hampered at different time points by the DENV factors controlling infection and the host immune 
response to the infection (Figure 1.6). Notably, there is a lag phase that is associated with immune 
responses (IgM/IgG) to detectable viraemia and the presence of DENV NS1. While virus detection 
is high quite early on during acute illness, the rise in antibody titre quickly decreases it to non-
detectable levels. The levels of DENV NS1 are not shown as these vary amongst individuals but its 
detection is possible up to 12 days after the onset of acute illness. Not shown in Figure 1.6 is the 
IgA immunological response to the presence of virus.  The IgA class of antibody is recruited in 
DENV infections and its levels have been to shown to be high in the acute phase of severe disease 
(DHF/DSS) (63). 
Diagnosis of DENV infections requires the aforementioned cognizance of the detection kinetics of 
the viral genome, antigenic NS1 and IgG/IgM antibodies against DENV. A study by Moi et al. (74) 
comparing the usefulness of viral genome and antigenic NS1 detection found that the sensitivity of 
NS1 detection was high from the onset of acute symptoms up to 10 days thereafter while the 
detection of the viral genome waned after just 5 days post the onset of acute symptoms. Antibody 
detection on the other hand, is linked closely with the convalescent phase of infection which begins 
at about 5 to 6 days post the onset of acute symptoms (18, 59, 82). It is therefore not surprising that 
the combination of DENV NS1 detection and IgM/IgG ELISA increases the DENV diagnostic 
window as has been reported in literature. Critically, in situations where there is a manifestation 
dengue hemorrhagic fever, its timing is concurrent with the decrease in fever which occurs when 
the antibody response peaks and starts to resolve the infection (82, 89). From a clinical perspective 
therefore, the diagnostic method that provides lengthy diagnosis of infection from the onset would 
be most beneficial in helping to plan appropriate courses of clinical action. It is for this reason that 
research input into improving the diagnostic sensitivity of DENV NS1 detection is crucial. 
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Figure 1.6 Detection kinetics of dengue virus, NS1, IgM and IgG in DENV infections 
(48). Shown are short lived viremea which is followed by either and IgM or IgG response 
depending on the presence of either a primary or secondary response. The presence of NS1 
is also indicated from quite early on in infection but the levels of NS1 which are variable 
are not shown. 
1.7 EVALUATION AND APPLICATION OF DENV NS1 AS A DIAGNOSTIC 
MARKER 
NS1 is a 46 - 55 kDa glycoprotein (96) produced by DENV but is absent from the virion. This 
protein has been shown to be a good surrogate marker for acute DENV infection (2, 66, 111). The 
recently resolved dimeric structure of NS1 (1) shown in Figure 1.6, indicates three main domains 
that make up each monomer; (i) a β-roll domain with a highly hydrophobic face and a free cysteine 
that allows dimerization on the interior side, (ii) a wing-like domain which includes an unresolved, 
highly disordered loop at residues 108 – 128 which have previously been reported to be immune-
dominant (35) and (iii) a C-terminal, rung-like, continuous β sheet that forms the plane of the dimer.  
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Figure 1.7 Structural domains of dimeric NS1 (1). The monomer shows a β–roll domain in 
blue, β-ladder domain in red and a wing domain in yellow. 
NS1 is produced as a monomer in infected cells. Following post-translational modification in the 
ER lumen, NS1 associates with the membranes of organelles in its dimeric form, held together by a 
disulfide bridge. The membrane-associated dimer plays a role in assisting replication of the virus. 
Dimeric NS1 is then transported to the surface of infected cells where it is secreted into circulation 
as a hexamer. The hexamer which is detergent sensitive (25, 39), associates by hydrophobic 
interaction of its β rolls (5, 11). The hexameric structure of about 310 kDa has been reported by 
Gutsche et al. (47) to carry a lipid cargo. The lipids were found to be similar to those involved in 
vascular hemostasis and endothelium function indicating that NS1 could potentially mimic or hijack 
lipid metabolic systems to mediate plasma leakage which is characteristic of severe disease.  It is 
the extracellular accumulation of secreted NS1 however which permits its use as a marker of 
infection.  
 
Detection of DENV NS1 can precede onset of symptoms and persist up to day 12 post infection (2, 
30, 66). DENV NS1 detection coincides with detectable viremia before an antibody response is 
mounted. Concentrations in serum vary and can reach up to 50 µg/mL (2, 111). Alcon et al. (2), in 
their work with polyclonal antibodies, showed that concentrations of DENV NS1 do not 
 19 
 
significantly differ between primary and secondary infections but the duration of antigen detection 
is shorter in secondary infections (103). The anamnestic B-cell response to flaviviral infection also 
differs from the initial response not only in swifter clearance of NS1 but also in a higher 
representation of memory B-cells that produce antibodies against immune-dominant regions of NS1 
(34). Despite the shorter duration of DENV NS1 in secondary infections, high titres of antigen have 
been found to be predictive of presentation with DHF/DSS (66). 
Different commercial DENV NS1 capture assays (Panbio-Alere, Standard Diagnostics, Bio-Rad 
Platelia) are available in the market for diagnosis of DENV and these have been the subject of many 
utility evaluations (4, 8, 31, 37, 49, 64, 67, 68, 72, 105, 112). Results generally showed that 
specificity of DENV diagnosis with no cross-reactivity to NS1 from othe flaviviruses was high 
(upwards of 80% and in some cases 100%) but there were clear deficits in sensitivity of DENV NS1 
detection. The highest sensitivity of NS1 detection was early during the course of infection and in 
primary infections. Sensitivity was particularly poor however in cases of secondary infection. 
Unexplainable geography-variable sensitivity was also reported with the Platelia Dengue NS1 (Bio-
Rad)  (49). Some evaluations have compared the utility of NS1 detection to serological detection of 
IgG/IgM (3, 10, 40, 45, 82) and the results indicated that the two assays are complementary and 
improve specificity and sensitivity when used in combination to offset the weaknesses of each 
individual assay. Algorithms have also been proposed for how different diagnostic assays such as 
real-time RT- PCR, IgM antibody capture ELISA, and DENV NS1 antigen capture can be 
combined to improve sensitivity and the window of DENV infection diagnosis as each of these 
assays have utilities in different phases of DENV infection (8, 40). 
Combining different infection markers for simultaneous detection in multiplexed assays is an 
attractive strategy to achieve validated sensitivity and specificity of at least 99.5% required for 
inclusion of a DENV diagnostic assay in blood screening programs (78). Transfusion of blood is a 
life-saving intervention with an invaluable role in certain cases of patient management. The 
mandate of national blood programs therefore, is to establish approaches that ensure screening for 
transfusion-transmissible infections. One of the challenges however, lies in the unavailability of 
screening assays for some transfusion-transmitted infections. DENV in particular has been shown to 
be transfusion-transmitted (21, 26, 99). The degree of transfusion transmission in endemic regions 
is difficult to ascertain without an appropriately specific and sensitive screening assay. This poses a 
risk to blood safety in endemic regions. Current mitigation of DENV transfusion transmission by 
the Australian Red Cross Blood Service (ARCBS) relies on exclusion of fresh component 
manufacture of blood products (platelets and red blood cells) from people that are identified from 
questionnaires and interviews as having travelled to areas that put them at risk of infection. When 
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there are DENV outbreaks, the repercussions are a decline in available stocks of fresh components 
and a substantial cost implication associated with discarding the fresh components. There are 
unfortunately no cost-benefit analyses available to determine the cost of the development of a 
DENV screening assay – cost per infection averted - and the risk of DENV transfusion 
transmission. DENV prevalence and incidence rates in endemic regions of the Americas and Asia-
Pacific however, justify the development of a DENV screening assay as has been done with West 
Nile Virus in the USA where it poses a significant threat to blood safety  (15).  
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1.8 PROJECT RATIONALE  
The significant deficiencies in sensitivity of DENV infection diagnosis by NS1 antigen detection 
indicate that there is scope of improvement of the antigen detection assay. The DENV NS1 
detection assays rely upon the use of at least two antibodies for capture and detection of the antigen. 
Presumably, commercial companies would develop assays with high affinity antibodies and 
therefore the shortfall is not due to antibody-antigen kinetic interactions. The sensitivity deficits that 
are seen in antigen detection particularly in secondary infections would point to an unavailability of 
a B-cell epitope recognized by either the capture or detection antibody during the secondary 
immune responses. Major immune-dominant antigens are shared between dengue and other 
flaviviruses (16) and antibody responses to these antigens can interfere with accurate detection of 
analytes such as DENV NS1 (34) in the absence of an immune-complex dissociation step (63). 
The project described herein endeavors to develop best in class reagents for DENV NS1 detection. 
The work focuses on using different phage libraries displaying human antibody fragments to isolate 
(i) antibodies that target discreet antigenic differences amongst NS1 from all four DENV serotypes 
and (ii) a pairing antibody that recognizes NS1 from all four DENV serotypes but avoids the 
immune-dominant region. We hypothesize that a serotyping assay of this nature can improve 
diagnostic sensitivity in secondary DENV infections as the pan-reactive binder used in the assay 
will target an alternate epitope, distinct from the immune-dominant epitope which is often bound by 
circulating endogenous antibodies that are clonally produced as a consequence of a previous, 
primary DENV infection. The assay would also lend itself well to epidemiological surveillance 
which is critical for predictions of epidemics and planning for responses to epidemics. Additionally, 
the reagents could be incorporated into a multiplexed assay with other markers of infection that 
could screen donated blood for active viraemia by using DENV NS1 as a proxy. 
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Chapter 2  
ISOLATION OF  
SEROTYPE-SPECIFIC AND PAN-REACTIVE BINDERS  
AGAINST DENV NS1  
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2.1 INTRODUCTION 
Non-structural protein 1 (NS1) is antigenic glycoprotein that is produced by dengue viruses and 
other flaviviruses. NS1 like other non-structural proteins produced by flaviviruses is not part of the 
virion. Its post translational processing and trafficking however, allows for its detection in 
circulation, making it an attractive diagnostic target (23). In DENV infections, the duration of NS1 
detection in circulation is longer than that of detectable viremea (9, 11). Furthermore NS1 detection 
precedes and overlaps with detectable antibody responses in acute infections (11). The kinetics of 
DENV NS1 secretion and detection therefore offer a widened window of diagnostic utility when 
compared with virus isolation, genome detection and serology. 
There is approximately 70% sequence homology amongst the four NS1 polypeptide sequences of 
each DENV serotype. The variation amongst DENV NS1 serotypes is not concentrated in any 
mutational hotspots but rather interspersed along the length of the polypeptide (Figure 2.1). This 
variation can be taken advantage of by isolating monoclonal antibodies that target serotype-specific 
regions. This is important because an ability to distinguish the infective serotype is regarded as an 
attractive characteristic of a DENV diagnostic assay (6, 12, 18) as the serotyping capability 
increases the specificity of the assay by distinguishing DENV infections from other flaviviral 
infections. The serotyping nature of the antibodies would also add novelty with a potentially cost 
cutting element in comparison to the current commercial DENV NS1 capture assays which require 
a subsequent test to reveal the infective DENV serotype. The targeting of distinct epitopes on NS1 
from each DENV serotype also allows for balanced diagnostic sensitivity across all four DENV 
serotypes. The use of antibodies with reactivity to NS1 from two or more DENV serotypes in 
current commercial assays results in varying affinities because of inevitably varied epitope 
conformations caused by NS1 sequence differences. By targeting NS1 from each DENV serotype 
individually, the desired affinities of the isolated antibodies for the antigen can subsequently be 
adjusted using affinity maturation strategies.  
Serotyping antibodies against DENV NS1 also have the potential to improve diagnostic sensitivity 
if paired with a pan-reactive antibody that avoids the immune-dominant region of DENV NS1. 
There exists a core immune-dominant epitope (YSWKTWG) that lies between residues 113-125 on 
NS1 from all four serotypes of DENV (10). Antibodies against this region are present in high 
proportions during secondary DENV infections. These antibodies sequester DENV NS1 in immune 
complexes and their binding to the immune dominant epitope can interfere with the ability of assay 
antibodies used in capture and detection of DENV NS1 to bind to their relevant epitopes. Improved 
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diagnostic sensitivity therefore relies on targeting two mutually exclusive epitopes on DENV NS1 
that are spatially distinct to the immune-dominant epitope. 
In seeking to isolate antibody binders against non immune-dominant epitopes, the preferred source 
of potential antibodies would minimize any antigen driven aspect. Phage display offers a 
technology that can be used to isolate such antibody fragments. Two different types of antibody 
display libraries exist, directed and naïve. Directed immune repertoires are constructed from mRNA 
that is enriched for target antigen-specific VH and VL genes through infection or immunization. A 
high proportion of the immunoglobulin mRNA encodes V genes with fine-tuned antigen binding 
properties. Conversely, naïve immune repertoires are assembled from pooled, existing V genes 
which are rearranged in vitro to offer varied antigen binding specificities of equally varying 
affinities. Naive libraries therefore offer an unshaped immune repertoire against a very large 
number of antigens. These libraries have been shown to have better utility in isolating binders to 
highly conserved proteins (16, 17). The premise behind this is that antibodies that are first produced 
in response to a previously un-encountered antigen will be varied and not optimized for antigen 
recognition. The epitopes to which these antibodies bind will therefore hypothetically vary from the 
epitopes for the fewer antibodies that are optimized for recognition on a subsequent encounter. The 
requirement for successful selection of antibodies that recognize the non-conserved regions 
however, depends on having a large and diverse library. 
Three different biopanning strategies were used to isolate binders against recombinant DENV NS1 
from three human, naïve phage libraries displaying VH domain antibody (dAb), scFv or Fab. The 
first strategy involved a subtractive biopanning protocol using NS1 from other DENV serotypes to 
isolate serotype-specific antibodies from scFv and Fab libraries. Five serotype-specific antibody 
fragments were isolated. Three serotype-specific antibody fragments were isolated from the scFv 
library (9H2 anti DENV-1 NS1, 6A5 anti DENV-4 NS1 and 6A7 anti DENV-4 NS1) while two 
were isolated from the Fab library (4C11 anti DENV-2 NS1 and 7G11 anti DENV-3 NS1). This 
panning strategy also isolated 11 unique pan-reactive antibodies, nine of which were from the Fab 
library. The scFv library was interrogated again in a non-subtractive manner for high-affinity pan-
reactive binders against DENV NS1. Two unique binders A1 and A2 were dominant in the panel of 
clones that were screened for binding to NS1 from all four DENV serotypes. The final strategy, 
using the VH dAb library, involved biopanning for pan-reactive binders against DENV NS1 in 
which the immune-dominant epitope had been masked by a bound murine antibody.  This strategy 
yielded a single unique antibody D1C2. The different biopanning strategies therefore collectively 
yielded five serotype-specific antibody fragments and 14 pan-reactive antibody fragments.  
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2.2 MATERIALS AND METHODS 
2.2.1 GENERAL RECIPES, STOCK REAGENTS AND EQUIPMENT 
2.2.1.1 Culture Media 
2YT – per litre; 10 g yeast extract, 16 g tryptone and 5 g NaCl  
Media was autoclaved at 121°C for 20 minutes. 
Variations 
2YT agar – per litre add 15g agar (added prior to autoclaving) 
The following supplements were added individually as required after autoclaving and cooling: 
 
Ampicillin (A) – 1/1000 dilution of a 100 mg/mL working stock 
 
Kanamycin (K) – 1/1000 dilution of a 30 mg/mL working stock 
Tetracycline (T) – 1/1000 dilution of a 3 mg/mL working stock 
Glucose (G) – to a total concentration of 2% 
 
Lysogeny broth (LB) – per litre; 5 g yeast extract, 10 g tryptone and 10 g NaCl 
Media was autoclaved at 121°C for 20 minutes. 
 
Variations 
LB agar – per litre add 15g agar (added prior to autoclaving) 
The following supplements were added individually as required after autoclaving and cooling: 
Ampicillin (A) – add 1/1000 dilution of a 100 mg/mL working stock 
 
Kanamycin (K) – add 1/1000 dilution of a 30 mg/mL working stock 
Glucose (G) – add to a total concentration of 2% 
Sucrose (S) – add to achieve 0.4 M in final volume 
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2.2.1.2 Solutions 
Phosphate Buffered Saline (PBS) prepared using 10 X Dulbecco’s PBS (Lonza) or tablets 
(Amresco) 
Solution autoclaved at 121°C for 20 minutes 
 
Variations 
M-PBS – add skim milk powder to varying weight/volume percentage concentrations. 
PBS-Glycerol – add to 20% final concentration 
PBS-T – add 0.1% Tween-20 
 
PEG-NaCl – 20% polyethylene glycol-6000 and 2.5 M NaCl  
Solution autoclaved at 121°C for 20 minutes 
 
 
Elution Solution – 200 mM glycine, pH 2.5 
Sterilized using vacuum-assisted filtration with a 0.45 μm HAWP membrane (Millipore) 
 
Neutralization Buffer – 1 M Trizma, pH 7.4 
Sterilized using vacuum-assisted filtration with a 0.45 μm HAWP membrane (Millipore) 
 
2.2.1.3 Phage Display Libraries 
Phage libraries displayed antibody fragments in fusion with the head capsid protein gIIIp of 
filamentous bacteriophage M13, achieved by cloning human antibody genes into specialised 
phagemid vectors.  The following human naïve libraries were sources:  The ‘Sheets’ scFv library, in 
pHEN1 phagemid vector, was obtained from Prof James Marks (UCSF) (20), a Fab library, in  
pCES1 phagemid vector (7), was obtained from the Australian Red Cross Blood Service 
(unpublished); and an aggregation-resistant VH library, in pR2 phagemid vector, was purchased 
from Geneservice (UK) (5). The phagemid vectors include an inducible bacterial promoter and a 
periplasmic signal sequence upstream of the antibody fragment sequence. Downstream are a c-myc 
and/or VSV and/or histidine tag, an amber stop codon and then the gIIIp sequence (22). 
Transformation of suppressor XL1-Blue bacteria (Strategene) with the phagemid vector followed 
 34 
 
by rescue of the phage with M13KO7 helper phage allows the production of phage particles that 
express and display antibody fragments on the tips of the gene III protein.  
Diversity of the Libraries 
VH – 3.0 x 109 
scFv – 6.7 x 109 
Fab – 1.0 x 1010 
 
Helper Phage - M13KO7 (NEB) 
2.2.1.4 Bacterial Strains 
Amber codon suppressor strain XL1-Blue (Agilent - Stratagene) 
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 
(Tetr)] 
 
Amber codon non- suppressor strain HB2151 (GE Healthcare) 
Genotype: K12 alr ara Δ(lac-proAB) thi-1/F’ proA+B  lacIq lacZΔM15 
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2.2.1.5 Recombinant Antigen 
Recombinant DENV-1, DENV-2, DENV-3 and DENV-4 NS1 were obtained from Professor 
Matthew Cooper (Institute for Molecular Bioscience, The University of Queensland). Unless where 
specified, all DENV NS1 used in this work was of a recombinant nature. The antigens were 
prepared by Alere Inc. (San Diego, U.S.A) using the NS1 sequences of clinical isolates from 
Western Pacific/1974 for DENV-1, Puerto Rico/1969 for DENV-2, Martinique/1999 for DENV-3 
and Singapore/1995 for DENV-4. The antigens were expressed in CHO-DG44 cells and their N-
terminal 7 x histidine tag was used for purification. The DENV NS1 sequences and relational 
homology are shown in Figure 2.1 and Figure 2.2 respectively. DENV NS1 was provided at 
different concentrations in a formulation buffer made up of PBS pH 7.4, 0.02% NaN3 and 10% 
glycerol. 
  
 36 
 
 
 
DENV-1          DSGCVINWKGRELKCGSGIFVTNEVHTWTEQYKFQADSPKRLSAAIGKAWEEGVCGIRSA 60 
DENV-3          DMGCVINWKGKELKCGSGIFVTNEVHTWTEQYKFQADSPKRLATAIAGAWENGVCGIRST 60 
DENV-2          DSGCVVSWKNKELKCGSGIFVTDNVHTRTEQYKFQPESPSKLASAIQKAHEEGICGIRSV 60 
DENV-4          DMGCVVSWSGKELKCGSGIFVADNVHTWTEQYKFQPESPARLASAILNAHKDGVCGIRST 60 
                * ***:.*..:**********:::*** *******.:** :*::**  * ::*:*****. 
 
DENV-1          TRLENIMWKQISNELNHILLENDMKFTVVVGDVSGILAQGKKMIRPQPMEHKYSWKSWGK 120 
DENV-3          TRMENLLWKQIANELNYILWENNIKLTVVVGDIIGVLEQGKRTLTPQPMELKYSWKTWGK 120 
DENV-2          TRLENLMWKQITSELNHILSENEVKLTIMTGDIKGIMQVGKRSLRPQPTELRYSWKTWGK 120 
DENV-4          TRLENVMWKQITNELNYVLWEGGHDLTVVAGDVKGVLTKGKRALTPPVNDLKYSWKTWGK 120 
                **:**::****:.***::* *.  .:*::.**: *::  **: : *   : :****:*** 
 
DENV-1          AKIIGADVQNTTFIIDGPNTPECPDNQRAWNIWEVEDYGFGIFTTNIWLKLRDSYTQVCD 180 
DENV-3          AKIVTAETQNSSFIIDGPNTPECPSASRAWNVWEVEDYGFGVFTTNIWLKLREVYTQLCD 180 
DENV-2          AKMLSTELHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLRLREKQDAFCD 180 
DENV-4          AKIFTPEARNSTFLIDGPDTSECPNERRAWNFLEVEDYGFGMFTTNIWMKFREGSSEVCD 180 
                **:. .: :* :*:****:*.***.  ****  ********:******:::*:    .** 
 
DENV-1          HRLMSAAIKDSKAVHADMGYWIESEKNETWKLARASFIEVKTCIWPKSHTLWSNGVLESE 240 
DENV-3          HRLMSAAVKDERAVHADMGYWIESQKNGSWKLEKASLIEVKTCTWPKSHTLWSNGVLESD 240 
DENV-2          SKLMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKSCHWPKSHTLWSNGVLESE 240 
DENV-4          HRLMSAAIKDQKAVHADMGYWIESSKNQTWQIEKASLIEVKTCLWPKTHTLWSNGVLESQ 240 
                 :*****:**.:************  * :*:: :**:****:* ***:***********: 
 
DENV-1          MIIPKIYGGPISQHNYRPGYFTQTAGPWHLGKLELDFDLCEGTTVVVDEHCGNRGPSLRT 300 
DENV-3          MIIPKSLAGPISQHNHRPGYHTQTAGPWHLGKLELDFNYCEGTTVVITENCGTRGPSLRT 300 
DENV-2          MVIPKNFAGPKSQHNNRPGYHTQTAGPWHLGKLEMDFDFCEGTTVVVTEDCGNRGPSLRT 300 
DENV-4          MLIPKSYAGPFSQHNYRQGYATQTVGPWHLGKLEIDFGECPGTTVTIQEDCDHRGPSLRT 300 
                *:***  .** **** * ** ***.*********:**. * ****.: *.*. ******* 
 
DENV-1          TTVTGKTIHEWCCRSCTLPPLRFKGEDGCWYGMEIRPVKEKEENLVKSMVSA 352 
DENV-3          TTVSGKLIHEWCCRSCTLPPLRYMGEDGCWYGMEIRPISEKEENMVKSLVSA 352 
DENV-2          TTASGKLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENLVSSLVTA 352 
DENV-4          TTASGKLVTQWCCRSCTMPPLRFLGEDGCWYGMEIRPLSEKEENMVKSQVTA 352 
                **.:** : :*******:****: *************:.*****:*.* *:* 
 
Figure 2.1 Alignment of clinical isolate sequences of DENV NS1. These sequences were 
used for recombinant expression of DENV NS1. ‘*’ denotes positions with fully conserved 
residues, ‘:’ denotes conservation of residues with similar properties ‘.’ denotes weakly 
similar amino acid residues while no symbol denotes no homology. The amino differences 
amongst NS1 from all four DENV serotypes are scattered along the length of the 
sequences.   
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Figure 2.2 Cladogram of the inferred homology amongst DENV NS1. DENV-4 NS1 is 
shown as the ancestral sequence that is most closely related to DENV-2 NS1. A 
divergence is then shown with both DENV-1 and DENV-3 NS1 which are more closely 
related to each other. 
2.2.1.6 Murine Antibodies 
Murine antibody GUS2 which recognizes an immune dominant epitope on NS1 from all four 
DENV serotypes was obtained from the laboratory of Professor Paul R. Young (School of 
Chemistry and Molecular Biosciences, The University of Queensland) 
2.2.1.7 Equipment 
OD600 measurements were performed using the BioPhotometer (Eppendorf) 
Absorbance values of chromogenic signals in plate formats were measured using the Spectramax 
(Molecular Devices) or the PowerWave XS2 (Biotek – Millenium Science). 
Protein and nucleic acid concentrations were measured using the NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific). 
Thermal cycling reactions were performed using the Veriti® 96-Well Thermal Cycler (Applied 
Biosystems). 
 
2.2.2 BIOPANNING USING PURIFIED ANTIGEN 
Three different panning strategies were employed to isolate binders depending on whether serotype-
specific or pan-reactive binders were sought. 
i. For isolation of serotype-specific antibodies, a subtractive panning strategy was employed. 1 
mL of NS1 at 45 μg/mL from all four DENV serotypes was diluted in PBS and added to an 
immunotube (Nunc). The tubes were incubated overnight at room temperature on a rotating 
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wheel to allow for antigen immobilisation to the walls of the tube. On day two, only one of 
the tubes was used as the positive antigen for that selection while the other three tubes were 
used as the negative antigens. The negative antigens were used in a subtractive manner to 
deplete any binders that recognize NS1 from any other DENV serotype. In instances where 
binders to DENV-1 NS1 were sought for example, the phage library was first added to an 
immunotube coated with DENV-2 NS1. Unbound phage were decanted from that 
immunotube and added to another immunotube coated with DENV-3 NS1 and then a 
DENV-4 NS1 coated immunotube, before finally being exposed to a DENV-1 NS1 coated 
on the last immunotube. The unbound phage were then discarded. 
 
ii. For isolation of pan-reactive binders, 1 mL of NS1 (45 μg/mL) from a single DENV 
serotype was diluted in PBS and added to an immunotube. NS1 from a different DENV 
serotype was used in each round of biopanning in order to isolate binders to NS1 from all 
four DENV serotypes. The tube with antigen was incubated overnight at room temperature 
on a rotating wheel to allow for antigen immobilisation. On day two, the phage library was 
added to the immunotubes. Unbound phage were discarded.  
 
iii. To isolate pan-reactive binders which recognize epitopes that are removed from the 
immune-dominant epitope, a pan-reactive antibody (GUS2) that binds that epitope was 
utilized. GUS2 was diluted in PBS and immobilized on an immunotube at a concentration of 
1 mg/mL. The tube was incubated overnight at room temperature on a rotating wheel. On 
day two, the immobilised antibody was used to capture NS1 (45 μg/mL) from a single 
DENV serotype. Excess DENV NS1 that was not captured was discarded. The phage library 
was then added to the tube with antibody-bound antigen. Unbound phage were discarded. 
  
 39 
 
Day 1 
DENV NS1 or GUS2 was diluted at an appropriate concentration in PBS and added to a 5 mL 
immunotube (Nunc). The tube(s) was/were capped and placed on a rotating wheel overnight at 
room temperature.  
5 ml 2YT broth with tetracycline was inoculated with a single colony of XL1-Blue from a streak 
plate and incubated overnight at 37 ˚C whilst shaking at 220 rpm. 
Day 2 
The contents of the immunotubes were discarded and the tubes were washed three times with PBS. 
The surface of the tubes was then saturated with 10% M-PBS to block any remaining binding sites 
on the immunotubes. The blocking proceeded for 1 hour on the rotating wheel at room temperature. 
Meanwhile, an appropriate concentration of DENV NS1 and/or phage library in a 1 mL volume was 
made in 2% M-PBS. The blocking solution was discarded and DENV NS1 in M-PBS or the phage 
library in M-PBS was added to the tube and incubated on the rotating wheel for 1 hour. In the first 
round of biopanning, 1 000-fold representation of the phage library was added. The input titre of 
phage recovered from each round, was decreased ten-fold with each subsequent iteration of 
biopanning. Biopanning was carried out as described for each strategy above and all incubations 
proceeded for 1 hour on the rotating wheel. 
In the final step of all three strategies, unbound non-specific phage particles were discarded. The 
tubes were washed three times with PBS and then three times with PBS-T. The number of washes 
with each buffer was increased by one for each biopanning iteration. The bound phage particles 
were pH eluted and then neutralized. Elution was performed by adding 1 mL of Elution Solution to 
the tube and incubating it for 8 minutes on a rotating wheel.  The phage eluate was added to 1 mL 
of Neutralisation Buffer. Glycerol to a final concentration of 20% was added to half of the 
neutralized eluate for storage at -80 ˚C. The other half was used to infect XL1-Blue cells for 
amplification of the isolated binders. 
375 μL of the overnight culture from day one was added to a fresh 15 mL volume of 2YT broth 
with tetracycline. The culture was incubated at 37 ˚C whilst shaking at 220 rpm until OD600 
between 0.6 and 0.8. 10 mL of the log phase culture was infected with 1 mL of neutralized eluate 
during  a 30 minute incubation at 37 ˚C.  
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150 μL of the infected culture was sampled and five, serial 10-fold dilutions were made to 
determine the output titre. 10 μL of each dilution was spotted on a 2YTAG plate. The plate was 
incubated overnight at 37 ˚C. 
Meanwhile, the rest of the infected cells were pelleted by centrifugation at 2 000 x g for 15 minutes. 
The cells were resuspended in 0.5 mL 2YT broth and spread evenly over two 150 mm 2YTAG agar 
plates. The plates were incubated overnight at 30 ˚C to ensure propagation of most clones. 
Day 3 
The output titre was calculated from dilutions of infected cells with countable colonies. An 
enrichment in the output (the number of cells infected with the eluted phage) relative to the input 
(the number of phage particles used for biopanning) should occur with each round of biopanning. 
Output titre/10 mL volume = number of colonies x dilution factor x 1000 (volume adjustment) 
Glycerol stocks of infected cells were made by scraping the bacterial cells from both overnight 
plates using 10 mL total volume of 2YTAG broth. Glycerol was added to the recovered bacterial 
slurry at a final concentration of 20%. Some of the glycerol stock was used for phage rescue while 
the rest was aliquoted and stored at -80 ˚C. 
Phage particles were prepared by sub-culturing a volume of the glycerol stock in 50 mL 2YTAG 
broth to achieve a starting OD600 between 0.05 and 0.1. The culture was incubated at 37 ˚C whilst 
shaking at 220 rpm until it reached OD600 between 0.4 and 0.6. 1 x 1011 M13KO7 helper phage 
particles were added to the culture. Infection with the helper phage occurred during a 30 minute 
incubation 37 ˚C. The culture was incubated for a further 30 minutes at 37 ˚C whilst shaking at 220 
rpm. Co-infected cells were recovered by centrifugation at 2 000 x g for 20 minutes. The cells were 
resuspended in 100 mL 2YTAK and incubated overnight at 30 ˚C whilst shaking at 220 rpm. 
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2.2.3 PHAGE PRECIPITATION 
Phage particles secreted into the culture media were harvested by centrifugation of the overnight 
culture at 2000 x g for 30 minutes. Phage particles were precipitated from the culture  supernatant 
by addition of 1/5 volume of PEG-NaCl and incubation on ice for 1 hour. The precipitate was 
pelleted by centrifugation at 10 000 x g at 4 ˚C for 20 minutes. The supernatant was discarded and 
the pellet resuspended in 10 mL cold PBS. The suspension was subjected to a second round of 
precipitation on ice using 1/5 volume of PEG-NaCl and centrifugation at 10 000 x g at 4 ˚C for 20 
minutes. The final pellet was resuspended in 3 mL cold PBS-glycerol and the purified phage 
particles were titred and stored in aliquots at -80 ˚C. 
 
2.2.4 PHAGE TITRE 
Day 1  
A single colony of XL1-Blue was picked from a streak plate and used to inoculate 5 mL 2YT with 
tetracycline. The culture was incubated overnight at 37 ˚C whilst shaking at 220 rpm. 
Day 2 
50 μL of the overnight culture was sub-cultured into a fresh 5 mL volume of 2YT with tetracycline. 
The culture was incubated at 37 ˚C whilst shaking at 220 rpm until OD600 between 0.6 and 0.8 as 
measured by the BioPhotometer (Eppendorf). Ten, ten-fold dilutions of purified phage in PBS were 
made in 1.5 mL tubes. 1 μL was removed from each dilution and transferred to a new 
corresponding 1.5 mL tube. 100 μL of the log-phase culture was added to each tube. Bacterial 
infection with phage occurred during a 30 minute incubation at 37 ˚C. 10 μL of each dilution was 
spotted on a 2YTAG agar plate which was incubated overnight at 37 ˚C 
Day 3  
The number of countable colonies that corresponded to the relevant phage dilution was used to 
calculate the phage titre.  
cfu/mL = number of colonies x dilution factor x 10 000 (volume adjustment) 
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2.2.5 MONOCLONAL PHAGE ELISA 
To determine the binding reactivity of isolated antibody fragments displayed on phage particles, 
direct binding ELISA against DENV NS1 was performed.  
Day 1 
Round 3 biopanning glycerol stock were 16-streaked onto multiple 2YTAG agar plates. The plates 
were incubated overnight at 37 ˚C.  
Day 2 
90 single colonies were picked and inoculated into a 96 well microtitre plate with 150 μL of 
2YTAG in each well. Wells H7 to H12 were kept as sterile technique controls. The plate was 
incubated overnight at 37 ˚C whilst shaking at 180 rpm. 
Day 3 
A new plate with 150 μL of 2YTAG in each well was used to sub-culture 5 μL of the overnight 
culture in corresponding wells.  Glycerol was added at 20% final concentration to the overnight 
culture plate and was stored at -80 ˚C. The new sub-cultured plate was incubated for 3 hours at 37 
˚C whilst shaking at 180 rpm. To rescue the phage, a 50 μL 2YT broth volume containing 4 x 108 
pfu of M13KO7 helper phage was added to each well. The plate was incubated at 37 ˚C for 30 
minutes and then a further 30 minutes at 37 ˚C whilst shaking at 180 rpm. The plate was spun at 3 
200 x g for 20 minutes and the supernatant was discarded. The bacterial pellets were resuspended in 
200 μL 2YTAK and incubated overnight at 30 ˚C whilst shaking at 180 rpm. 
200 µL of purified DENV1-4 NS1 was diluted to 3 µg/mL in PBS (Lonza), and used to coat the 
wells of a MaxiSorp plate (NUNC). The plate was incubated overnight at 4 ˚C.  
Day 4 
Soluble phage particles were harvested by centrifugation of the overnight culture plate at 3 200 x g 
for 10 minutes. The supernatants were transferred into a new microtitre plate in corresponding 
wells.  
The unbound DENV NS1 was discarded. This was followed by three consecutive washes with PBS-
T. The plate was blocked for 1 hour using 10% M-PBS and then the blocking buffer was discarded. 
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100 µL of the phage supernatants, diluted 1:1 in the blocking buffer, was added to relevant wells.  
Following a 1 hour incubation, three washes with PBS-T were performed. Probing for phage 
binding was performed with 200 µL of HRP-conjugated anti-M13 (GE Healthcare) diluted to 0.1 
µg/mL in 10% M-PBS. Three final washes with PBS-T were performed, then 100 µL TMB 
substrate (Sigma Aldrich) was added to develop the chromogenic signal. The reaction was stopped 
with 2N sulphuric acid and the absorbance at 450 nm was measured. 
2.2.6 SEQUENCING OF PHAGEMIDS 
Glycerol stocks of relevant clones were streaked out on a 2YTAG agar plate and incubated 
overnight at 37 ˚C. The next day, a single colony was picked with a sterile loop and used to 
inoculate 5 mL 2YTAG broth. The culture was incubated at 37 ˚C overnight while shaking at 220 
rpm. The next day, phagemid DNA was extracted using HiYield™ Plasmid Mini Kit (Real Biotech 
Corporation) as per the manufacturer’s instructions. The concentration of the phagemid DNA was 
determined using the NanoDrop 1000 (Thermo Scientific). 12 μL total volume reactions with 600 
ng of phagemid DNA and 1 μL of 10 μM working stock concentration of the appropriate phagemid-
specific forward or reverse primers (Table 2.1 Primers for sequencing of pahgemid-encoded 
antibody fragments) were sent for Sanger Sequencing by the Australian Genome Research Facility 
(Brisbane). 
Table 2.1 Primers for sequencing of phagemid-encoded antibody fragments  
Phagemid Vector Primer 
pR2 For 5’-CAGGAAACAGCTATGAC-3’ 
pR2 Rev 3’-CCTCATACAGAAAATTC-5’ 
pHEN1 For 5’-CAGGAAACAGCTATGAC-3’ 
pHEN1 Rev 3’-CCTCATACAGAAAATTC-5’ 
pCES1 VL For 5’-TTATTCGCAATTCCTTTAGTTGTTCC-3’ 
pCES1 CL Rev 3’-GGCTGCCGTAGGCAATAGG-5’ 
pCES1 VH For 5’-GGCGCGCCAATTCTATTTCAAGG-3’ 
pCES1 CH Rev 3’-CCCATTCAGATCCTCTTCTGAGATGAG-5’ 
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2.2.7 QUIKCHANGE SITE DIRECTED MUTAGENESIS 
Clone D1C2 VH dAb sequence included within its sequence, a T-A-G amber stop codon. To avoid 
expression of a truncated polypeptide in non-suppresor expression hosts, a single point mutation 
was performed to allow coding for a glutamine residue (C-A-G) instead. This change was 
performed using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) according 
to manufacturer’s instructions. Two primers were designed to effect the relevant mutation. 
QuikChange Mutagenesis 
20 ng DNA template 
125 ng forward primer 
125 ng reverse primer  
1μL dNTP mix (Bioline) 
25U Pfu Turbo DNA polymerase 
10 x reaction buffer 
H2O to 50 μL total volume 
 
Forward primer 5’ – GAGTGGGTATCAGGCATTCAGGTGCAAAACGGTAGC – 3’ 
Reverse primer 3’ – GCTACCGTTTTGCACCTGAATGCCTGATACCCACTC – 5’ 
 
 
PCR Cycling Conditions 
95 ˚C – 30 seconds 
12 cycles of: 
95 ˚C – 30 seconds 
55˚C – 30 seconds 
68˚C – 5.5 minutes 
4˚C – hold 
 
DpnI digestion of parental phagemid was performed by gently mixing 10 units of DpnI restriction 
endonuclease with the PCR amplification reaction. The mixture was centrifuged briefly and then 
incubated for 1 hour at 37 ˚C. 
The DpnI digested plasmid was transformed into XL1-Blue Supercompetent Cells (Stratagene). 50 
μL of the cells were incubated on ice for 30 minutes with 5 μL of DpnI treated DNA. The cells 
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were heat pulsed at 42 ˚C for 45 seconds and then returned to ice for 2 minutes. 500 μL of SOC 
medium was added to the cells which were incubated at 37 ˚C for 1 hour while shaking at 220 rpm. 
100 μL of the transformation reaction was spread on a lysogeny broth agar plate supplemented with 
ampicillin and incubated overnight at 37 ˚C. 
Confirmation of the incorporation of the desired mutation was performed by sequencing of the 
phagemid DNA from a few colonies picked from the overnight agar plate. 
 
2.2.8 PERIPLASMIC EXPRESSION OF SOLUBLE ANTIBODY FRAGMENTS 
Day 1 
A scraping of HB2151 non-supressor strain glycerol stock was 16-streaked onto a LB agar plate. 
The plate was incubated for 10 hours at 37 ˚C.  
Day 2  
10 mL of LB was inoculated with a single colony of HB2151. The culture was incubated overnight 
at 37 ˚C while shaking at 220 rpm.  
Day 3 
250 μL of the overnight culture was added to 10 mL of LB and incubated at 37 ˚C whilst shaking at 
220 rpm until OD600 of between 0.6 and 0.8 is reached as measured on the BioPhotometer 
(Eppendorf). Ten, ten-fold serial dilutions of purified phage from the relevant clone were made in 
PBS. 100 μL of the HB2151 culture was added to each dilution. To infect the bacteria with phage, 
the mixtures were incubated at 37 ˚C for 30 minutes. 20 μL of the mixtures that correspond with 
phage dilutions 10-5 up to 10-10 were spread on LBAG plates and incubated overnight at 37 ˚C. 
Day 4 
A single colony of infected HB2151 was picked from a plate with an appropriate dilution of phage 
that yielded separate single colonies. The colony was used to inoculate 10 mL LBAG and incubated 
overnight at 37 ˚C. 
Day 5  
1 mL of the overnight culture was stocked by adding glycerol to a final concentration of 20%. The 
glycerol stocks were stored at - 80 ˚C.  
 46 
 
3.5 mL of the overnight culture was also added to 350 mL LBAG and incubated at 37 ˚C whilst 
shaking at 220 rpm until OD600 of between 0.8 and 0.9. The bacterial cells were harvested by 
centrifugation at 1 500 x g for 10 minutes. The supernatant was discarded and the pellet 
resuspended in the same volume of LBSA with isopropyl-beta-D-thiogalactopyranoside (IPTG) at a 
final concentration of 0.2 mM. The culture was incubated for 16 hours at room temperature whilst 
shaking at 180 rpm. 
Day 6 
The bacterial cells were collected from the culture by centrifugation at 3 200 x g for 20 minutes. 
The supernatant was decanted and kept at 4 ˚C. The cells in the bacterial pellet were gently lysed 
with cold TES buffer (200 mM Tris HCl, 20% sucrose, 1 mM EDTA, pH 8.0) by resuspending and 
shaking at 180 rpm whilst on ice for 1 hour. The cell suspension was then centrifuged at 10 000 x g 
for 40 minutes at 4 ˚C. The supernatant, made up of the soluble periplasmic extract was then pooled 
with the cell culture supernatant and then subjected to appropriate Affinity Chromatography 
Purification 2.2.12. 
2.2.9 REFORMATTING OF ANTIBODY FRAGMENTS INTO HUMAN IGG1 
The In-Fusion® HD Cloning Kit (Clontech) was used to enable ligation-free insertion of variable 
regions of the isolated antibody fragments into separate mAbXpress vectors (15) that code for 
human constant regions of either the κ/λ light chains or the IgG1 heavy chain.  
Variable gene-specific (VH and VL) primers (Geneworks) with 15 bp extensions complementary to 
the expression vector ends were used to PCR amplify the variable genes from the phagemid vectors. 
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PCR 
DNA Template 0.1 pg – 20 ng 
200 nM Forward Primer 
200 nM Reverse Primer 
10 x AccuPrime™ PCR Buffer (Life Technologies) 5 µL 
AccuPrime™ Taq High Fidelity (Life Technologies)  0.2 µL 
Nuclease-Free Water to 50 µL 
 
PCR Cycling Conditions 
95 ˚C – 2 minutes 
30 cycles of: 
95 ˚C – 15 seconds 
55 ˚C – 15 seconds 
68 ˚C – 30 seconds 
68 ˚C – 7 minutes 
4 ˚C – hold 
 
Part of the PCR reaction volume was used to analyze the amplification products by agarose gel 
electrophoresis.  
5 µL of the PCR reaction was treated with 2 µL of Cloning Enhancer (Clontech). The mixture was 
incubated at 37 ˚C for 15 minutes and then 80 ˚C for 15 minutes in a thermal cycler. 
 κ light chain (NBF304) Figure 2.1, λ light chain (NBF326) Figure 2.4 and IgG1 heavy chain 
vectors (NBF305) Figure 2.5 were linearized using a single endonuclease restriction enzyme: SacI 
(NEB).  
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Figure 2.3 Plasmid map of κ light chain vector (NBF304). SacI linearization site used for 
In-Fusion® cloning is shown between the signal peptide and the kappa light chain constant 
gene sequence. 
 
Figure 2.4 Plasmid map of λ light chain vector (NBF326). SacI linearization site used for 
In-Fusion® cloning is shown upstream of the lambda light chain constant gene sequence. 
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Figure 2.5 Plasmid map of IgG1 heavy chain vector (NBF305). SacI linearization site used 
for In-Fusion® cloning is shown between the signal peptide and the IgG1 constant gene 
sequence. 
 
Restriction Endonuclease Digest 
1 µg DNA Vector  
10 x Buffer 4 (NEB) 2 µL 
10 x BSA 2 µL 
SacI (NEB) 10 units  
Nuclease-Free Water to 20 µL Volume  
Incubate 37 C for 4hours 
 
The linearized vector was electrophoresed on a 1% agarose gel and the appropriate band was 
excised and purified using the QIAEX II Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. 
Cloning enhancer-treated PCR products were cloned into the linearized vectors using In-Fusion® 
HD Enzyme (Clontech). 
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In-Fusion® Cloning 
Linearized Vector 50-200 ng  
Cloning enhancer-treated PCR product 4 µL 
5 x In-Fusion® HD Enzyme Premix 
Nuclease-Free Water to 10 µL Volume 
 
All components were incubated at 50 ˚C for 15 minutes and then used for transformation of Gold 
efficiency, α-Select Chemically Competent Cells (Bioline) according to manufacturer’s instructions. 
100 µL of the transformation reaction was spread on LB-Kanamycin agar plates and incubated 
overnight at 37 ˚C. 
Colonies that grew overnight were screened by colony PCR. 
Colony PCR 
Bacterial Colony – DNA Template 
100 nM Forward Primer 
100 nM Reverse Primer 
Platinum PCR SuperMix High Fidelity (Life Technologies) 10 µL 
 
In all instances the forward primer was mAbX Seq For. The reverse primers were mAbX Seq hG1 
Rev, mAbX Seq hκ Rev or mAbX Seq hλ Rev. 
PCR Cycling Conditions 
95 ˚C – 2 minutes 
25 cycles of: 
95 ˚C – 15 seconds 
55 ˚C – 15 seconds 
68 ˚C – 45 seconds 
68 ˚C – 1 minute 
4 ˚C – hold 
 
The presence of an insert of an appropriate size during colony PCR screening was confirmed by 
agarose gel electrophoresis. Relevant colonies were grown overnight in 5 mL LB broth 
supplemented with kanamycin. The cultures were grown at 37 ˚C whilst shaking at 220 rpm. The 
PureLink™ Quick Plasmid Miniprep Kit (Life technologies) was used to purify plasmid DNA for 
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Sanger sequencing at AGRF (Sequencing of Plasmids 2.2.6) The primers used for colony PCR 
screening were also utilized for sequencing. 
Following correct sequence confirmation, PureLink™ HiPure Plasmid Filter Maxiprep Kits (Life 
Technologies) were used for DNA purification from a 400 mL LB broth and kanamycin culture. 
The DNA was used for mammalian cell expression of IgG1 antibodies.  
2.2.10 REFORMATTING OF ANTIBODY FRAGMENTS INTO HUMAN DAB FC 
VH dAb D1C2 was sub-cloned into a proprietary dAb Fc mammalian expression vector (NBF218) 
using endonuclease restriction sites BamHI and NheI.  This vector contains an immunoglobulin 
kappa leader sequence, followed by BamHI and NheI sites for insertion of a gene of interest, 
followed by a human Fc coding region.  The vector carries the β–lactamase gene that confers 
ampicillin resistance for propagation in E. coli. 
PCR amplification of the VH dAb from phagemid DNA utilized primers that introduced the BamHI 
and NheI restriction endonuclease sites.  
VH dAb D1C2 For 5’- GTGCCCGGATCCACCGGCGAGGTGCAGCTGTTGGAGTC – 3’ 
VH dAb D1C2 Rev 3’ – GGGACCAGTGGCAGAGCTCGCGATCGTGGGTG – 5’  
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PCR 
50 ng Phagemid DNA Template 
200 nM Forward Primer 
200 nM Reverse Primer 
Platinum PCR SuperMix High Fidelity (Life Technologies) 50 µL 
 
PCR Cycling Conditions 
95 ˚C – 2 minutes 
25 cycles of: 
95 ˚C – 15 seconds 
55 ˚C – 15 seconds 
68 ˚C – 45 seconds 
68 ˚C – 1 minute 
4 ˚C – hold 
 
The PCR products and the NBF218 vector were both subjected to restriction endonuclease digestion 
with BamHI and NheI. Digested insert and vector were both run on a 1% agarose gel at 90 V for 25 
minutes. The appropriate bands were excised and purified using the Wizard SV Gel and PCR 
Clean-Up System (Promega) 
 
Restriction Endonuclease Digest 
3 µg NBF218 Vector OR 0.5 μg VH dAb D1C2 insert 
10 x CutSmart™ buffer (NEB) 5 μL 
BamHI (NEB) 20 units 
NheI (NEB) 20 units 
Nuclease-Free Water to 50 µL Volume 
Incubate 37 C for 8h 
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Ligation of the NBF218 vector and VH dAb D1C2 insert was performed using Rapid DNA Ligation 
Kit (Roche). 
Ligation Conditions 
150 ng digested insert VH dAb D1C2 
50 ng digested and gel purified NBF218 Vector 
1uL 5x DNA Dilution Buffer 
5uL 2X DNA Ligation Buffer 
0.5uL DNA Ligase 
10 µL total volume reaction was incubated at room temperature for 15 minutes and then 2 µL  used 
for transformation of Gold efficiency, α-Select Chemically Competent Cells (Bioline) according to 
manufacturer’s instructions. 
100 µL of the transformation reaction was spread on LB-Ampicillin agar plates and incubated 
overnight at 37 ˚C. 
Colonies that grew overnight were screened by colony PCR as previously outlined for Reformatting 
of Antibody Fragments into Human IgG1 2.2.9. The same clone-specific primers were used for both 
PCR amplification and sequencing to ascertain that the correct dAb sequence was integrated into 
the NBF218 vector. 
Following correct sequence confirmation, PureLink™ HiPure Plasmid Filter Maxiprep Kits (Life 
Technologies) were used for DNA purification from a 400 mL LB broth and ampicillin culture. The 
DNA was used for mammalian cell expression of VH dAb Fc.  
 
2.2.11 MAMMALIAN CELL EXPRESSION OF ANTIBODIES 
For expression of fully assembled IgG1, a κ or λ light chain plasmid and a IgG1 heavy chain 
plasmid were co-transfected into Chinese hamster ovary cells adapted for suspension culture (CHO-
S). For expression of VH dAb Fc, the NBF218 vector was singly transfected into CHO-S cells. 
A cell density of 3.0 x 106 CHO-S cells per mL cultured in CD-CHO medium (Life Technologies) 
supplemented with 8 mM GlutaMAX™ (Life Technologies) was used for transfection. Transfection 
complexes were prepared using serum-free complex medium OptiPRO™ (Life Technologies), 
transfection reagent PEIpro™ (Polyplus transfection) and plasmid DNA.  
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Transfection Complexes for 1 L Total Culture Volume 
267 mL of 3.0 x 106 CHO-S cells/mL 
67 mL OptiPRO™ 
2.1 mL PEIpro™ 
533 μg plasmid DNA (266 µg per LC/HC plasmid) 
 
Complexes were prepared in sterile 50 mL tubes (BD) by adding plasmid DNA into half the 
required OptiPRO™ (33.5 mL) and adding PEIpro™ to the other half the required volume of 
OptiPRO™ (33.5 mL). The two volumes of OptiPRO™ with both DNA and PEIpro™ were gently 
combined and incubated at room temperature for 15 minutes. The complexes were then added to the 
CHO-S cells and incubated at 37 ˚C for 4 hours in a humidified 7.5% CO2 incubator whilst shaking 
at 130 rpm. 
After the 4 hour incubation, the transfected CHO-S cells were subjected to a 1 : 2 dilution post-
transfection feed. 512 mL of fresh CD-CHO with 8 mM GlutaMAX™ (Life Technologies)  was 
supplemented with 75 mL Efficient Feed A  (Life Technologies), 75 mL Efficient Feed B  (Life 
Technologies), and 4 mL Anti-Clumping Agent (Gibco). 
The fed culture was incubated at a hypothermic 32 ˚C in a humidified, 7.5% CO2 incubator whilst 
shaking at 130 rpm. Antibodies were secreted into the culture media during the continuous culture 
which was maintained for up to 14 days or until cell viability dropped to 70%. 
2.2.12 AFFINITY CHROMATOGRAPHY PURIFICATION 
Affinity chromatography purification was performed using the AKTA Explorer chromatography 
system (GE Healthcare). Either a 5 mL HiTrap® MabSelect™ SuRe column (GE Healthcare) or a 5 
mL HisTrap™ Excel column (GE Healthcare) was used for purification depending on the affinity 
tags that were present. The system and columns were cleaned by flushing with 0.5 M NaOH 
followed by neutralization with 1 M Tris HCl pH 8.3. 
HisTrap™ Excel column (GE Healthcare) 
The system and column were equilibrated using a pH 7.4 basic buffer made with 20 mM Na2HPO4 
and 500 mM NaCl. Clarified supernatant [ultra-centrifugation or double filtration with Sartobran 
P300, 0.45/0.2 µm capsule filters (Sartorium Stedim)] was pH adjusted to 7.1 and  loaded onto the 
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column at a flow rate of 1 mL per minute. Elution was performed using basic buffer that had been 
supplemented with a gradient of imidazole concentrations (50 mM, 300 mM and 500 mM). The 
eluted product was desalted, buffer-exchanged and concentrated using Macrosep Advance 
Centrifugal Devices (Pall) of an appropriate molecular weight cut-off.   
HiTrap® MabSelect™ SuRe (GE Healthcare)  
Packed recombinant Protein A Sepharose Fast Flow (GE Healthcare) 
The system and column were equilibrated using 1 x PBS (Lonza). Clarified supernatant [ultra-
centrifugation or double filtration with Sartobran P300, 0.45/0.2 µm capsule filters (Sartorium 
Stedim)] was pH adjusted to 7.1 and was loaded onto the column at a flow rate of 1 mL per minute. 
Elution was performed using 0.1 M glycine pH 2.7 followed by neutralization with 1/10 total 
elution volume of 1 M Tris HCl pH 8.3. The neutralized product was desalted, buffer-exchanged 
and concentrated using Macrosep Advance Centrifugal Devices (Pall) of an appropriate molecular 
weight cut-off.   
2.2.13 DIRECT ELISA 
To determine the binding reactivity of soluble antibody fragments produced by periplasmic 
expression in HB2151 bacterial cells or antibodies expressed in CHO-S culture, a direct binding 
ELISA against DENV NS1 was performed. 200 µL of purified recombinant DENV1-4 NS1 was 
diluted to 3 µg/mL in PBS. The diluted antigen was coated on a MaxiSorp plate (Nunc) overnight at 
4˚C. The unbound protein was discarded and followed by 3 consecutive washes with PBS-T. The 
plate was blocked using 400 µL of 2% M-PBS. The blocking buffer was discarded after incubation 
for 1 hour at room temperature. 200 µL of 3 µg/mL soluble antibody fragments or reformatted 
antibodies diluted in 2% M-PBS were added to relevant wells.  Following one hour incubation, 
three washes with PBS-T were performed. The plate was probed with 200 µL of HRP-conjugated 
anti-human lambda/anti-human kappa (The Binding Site) or HRP-conjugated anti human c-Myc 
(Miltenyi Biotec) or HRP-conjugated anti human IgG [γ chain specific] (Sigma Aldrich) diluted to 
0.1 µg/mL in 2% M-PBS. The plate was incubated for an hour at room temperature. Three final 
washes with PBS-T were performed and then 100 µL TMB substrate (Sigma Aldrich) was added to 
develop the chromogenic signal. The reaction was stopped with 2N sulphuric acid and the 
absorbance at 450 nm was measured.  
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2.3 RESULTS 
The success of a biopanning campaign is determined by the enrichment of target-specific binders 
from the phage displayed antibody library in iterative biopanning cycles as well as the isolation of 
unique monoclonal antibody fragments. A comparison of the number of titred phage particles input 
into the biopanning process versus the number of cells that were infected by the eluted phage 
particles (output) was performed to determine enrichment between each successive biopanning 
round. A monoclonal phage ELISA was performed with up to 90 clones displaying varying 
antibody fragments that were randomly screened for their ability to recognize their target antigen. 
Linkage of phenotype and genotype in phage display systems allowed for the phagemid DNA of the 
identified clones to be sequenced in order to deduce the amino acid sequence of the antibody 
fragments that bind the target antigen. Clustal Omega (EMBL-EBI) was used to determine the 
uniqueness of each isolated clone by performing amino acid sequence alignments. IMGT/V-
QUEST online software was used to facilitate the identification of the complementarity determining 
regions (CDRs), and variable gene families of each heavy and/or light chain by using the clones’ 
nucleotide sequences.  
In the phage display system the antibody fragment is tethered to the bacteriophage as a fusion 
protein with gIIIp. To determine the ability of the antibody fragment to recognize the target antigen 
on its own, periplasmic expression of the soluble antibody fragments was performed using non-
suppressor E. coli strain HB2151. Furthermore, the scFv and Fab were reformatted into fully 
assembled IgG1 and VH dAb into VH dAb Fc. The reformatted antibodies were expressed in CHO-S 
cells. The reactivity of all three formats per clone was evaluated.  
2.3.1 SUBTRACTIVE BIOPANNING FOR ISOLATION OF SEROTYPE-SPECIFIC BINDERS 
OF DENV NS1 
Two phage libraries displaying scFv or Fab antibody fragments were interrogated for binders to 
DENV NS1. A subtractive biopanning strategy with up to four iterative rounds of biopanning of 
each library employed to isolate serotype-specific binders against DENV NS1. Between rounds of 
biopanning, an enrichment of target specific phage is expected. The number of target-specific phage 
generally showed a positive enrichment trend through iterative rounds of biopanning for serotype-
specific binders (Table 1). Only three rounds of subtractive biopanning were performed for target 
antigens DENV-2, DENV-3 and DENV-4 NS1. Meanwhile, four rounds of biopanning were 
required to sufficiently enrich for DENV-1 NS1 binders.  
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Table 2.2 Enrichment of serotype-specific phage. A specific amount of library phage 
particles were exposed to the target antigen in the first round (rnd) of biopanning. The 
amount of phage particles bound to the antigen were enumerated by infecting and titering 
bacterial cells. The infected bacterial cells were amplified and phage particles produced 
and purified. 10-fold less phage was input into the next round of biopanning and the 
output determined. The product of ratios before and after selection was used to calculate 
the enrichment factor between sequential rounds of biopanning. 
  
 58 
 
Serotype-Specific 
DENV-1 NS1(scFv) 
Input Output Fold Enrichment 
Rnd 1 1.0 x 1012 7.2 x 105 - 
Rnd 2 1.0 x 1011 2.0 x 106 30 
Rnd3 1.0 x 1010 1.3 x 104 0.063 
Rnd 4 1.0 x 109 1.6 x 104 12.5 
Serotype-Specific 
DENV-1 NS1(Fab) 
Input Output Fold Enrichment 
Rnd 1 1.0 x 1012 3.2 x 105 - 
Rnd 2 1.0 x 1011 1.8 x 106 54 
Rnd3 1.0 x 1010 1.2 x 105 0.70 
Rnd 4 1.0 x 109 9.7 x 103 0.79 
Serotype-Specific 
DENV-2 NS1(scFv) 
Input Output Fold Enrichment 
Rnd 1 2.05 x 1012 1.9 x 108 - 
Rnd 2 4.2 x 1011 8.0 x 106 0.21 
Rnd3 1.1 x 1010 1.4 x 106 6.68 
Serotype-Specific 
DENV-2 NS1(Fab) 
Input Output Fold Enrichment 
Rnd 1 1.8 x 1012 8.0 x 107 - 
Rnd 2 1.7 x 1011 2.1 x 105 0.02 
Rnd3 8.6 x 109 9.8 x 106 922 
Serotype-Specific 
DENV-3 NS1(scFv) 
Input Output Fold Enrichment 
Rnd 1 2.1 x 1012 3.3 x 108 - 
Rnd 2 9.4 x 1011 1.6 x 107 0.11 
Rnd3 1.0 x 1010 1.5 x 106 8.8 
Serotype-Specific 
DENV-3 NS1(Fab) 
Input Output Fold Enrichment 
Rnd 1 1.8 x 1012 7.8 x 107 - 
Rnd 2 1.5 x 1011 9.5 x 105 0.15 
Rnd3 6.9 x 1010 5.0 x 106 11 
Serotype-Specific 
DENV-4 NS1(scFv) 
Input Output Fold Enrichment 
Rnd 1 2.1 x 1012 1.3 x 108 - 
Rnd 2 6.0 x 1011 2.5 x 105 6.6 x 10-3 
Rnd3 9.8 x 1010 9.1 x 105 22 
Serotype-Specific 
DENV-4 NS1(Fab) 
Input Output Fold Enrichment 
Rnd 1 1.8 x 1012 1.2 x 108 - 
Rnd 2 1.3 x 1011 4.0 x 105 0.05 
Rnd3 2.0 x 1010 1.0 x 106 16.3 
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Because two different libraries were biopanned for binders against NS1 from each DENV serotype, 
the different subtractive biopanning protocols were designated campaign numbers which were used 
to denote clone prefixes for easy identification of the source of the clones. The glycerol stocks 
containing phage particles that were rescued from the last rounds of each subtractive biopanning 
campaign were streaked out on agar plates and up to 90 individual clones were randomly picked 
and screened for their ability to recognize NS1 from the target DENV serotype in a monoclonal 
phage ELISA. There was a dominance of target-specific clones isolated from the scFv library that 
was biopanned for serotype-specific binders against DENV-1 NS1 (Figure 2.6). Serotype-specific 
binders against DENV-2 NS1 [2C3, 4A1, 4B8, 4C11] (Figure 2.9), DENV-3 NS1 [7G11] (Figure 
2.11) and DENV-4 NS1 [6A5, 6A7, 6G8] (Figure 2.12) however, were in much less abundance. 
Both scFv and Fab libraries yielded an assortment of binders with varied reactivities. For example, 
binders against DENV-1 and DENV-2 NS1 (8B5, 8B7 and H2) were isolated from the Fab library 
when binders against DENV-1 NS1 were sought (Figure 2.7). Pan-reactive binders 1A1, 1D4, 1D12 
(Figure 2.10), 3A10, 3B6, 3D3, 3D12, 3E6, 3F10 (Figure 2.13), 4A5 (Figure 2.9), 6H2 (Figure 
2.12), 7B5, 7C2 and 7E5 (Figure 2.11) were also isolated despite using a subtractive strategy to 
deplete binders against homologous regions on NS1 from all four DENV serotypes.  
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Figure 2.6 Recognition of DENV-1 NS1 by phage displayed fragments from the scFv library in a direct ELISA (Campaign 9). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the fourth 
round of subtractive biopanning against DENV-1 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody 
against M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.7 Recognition of DENV-1 NS1 by phage displayed fragments from the Fab library in a direct ELISA (Campaign 8). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the fourth 
round of subtractive biopanning against DENV-1 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody 
against M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.8 Recognition of DENV-2 NS1 by phage displayed fragments from the scFv library in a direct ELISA (Campaign 2).  NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third round 
of subtractive biopanning against DENV-2 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against 
M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.9 Recognition of DENV-2 NS1 by phage displayed fragments from the Fab library in a direct ELISA (Campaign 4). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third round 
of subtractive biopanning against DENV-2 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against 
M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.10 Recognition of DENV-3 NS1 by phage displayed fragments from the scFv library in a direct ELISA (Campaign 1). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third round 
of subtractive biopanning against DENV-3 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against 
M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.11 Recognition of DENV-3 NS1 by phage displayed fragments from the Fab library in a direct ELISA (Campaign 7). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third round 
of subtractive biopanning against DENV-3 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against 
M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
A1
 
A3
 
A5
 
A7
 
A9
 
A1
1 B1
 
B3
 
B5
 
B7
 
B9
 
B1
1 C1
 
C3
 
C5
 
C7
 
C9
 
C1
1 D1
 
D3
 
D5
 
D7
 
D9
 
D1
1 E1
 
E3
 
E5
 
E7
 
E9
 
E1
1 F1
 
F3
 
F5
 
F7
 
F9
 
F1
1 G1
 
G3
 
G5
 
G7
 
G9
 
G1
1 H1
 
H3
 
H5
 
Ab
so
rb
an
ce
 (4
50
 n
m
)  
Clone Identifier 
DENV-1 NS1 
DENV-2 NS1 
DENV-3 NS1 
DENV-4 NS1 
 66 
 
 
Figure 2.12 Recognition of DENV-4 NS1 by phage displayed fragments from the scFv library in a direct ELISA (Campaign 6).  NS1 
from each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third 
round of subtractive biopanning against DENV-4 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody 
against M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Figure 2.13 Recognition of DENV-4 NS1 by phage displayed fragments from the Fab library in a direct ELISA (Campaign 3). NS1 from 
each DENV serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the third round 
of subtractive biopanning against DENV-4 NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against 
M13 bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB. 
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Serotype-specific and pan-reactive binders that were isolated from the different biopanning 
campaigns using both scFv and Fab libraries were sequenced to determine the uniqueness of the 
clones. 5 unique serotype-specific (9H2 α DENV-NS1, 4C11 α DENV-2 NS1, 7G11 α DENV-3, 
6A5 α DENV NS1 and 6A7 α DENV-4 NS1) and 11 pan-reactive antibodies were identified. The 
VH and VL CDR3 regions as well as the variable gene families of the unique clones were 
determined (Table 2). The heavy and light chain CDR sequences of the serotype-specific binders 
showed diversity in length and composition. On the contrary, the VH CDR3 sequence 
ARGRDDFWSGYYFDDAFDI from the Fab library dominated pan-reactive recognition regardless 
of variations in the light chain CDR sequences. This indicated that the pan-reactive interaction 
between the antigen and the antibody may not be dependent on cooperation between both variable 
domains. The variable regions of the isolated binders were derived from mostly VH1 and VH3 gene 
families and six VL gene families of both kappa and lambda light chains (Vκ1, Vκ3, Vλ1, Vλ2, Vλ3 
and Vλ6).  
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Table 2.3 Variable gene families and VH CDR3 and VL CDR3 sequences of unique antibody fragments from subtractive biopanning 
against DENV NS1. The variable gene families and CDRs were determined by inputting the clone nucleotide sequences into the 
Immunogenetics (IMGT)-V-QUEST software [http://imgt.org/IMGT_vquest/share/textes/]. (f) and (s) following clone identifiers denote 
isolation from either the Fab or scFv library. Clone 9 H2 is DENV-1 NS1 specific, clone 4 C11 is DENV-2 NS1 specific, clone 7 G11 is 
DENV-3 NS1 specific, and clones 6 A5 and 6 A7 are DENV-4 NS1 specific. Clones  1 A1, 1 D4, 3 B6, 3 D12, 3 E6, 4 A5, 5 A3, 6 H2, 7 
C2 and 7 E5 recognize NS1 of all four DENV serotypes. 
 
CLONE VH Family VH CDR3 VL Family VL CDR3 
1A1 (s)  VH1 G S - - - - Y G G N S G - - F D Y - - - - - Vλ3 S S R D N R G T H R W V 
1D4 (s)  VH1 G F R - A T V D Y Y G - - - M D V - - - - - Vκ1 Q K L S S Y P L T - - - 
3B6 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vκ1 Q - - - Q S Y S T P W T 
3D12 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vλ1 G T W D S S L R G - - V 
3E6 (f)  VH3 A R D H G D F W S G Y F V N Y Y Y Y G M D V Vλ6 Q S Y D S S G Q - - - V 
4A5 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vκ1 Q - - - Q S H S S P Y T 
4C11 (f)  VH3 A R D T - - - - - - - - - - - A M V I L D Y Vλ1 Q S Y D S S L G G F Y V 
5A3 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vκ1 Q - - - Q S Y S T P R T 
6A5 (s)  VH3 G F R K D S S G W Y E I T P I D Y - - - - - Vκ1 Q K L S S Y P L T - - - 
6A7 (s)  VH3 - - - - - - G G G L E L R T F Q H - - - - - Vλ3 K S R D S S G N Y - - V 
6H2 (s)  VH3 D S N D F W S G Y F D P G E F D Y - - - - - Vλ2 S S Y A G N R N L - - V 
7C2 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vκ1 Q - - - Q S Y S T - R T 
7E5 (f)  VH1 A R G R D D F W S G - - - Y Y F D D A F D I Vκ3 Q - - - Q Y G N S - R T 
7G11 (f)  VH4 A  R G R G - - - - - - - - - - - - - G S Y Y Vλ1 E T W D D N L S - A V V 
9H2 (s)  VH1 A S S - - S S S F Y Y Y Y G M D V - - - - - Vλ3 Q V W - D S S S D H Q V 
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Evaluation of the binding reactivities of phage displayed antibody fragments, soluble scFv/Fab or 
reformatted IgG1 antibodies showed that phage displayed antibody fragments and IgG1 had 
identical immune-reactivity to DENV NS1 (Figure 2.14). Soluble antibody fragments produced by 
periplasmic expression in HB2151 cells did not always yield a binding response due to variability in 
expression; however when expression was sufficient the expected response to the target antigen was 
observed.  
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Figure 2.14 Immunoreactivity of a panel of serotype-specific and pan-reactive phage 
particles, scFv (s)/Fab (f) and IgG1 to DENV NS1. NS1 from all four DENV serotypes 
was immobilized on a polystyrene plate. Phage particles (top panel), scFv/Fab (middle 
panel) or IgG (bottom panel) isolated from a subtractive biopanning strategy that sought 
serotype-reactive binders to DENV NS1 were added to the immobilized antigen. The 
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reactivity of the clones in their different formats was determined by the absorbance value 
measured after probing with HRP-conjugated α–M13 (top panel), HRP-conjugated α-
human κ/λ (middle panel) or HRP-conjugated α-human γ-Fc (bottom panel). The serotype-
specific antibodies acted as negative controls for NS1 from other DENV serotypes. 
 
2.3.2 DIRECT BIOPANNING ON IMMOBILIZED ANTIGEN FOR  ISOLATION OF PAN-
REACTIVE DENV NS1 BINDERS 
Despite being designed for the isolation of serotype-specific antibody fragments, many pan-reactive 
binders against DENV-NS1 were still isolated in the subtractive biopanning strategy described 
above (Figure 2.14).  However, due to the design of the panning strategy, it was resolved that these 
pan-reactive antibodies would likely have low affinity, as high affinity binders would be lost in the 
subtractive steps.  The scFv library was therefore specifically interrogated for pan-reactive binders 
against DENV NS1. The Fab library was excluded from this biopanning campaign because of the 
previous dominance of a single VH chain in the pan-reactive clones isolated from the subtractive 
biopanning strategy. It was posited that the high frequency of that VH chain originating from a 
common B-cell clone, could perhaps be predictive of an immune-dominant response in the library 
repertoire which would still remain apparent. 
NS1 from a single serotype of DENV was immobilized on polystyrene tubes in each round of 
biopanning. 1.0 x 1013 purified phage particles from the scFv library were used for the first round of 
biopanning. Ten-fold less phage were used in each subsequent round of biopanning. Enumeration of 
eluted phage from each iteration of biopanning showed high enrichment of pan-reactive binders 
against DENV NS1 (Table 2.4). 
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Table 2.4 Enrichment of pan-reactive phage. A specific amount of library phage particles 
were exposed to the target antigen in the first round of biopanning. The amount of phage 
particles bound to the antigen were enumerated by infecting and titering bacterial cells. 
The infected bacterial cells were amplified and phage particles produced and purified. 10-
fold less phage was input into the next round of biopanning and the output determined. 
The product of ratios before and after selection was used to calculate the enrichment factor 
between sequential rounds of biopanning. 
 
Pan-Reactive 
DENV-1, 2, 3 and 4 NS1 
(scFv) 
 
Input Output Fold Enrichment 
Rnd 1 1.0 x 1013 9.0 x 105 - 
Rnd 2 1.0 x 1012 9.0 x 105 10 
Rnd3 1.0 x 1011 9.9 x 105 110 
Rnd 4 1.0 x 1010 1.20x106 12 
 
90 scFv binders that were rescued from the fourth round of biopanning were screened for their 
ability to recognize NS1 from all four DENV serotypes (Figure 2.15). A significant proportion of 
the isolated binders recognized DENV NS1. Sequencing of the clones revealed two dominant 
clones – A1 and A2 (Table 2.5). The heavy and light chain usage of the two clones was analyzed 
and showed use of VH3 and Vλ3 gene families for clone A1 while clone A2 utilized VH1 and Vλ1 
gene families. The VH CDR3 regions of the two clones showed sequence diversity while some 
modest homology of residues in the VL CDR3 regions was noted. 
An evaluation of the ability of A1 and A2 phage particles, soluble scFv or reformatted IgG to 
recognize DENV NS1 (Figure 2.16) showed a deficit in the ability of A1 soluble scFv to recognize 
DENV-3 NS1. A slight reduction in the ability of A2 soluble scFv to recognize DENV-1 and 
DENV-3 NS1 was also noted. Pan-reactive recognition of DENV NS1 by phage particles and 
reformatted IgG1 was again identical in this instance. 
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Figure 2.15 Recognition of DENV NS1 by phage displayed fragments from the scFv library in a direct ELISA. NS1 from each DENV 
serotype was immobilized onto four 96-well polystyrene plates. 90 single clone-derived phage particles from the fourth round of 
biopanning against DENV NS1 were added to respective wells on all four plates. An HRP-conjugated antibody against M13 
bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB.  
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Table 2.5 Variable gene families and VH CDR3 and VL CDR3 sequences of isolated pan-reactive antibody fragments against DENV-NS1. 
The variable gene families and CDRs were determined by inputting the clone nucleotide sequences into the Immunogenetics (IMGT)-V-
QUEST software [http://imgt.org/IMGT_vquest/share/textes/]. (s), following the clone identifiers denotes isolation from the scFv library.  
Clone VH Family     VH CDR3 VL Family VL CDR3 
A1 (s)  VH3 A K D S G D Y D F W S G Y Y T R W F D P Vλ3 N S R D S S G N H L V 
A2 (s)  VH1 A S G D F W S G H Y Y Y Y G M D V - - - Vλ1 G T W D S S L S V V V 
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Figure 2.16 Immunoreactivity of A1 and A2 phage particles, scFv and IgG1 to DENV 
NS1. NS1 from all four DENV serotypes was immobilized on a polystyrene plate. A1 and 
A2 phage particles (top panel), scFv (middle panel) or IgG (bottom panel) isolated from a 
biopanning strategy that sought pan-reactive binders to DENV NS1 were added to the 
immobilized antigen. The reactivity of the A1 and A2 clones in their different formats was 
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determined by the absorbance value measured after probing with an appropriate HRP-
conjugated secondary antibody. HRP-conjugated secondary antibody added to wells with 
just the immobilized antigen was used as the negative control. 
2.3.3 TANDEM BINDING BIOPANNING USING AN IMMUNE-DOMINANT ANTIBODY 
FOR ISOLATION OF PAN-REACTIVE DENV NS1 BINDERS 
Having isolated pan-reactive binders against DENV-NS1 from the scFv library, it was conceived 
that these antibodies may bind to the immune-dominant epitope which we sought to avoid in the 
DENV NS1 capture assay. To this end, a biopanning strategy was devised to first immobilize GUS-
2 on an immunotube. GUS-2 antibody binds the immune-dominant epitope and would be used to 
capture DENV NS1 in four biopanning campaigns against NS1 from each DENV serotype 
(designated campaign D1, D2, D3 and D4). A phage library displaying aggregation-resistant VH 
domains was the exposed to the GUS-2 captured DENV NS1. Three rounds of biopanning were 
performed and the enrichment of binders between sequential round of biopanning as measured by 
the ratio of phage input and phage output titre. The ratios in this instance were generally low (Table 
2.6).  
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Table 2.6 Enrichment of pan-reactive phage that bind non immune-dominant epitopes. A 
specific amount of library phage particles were exposed to the target antigen in the first 
round (rnd) of biopanning. The amount of phage particles bound to the antigen were 
enumerated by infection and then obtaining a titre of the infected bacterial cells. The 
infected bacterial cells were amplified and phage particles produced and purified. 10-fold 
less phage was input into the next round of biopanning and the output determined. The 
product of ratios before and after selection was used to calculate the enrichment factor 
between sequential rounds of biopanning. 
Pan-Reactive 
GUS2 → DENV-1 NS1 
(VH dAb) 
 
Input Output Fold Enrichment 
Rnd 1 3.0 x 1011 2.8 x 105 - 
Rnd 2 3.0 x 1010 3.5 x 104 1.3 
Rnd3 3.0 x 109 2.1 x 103 0.6 
Pan-Reactive 
GUS2 → DENV-2 NS1 
(VH dAb) 
 
Input Output Fold Enrichment 
Rnd 1 3.0 x 1011 2.7 x 105 - 
Rnd 2 3.0 x 1010 2.3 x 104 0.9 
Rnd3 3.0 x 109 5.0 x 103 2.2 
Pan-Reactive 
GUS2 → DENV-3 NS1 
(VH dAb) 
 
Input Output Fold Enrichment 
Rnd 1 3.0 x 1011 2.3 x 105 - 
Rnd 2 3.0 x 1010 7.0 x 103 0.3 
Rnd3 3.0 x 109 6.5 x 103 9.3 
Pan-Reactive 
GUS2 → DENV-4 NS1 
(VH dAb) 
 
Input Output Fold Enrichment 
Rnd 1 3.0 x 1011 2.1 x 105 - 
Rnd 2 3.0 x 1010 3.9 x 104 1.9 
Rnd3 3.0 x 109 6.0 x 102 0.2 
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Low enrichment notwithstanding, the output phage particles from the third round of biopanning in 
all four separate campaigns were screened for their ability to recognize DENV NS1 in monoclonal 
phage ELISAs. The monoclonal phage were also screened against GUS-2 in order to confirm that 
the isolated binders were not interacting with the murine antibody used for DENV NS1 capture. 
Pan-reactive antibodies against DENV NS1 were mainly isolated in the biopanning campaign that 
used GUS-2 to capture DENV-1 NS1 (Figure 2.17). Monoclonal phage isolated from the 
biopanning campaigns that captured DENV-3 NS1 (Figure 2.19) and DENV-4 NS1 (Figure 2.20) 
dominantly had cross-reactivity with GUS-2.  
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Figure 2.17 Recognition of DENV NS1 by phage displayed fragments from the VH dAb library in a direct ELISA (Campaign D1). Five 
96-well polystyrene plates had their wells coated with one of DENV-1 NS1, DENV-2 NS1, DENV-3 NS1, DENV-4 NS1or GUS-2 (an 
antibody that was used for capture of DENV NS1 in the biopanning strategy). 90 single clone-derived phage particles from the third 
round of biopanning against DENV-1 NS1 were added to respective wells on all five plates. An HRP-conjugated antibody against M13 
bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB.  
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Figure 2.18 Recognition of DENV NS1 by phage displayed fragments from the VH dAb library in a direct ELISA (Campaign D2). Five 
96-well polystyrene plates had their wells coated with one of DENV-1 NS1, DENV-2 NS1, DENV-3 NS1, DENV-4 NS1or GUS-2 (an 
antibody that was used for capture of DENV NS1 in the biopanning strategy). 90 single clone-derived phage particles from the third 
round of biopanning against DENV-2 NS1 were added to respective wells on all five plates. An HRP-conjugated antibody against M13 
bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB. 
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Figure 2.19 Recognition of DENV NS1 by phage displayed fragments from the VH dAb library in a direct ELISA (Campaign D3). Five 
96-well polystyrene plates had their wells coated with one of DENV-1 NS1, DENV-2 NS1, DENV-3 NS1, DENV-4 NS1or GUS-2 (an 
antibody that was used for capture of DENV NS1 in the biopanning strategy). 90 single clone-derived phage particles from the third 
round of biopanning against DENV-3 NS1 were added to respective wells on all five plates. An HRP-conjugated antibody against M13 
bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB. 
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Figure 2.20 Recognition of DENV NS1 by phage displayed fragments from the VH dAb library in a direct ELISA (Campaign D4). Five 
96-well polystyrene plates had their wells coated with one of DENV-1 NS1, DENV-2 NS1, DENV-3 NS1, DENV-4 NS1or GUS-2 (an 
antibody that was used for capture of DENV NS1 in the biopanning strategy). 90 single clone-derived phage particles from the third 
round of biopanning against DENV-4 NS1 were added to respective wells on all five plates. An HRP-conjugated antibody against M13 
bacteriophage was used for detection of binding. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB. 
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Sequencing of the pan-reactive binders against DENV NS1 yielded a single dominant clone: D1C2 
VH dAb that binds an epitope that is spatially removed from that of GUS-2. The clone was derived 
from the VH3 gene family and its VH CDR3 sequence (Table 2.7) varied from the VH CDR3 
sequences of the pan-reactive binders isolated from the scFv library (Table 2.5). 
Table 2.7 Variable gene family and VH CDR3 sequence of the isolated pan-reactive 
antibody fragment that binds a non immune-dominant epitope on DENV NS1. The variable 
gene familiy and VH CDR3 were determined by inputting the clone nucleotide sequences 
into the immunogenetics (IMGT)-V-QUEST software 
[http://imgt.org/IMGT_vquest/share/textes/]. The clone was isolated from a VH dAb phage 
library  
Clone VH Family VH CDR3 
D1C2 VH dAb VH3 V F K W C E T L G A H P L D F 
 
An evaluation of the recognition of DENV NS1 by D1C2 phage particles, soluble VH dAb and 
reformatted VH dAb Fc once again indicated correlating recognition of DENV NS1 by the phage 
particles and VH dAb Fc (Figure 2.21). The soluble VH dAb however, had low reactivity to DENV-
2 NS1. 
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Figure 2.21 Immunoreactivity of D1C2 phage particles, VH dAb and dAb Fc to DENV 
NS1. NS1 from all four DENV serotypes and GUS-2 a murine antibody against an 
immune-dominant epitope on DENV NS1 were immobilized on a polystyrene plate. D1C2 
phage particles (top panel), VH dAb (middle panel) or dAb Fc (bottom panel) isolated from 
a biopanning strategy that masked the GUS-2 epitope of DENV NS1 were added to the 
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immobilized antigen. The reactivity of the clone in its different formats to DENV NS1 and 
GUS2 was determined by the absorbance value measured after probing with an appropriate 
HRP-conjugated secondary antibody. HRP-conjugated secondary antibody added to wells 
with just the immobilized antigen or GUS-2 was used as the negative control.   
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2.4 DISCUSSION 
Biopanning for binders against a target antigen is not always straight forward. The nature of the 
antigen, presentation of the antigen and the biopanning strategy that is used can determine whether 
relevant binders against an antigen are isolated. Despite these challenges, we successfully isolated 
serotype-specific antibodies against NS1 from each of the four DENV serotypes and at least one 
pan-reactive antibody against a non immune-dominant epitope on DENV NS1. 
High homology amongst polypeptides can result in isolation of cross-reactive binders (1, 17). In 
this work, high homology amongst the polypeptide sequences of DENV NS1 affected the ability to 
solely isolate binders to serotype-specific regions even when a subtractive protocol was used to 
deplete binders to homologous regions. Although serotype-specific binders were successfully 
isolated from the scFv and Fab libraries, these were proportionally low in representation compared 
to the isolated pan-reactive binders. The nature of naïve libraries are such that the frequency of 
antigen-specific binders is low but it does not preclude the entire library from containing target-
specific binders. When using a subtractive biopanning strategy, high affinity pan-reactive antibodies 
would be depleted in negative selection while moderate to low affinity pan-reactive antibodies may 
be inadvertently isolated during positive selection. This rationale was the basis for separately 
interrogating the phage-displayed antibody fragment libraries again for pan-reactive binders against 
DENV NS1. One strategy utilized immobilized NS1 from a different DENV serotype in each round 
of biopanning and yielded two unique scFv binders. The other strategy utilized a murine antibody 
(GUS-2) that masked an immune-dominant epitope that is implicated in reducing diagnostic 
sensitivity of NS1 capture assays in secondary DENV infections (10). This strategy separately used 
immobilized GUS-2 as bait for NS1 from all four DENV serotypes before exposure to the VH dAb 
phage library. A single VH dAb was isolated using this strategy. What was starkly evident about this 
strategy was the dominant isolation of antibodies against GUS-2. This was not the intended 
outcome but it arose because equi-molar concentrations of immobilized GUS-2 and captured DENV 
NS1 were not used. Furthermore, the stability of the interaction (affinity) between the GUS-2 and 
each DENV NS1 differs. Any free antibody either from excess immobilization or from antibody-
antigen dissociation would have therefore presented itself as a potential target for isolation of 
binders from the VH dAb library. 
Variable levels of enrichment were noted during sequential rounds of biopanning. This enrichment 
did not however always translate to a high frequency of target-specific binders when a monoclonal 
phage ELISA was performed. The ratio of input to output is an indication of the number of phage 
that are carried through in each round, not necessarily a reflection of antigen-specific phage. Non-
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specific or aberrant phage particles with growth advantages can increase background binding. 
Propagation can be aided by the absence of the functional insert or the presence of a non-toxic 
sequence therefore impacting on assembly of bacteriophage particles and their potential for 
infectivity (13, 21).  A resolution that has been suggested to minimize this problem is to use eluted 
phage from the first round of panning in the next round without employing an amplification step 
(14). Furthermore, stringent washing conditions and more rounds of biopanning could be employed 
to improve the frequency of unique binders with desired properties. 
Regardless of apparent levels of enrichment, the true determinant of successful biopanning is 
isolation of unique monoclonal binders which are subjected to physico-chemical and 
immunological characterization. Characterization of antibody fragments whilst tethered to phage 
particles is limited, as the actual concentration of binding sites cannot be controlled.  Incorporation 
of the antibody fragment-gIIIp fusion protein into the phage particle is inefficient compared with 
incorporation of the wildtype gIIIp.  As a result, the majority of phage particles contain no 
displayed binding fragment, some contain one binding fragment, whilst some may contain many 
(4). Periplasmic expression of soluble antibody fragments in E.coli can therefore be useful for 
characterization work during the early stages of antibody discovery. The disadvantage however is 
that while Fabs are monovalent and the VH dAb phage library used in this work is aggregation 
resistant, scFvs can form dimers, trimers and higher aggregates (2, 4). Some eukaryotic protein 
sequences can also adversely affect their levels of expression and their stability when produced 
using prokaryotic host systems (8). Furthermore, work by Cabezas et al. (3) previously showed that 
phage-displayed antibody fragments do not always retain their binding activity when they are 
expressed as soluble antibody fragments. This therefore impacts on the utility of such fragments as 
was observed in some instances in this work. This problem was circumvented by reformatting the 
antibody fragments to include stabilizing Fc regions. It has been previously been reported that 
reformatted IgG can sometimes impede target recognition (19) but in this current work, all instances 
of IgG reformation led to identical reactivity between phage-displayed antibody fragments and 
phage antibodies with the antigen. 
To conclude, we have been successful in isolating antibodies that bind NS1 from all four serotypes 
of DENV and at least one pan-reactive binder that recognizes a non immune-dominant epitope on 
DENV NS1.  This is a challenging task because NS1 of DENV serotypes 1, 2, 3 and 4 share 
structure and 70% sequence homology and thus isolating antibodies that bind to serotype-specific 
epitopes is dependent on the extent of surface exposure of the variations that are interspersed 
throughout the NS1 sequence. Using hybridoma technology would require rigorous screening to 
identify the appropriate antibodies as antibodies against immune-dominant epitopes would 
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dominate the induced immune response. High quality and diverse naïve libraries, together with 
perceptive biopanning strategies of phage-displayed antibody fragment libraries are required to 
isolate binders against serotype-specific epitopes and pan-reactive non immune-dominant epitopes. 
These binders were isolated due to the sheer size of the libraries, the diversity of the libraries, and 
the creation of new specificities inherent in the VH and VL chain shuffling process that occurs upon 
library creation. Furthermore subtractive biopanning strategies and tandem binding biopanning 
strategies are pre-emptive of the possible challenges of isolating appropriate antibodies and were 
thus used to deplete the libraries of antibodies that we did not desire.  
In the next chapter, the ability of the generated serotype-specific antibodies; 9H2 α DENV-1 NS1, 
4C11 α DENV-2 NS1, 7G11 α DENV-3 NS1, 6A5 α DENV-4 NS1 and 6A7 α DENV-4 NS1, to be 
used in a sandwich ELISA for capture of DENV NS1 and its detection through pairing with all the 
isolated pan-reactive antibodies shall be evaluated.  
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Chapter 3   
 
DEVELOPMENT OF A 
SEROTYPING 
DENV NS1 CAPTURE ASSAY 
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3.1 INTRODUCTION 
The hallmark of antibody-based diagnostic assays (immunoassays) is the formation of specific and 
stable interactions between antibodies and antigens. The enzyme-linked immunosorbent assay 
(ELISA) is the most common immunoassay format. Lateral flow assays, bead assays based on the 
Luminex system and flow cytometry-based assays have gained popularity as diagnostic 
immunoassay formats but the ELISA remains the gold standard of in vitro analysis of biomarkers 
and analytes in healthcare (13). The ELISA has proven to be a reliable and sensitive immunoassay 
particularly in a sandwich format (8, 17) which was developed by Wide (15). The sandwich ELISA 
involves the use of one or more antibodies for solid-phase capture of antigen. The capture 
antibodies recognize sites on the antigen, which are different to the site that is recognized by 
another antibody that is used for detection. The detection antibody has an enzyme conjugate that 
provides a signal for detection of antigen recognition.  
The molecular determinants of antigen recognition are applied to the artificial pairing of antibodies 
used to capture and detect a soluble analyte in a diagnostic assay.  Successful antibody pairing is 
governed by principles of valency, steric hinderance and cooperativity (5). IgG are regarded as 
bivalent molecules because a single paratope appears once in each arm of the antibody and thus a 
maximum of two binding sites can simultaneously bind antigen. The number of epitopes that can 
concurrently be bound by antibodies on the other hand represents the valency of the antigen. It is 
not always possible for different combinations of antibodies to maximally bind the epitopes on a 
single antigen because antigens have many overlapping epitopes which lead to spatial limitation of 
antibody binding referred to as steric hinderance. Furthermore, binding of one antibody can distort 
or enhance the epitope for another antibody leading to a negative or positive cooperativity between 
the antibody pair (4, 11). 
Characterization and optimization of antibody pairs is central to the development of antibody 
assays. Determination of epitopes bound by the antibodies is one of the characterization studies that 
are often undertaken. The epitopes can be of either a contiguous or conformational nature. 
Contiguous epitopes are a specified linear peptide length recognized by antibodies while 
conformational epitopes rely on the juxtaposition of non-contiguous regions within spatial 
proximity, to constitute the antigenic determinant. The boundaries of either type of epitope can be 
difficult to determine. Contiguous epitopes however are somewhat easier to determine 
experimentally using synthesized, overlapping peptides that span the length of the antigen. 
Determination of conformational epitopes on the contrary is a much more involved undertaking. 
Conformational epitopes can only be defined in structural terms and therefore require knowledge of 
 95 
 
the detailed crystal structure of antibody-antigen complexes through techniques such as X-ray 
diffraction or information regading structure in solution by nuclear magnetic resonance 
spectroscopy. 
  
Optimally paired antibodies are pivotal for immunoassays because the aim is to either qualitatively 
detect a soluble analyte or quantitatively measure a soluble analyte with high reliability. The 
strength and stability of the antibody-antigen interaction is critical to the detection or quantification 
of the macromolecular complex. The kinetics of the interaction as signified by association and 
dissociation phases are influenced by the concentration of antibody ligand, the concentration of the 
antigen analyte, and the rate constants of the intrinsic association and dissociation of the antibody 
with the antigen (ka and kd, respectively) (12).  Measured ka and kd, are used to calculate the affinity 
or the strength of the antibody-antigen interaction. At optimized concentrations of capture and 
detection antibodies, antigen affinity and/or positive cooperativity of the antibodies can be exploited 
in a sandwich ELISA to detect antigen at varying concentrations dependent on individuals’ 
responses to disease. NS1 concentrations in serum vary in DENV infections. DENV NS1 levels can 
reach upwards of 15 μg/mL (2, 16). Using polyclonal mouse and rabbit antibodies against DENV-1 
NS1, Alcon et al. (2) determined that DENV-1 NS1 concentrations in primary infections ranged 
between 0.04 and 2 μg/mL while a slightly lower concentration range between 0.01 and 2 μg/mL 
was measured in secondary infections (2). Diagnostically relevant immunoassays therefore need to 
be able to sensitively detect the lower limits of DENV NS1 in the sera of infected patients.  
This chapter focuses on using generated IgG antibodies against DENV NS1 to develop a qualitative 
assay that serotypes DENV infections. The utility of individual serotype-specific and pan-reactive 
antibodies in a sandwich ELISA assay was evaluated. Pan-reactive antibodies were used for antigen 
capture followed by detection with serotype-specific antibodies. Pan-reactive antigen capture was 
unsuccessful except in the instance where a control murine antibody GUS-2 which binds the 
immune dominant epitope was used for DENV NS1 capture. The assay was inverted to capture 
DENV NS1 with serotype-specific antibodies, and detect with pan-reactive phage particles. The 
inversion still failed to yield a detectable pan-reactive signal except where GUS-2 antibody was 
again used for detection. The serotype-specific antibodies were taken forward for further 
characterization. The antibodies showed an ability to bind native NS1 antigen in a serotype-specific 
manner. The serotype-specific antibodies were found to recognize spatially clustered 
conformational epitopes. The calculated equilibrium dissociation constants of the interactions of the 
serotype-specific antibodies with DENV NS1 ranged from 2.9 x 10-7 to 3.5 x 10-9 M. Serotype-
specific antibodies were paired with GUS-2 for proof-of-principle serotyping capability and limit of 
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DENV NS1 detection sandwich ELISA assay. The results showed that DENV NS1 could be 
detected in the ng/mL range with DENV-1 NS1 being able to be detected at 0.04 ng/mL using 
GUS-2 antibody capture and 9H2 antibody detection.  
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3.2 MATERIALS AND METHODS 
3.2.1 MURINE ANTIBODIES 
Murine antibodies 1G5, 1H7, 3D1 and GUS-2 used in this research were kindly provided by 
Professor Paul Young (School of Chemistry and Molecular Biosciences, The University of 
Queensland). 
3.2.2  HRP CONJUGATION OF ANTIBODIES 
 
1 mg of each antibody was buffer exchanged into 500 μL of bicarbonate buffer (Thermo Scientific) 
using Zeba Spin Desalting Columns, 7K MWCO (Thermo Scientific). Amine conjugation of 
antibody with horseradish peroxidase (HRP) was performed using the EZ-Link Plus Activated 
Peroxidase Kit (Thermo Scientific) according to manufaturer’s instructions. Removal of excess 
unconjugated HRP was performed using the Zeba Spin Desalting Columns, 7K MWCO. 
Concentration of each antibody following desalting and conjugation was determined on the 
NanoDrop™ 1000 Spectrophotometer (Thermo Scientific). 
3.2.3 SANDWICH ELISA 
3 µg/mL of capture antibody was prepared in phosphate buffered saline (PBS) and used to coat a 
MaxiSorp™ plate (Nunc) overnight at 4 ˚C. Any unbound antibody was discarded and followed by 
three consecutive washes with a wash buffer made with 1 x phosphate buffered saline (PBS) and 
0.01% Tween20. Excess binding sites on the plate were blocked using a blocking buffer made with 
PBS supplemented with 2.5% skim milk powder (M-PBS). The blocking buffer was discarded and 
1 µg/mL of DENV NS1 made in 2.5% M-PBS was added and incubated for an hour. The incubation 
was followed by three washes with wash buffer. 3 µg/mL of detection antibody or phage diluted in 
blocking buffer was added to the wells.  Following one hour incubation, three washes with the wash 
buffer were performed and the plate was probed with 200 µL of HRP-conjugated anti-M13 (GE 
Healthcare) or HRP-conjugated goat anti mouse [H+L] IgG (Life Technologies) or HRP-conjugated 
goat anti human IgG [γ chain specific] (Sigma) diluted to 0.1 µg/mL in M-PBS. Three final washes 
with the wash buffer were performed then 100 µL TMB substrate (Sigma Aldrich) was added to 
develop the chromogenic signal. The reaction was stopped with 2N sulphuric acid and the 
absorbance at 450 nm was read using the Spectramax (Molecular Devices) or the PowerWave XS2 
(Biotek – Millenium Science). 
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3.2.4 ELISA WITH IMMOBILIZED PEPTIDES 
A peptide corresponding to amino acid residues 111-125 of DENV-1 NS1 
(CGGHKYSWKSWGKAKIIG) and a control unrelated peptide (CGGSKGTPMYSVDL), both 
with cysteine-glycine-glycine leader residues were synthesised by the Australian Biobest 
Biotechnology Service. The underlined residues are conserved on NS1 across all four serotypes. 
The peptides were reconstituted to 5 mg/mL using 1 x PBS. The cysteine residue was used to 
immobilize and orientate 10 µg/mL of the peptide diluted in binding buffer, on maleimide activated 
clear 8-well strips (Thermo Scientific) as per manufacturer’s instructions. A blocking step with PBS 
supplemented with 2% skim milk powder (M-PBS) was included after inactivating excess 
maleimide groups using a cysteine solution. GUS-2, 3D1, 9H2, 4C11, 7G11 and 6A5 test antibodies 
were used at a concentration of 10 µg/mL in M-PBS. HRP-conjugated anti mouse IgG (H+L) (Life 
Technologies) or HRP-conjugated anti human IgG [γ chain specific] (Sigma Aldrich) were used at 
concentration of 0.1 µg/mL in M-PBS. TMB substrate was used to develop the chromogenic signal 
and absorbances were measured using the Spectramax (Molecular Devices).  
3.2.5 VERO CELL INFECTION 
Vero (African green monkey kidney) cells were adapted and grown using Opti-MEM (Gibco) 
supplemented with 3% fetal calf serum (Bovogen) in T25 vented flasks (Greiner Bio-One) in a 
humidified, 37 ˚C incubator with 5% C02. Cells were split using 0.5% Trypsin versene (Gibco) and 
seeded at 50% confluence in either T25 vented flasks or in 96-well cell culture plates (Corning® 
Costar®). Cells were infected with DENV-1, DENV-2, DENV-3, DENV-4 (all East Timor strains 
corresponding to GenBank entries 440432.1, 440433.1, 440434.1 and 440435.1 respectively) or 
Kunjin virus (KUNV, a highly attenuated, Australasian variant of West Nile virus) at 0.1 
multiplicity of infection in serum-free Opti-MEM for 2 hours at 37 ˚C. After infection, the infection 
medium was replaced with Opti-MEM supplemented with 2% fetal calf serum. DENV infected 
cells were cultured for three days while KUNV infected cells were cultured for two days. Cell 
culture supernatants from T25 flasks were harvested and concentrated (Macrosep Advance 
Centrifugal Devices, Pall) then used in a sandwich ELISA to detect secreted NS1 while infected 
cells in 96-well cell culture plates were fixed and used in immunofluorescence assays. 
3.2.6 IMMUNOFLUORESCENCE ASSAYS 
Immunofluorescence assays were performed on cells fixed with paraformaldehyde and 
permeabilised with 0.1% Triton x100. Wells were blocked with 2% casein in PBS with 0.01% 
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Tween 20 (PBS-T). Serotype-specific antibodies against DENV NS1 were used at a concentration 
of 10 µg/mL in blocking solution, while the mouse antibody against the flaviviral envelope protein 
was used at a concentration of 1 µg/mL also in blocking solution. Following one hour incubation, 
three washes were performed using PBS-T. Anti mouse Alexa Fluor 546 (Life Technologies), anti-
human Alexa Fluor 488 (Jackson ImmunoResearch) and Hoescht (Thermo Scientific) in blocking 
buffer were added to the wells and incubated for a further hour before another 3 washes with PBS-
T. Immuno-fluorescence imaging was performed at 40 x magnification using the InCell Analyzer 
(GE Healthcare). 
3.2.7 WESTERN BLOTTING 
Determination of antibody binding to linear epitopes was performed by Western blot. 5 μg/mL of 
DENV NS1 and 15 μg/mL of bi-specific antibody NBF 736 (scFv – human Fc – scFv) were 
denatured at 90 ˚C for 7 minutes in a reaction with 4 x LDS buffer (NuPAGE), 10 X reducing agent 
(NuPage). 20 μL reactions of reduced proteins were loaded into single wells of a Mini Protean® 
TGX Stain-Free™ Gel. 10 μL of SeeBlue Plus 2 marker was used as a standard to determine the 
molecular mass of sample proteins. The proteins were electrophoresed at 200 volts for 30 minutes 
using the Tris/Glycine/SDS Buffer (BioRad) in a Mini Protean® Tetra System (BioRad). The 
proteins from the gel were turbo-blotted for 7 minutes onto a 0.2 μm PVDF membrane from the 
Trans-Blot® Turbo™ Mini PVDF Transfer Packs using the Trans-Blot® Turbo™ Transfer System. 
Each membrane was blocked for 30 minutes in a tray with 25 mL blotting buffer (25 mM Trizma 
base, 0.15 M NaCl and 0.1% Tween-20) supplemented with 2% skim milk powder. 5 μg of test 
antibody in 25 mL blocking buffer was added to each membrane and incubated for an hour. The 
blocking buffer was discarded and rinsed once with blotting buffer. 1 μg of HRP-conjugated goat 
anti mouse [H+L] IgG (Life Technologies) or HRP-conjugated goat anti human IgG [γ chain 
specific] (Sigma) in 25 mL blocking buffer was added to each membrane and incubated for another 
hour. The membranes were washed three times with blotting buffer. The signal from the HRP 
conjugate was developed using the Clarity™ Western ECL Substrate (Bio-Rad) for 5 minutes and 
exposed to UV light for 3 minutes using the ChemiDoc MP System (Bio-Rad). 
3.2.8 SURFACE PLASMON RESONANCE 
Antigen–antibody interaction kinetics and affinity were determined by Surface Plasmon Resonance 
(SPR) using the Biacore T100 (GE Healthcare). About 9 000 resonance units (RU) of anti human 
Fc (GE Healthcare, Human Antibody Capture Kit) or anti mouse Fc (GE Healthcare, Mouse 
Antibody Capture Kit) were immobilized on CM5 sensor chips. One flow cell acted as the reference 
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surface for the assay and did not have any antibody captured on its surface. The other flow cell 
acted as the active surface for the assay where the captured anti-DENV NS1 was used to assess 
interaction with the recombinant DENV NS1 analyte. Two-fold, serial dilutions of NS1 were made 
from 1 µM to 62.5 nM using the instrument running buffer (1 X HBS EP+) with a final 300 mM 
NaCl concentration. Single cycle kinetics assays or high performance multi-cycle kinetics assays 
were performed. The flow rate used for injection of the capture antibody and the analyte was 30 
µL/minute. Variable anti DENV NS1 capture times were used to allow approximately 140 RU of 
capture, then association with different concentrations of analyte proceeded for 3 minutes. 
Dissociation of the antigen from the antibody was measured over 10 or 15 minutes. Regeneration of 
the anti human Fc surface with 3M MgCl2 was performed after each capture and analyte binding 
while regeneration of the anti mouse Fc surface was performed with 10 mM Glycine.HCl at pH 1.7 
after each single cycle. The flow rate used for regeneration was 10 µL/minute for 30 seconds. The 
evaluation software generated sensorgrams of the antigen-antibody interactions yielding association 
and dissociation rate constants, from which the equilibrium dissociation constant was calculated 
assuming a 1:1 model of interaction. 
3.2.9 LIMIT OF DETECTION ELISA 
Checkerboard titration of capture and detection antibodies was performed in a sandwich ELISA 
format by immobilizing capture antigen in two-fold serial dilutions across the plate ranging in 
concentration from 10 μg/mL to 4.9 ng/mL. A single concentration of DENV NS1 (200 ng/mL) was 
captured in all the wells. Detection of capture was carried out using HRP-conjugated antibody that 
was titrated two-fold, down the plate starting at concentrations that ranged from 625 ng/mL to 4.9 
ng/mL. Absorbance signals were measured at 450 nm after addition of TMB and 2N sulphuric acid. 
The concentrations of capture and detection antibodies that yielded the highest absorbance signal 
with minimal background noise were chosen to perform a titration of DENV NS1 in a sandwich 
ELISA to determine the limit of DENV NS1 detection by the antibody pair. 
To determine the limit of DENV NS1 detection, a sandwich ELISA was performed using capture 
antibodies at 10 µg/mL and HRP-conjugated detection antibody at 625 ng/mL. The antigen to be 
detected by the antibody sandwich was prepared in PBS as two-fold serial dilutions of DENV NS1 
ranging from 1.6 μg/mL to 49 pg/mL. The signal from the HRP-conjugated detection antibody was 
developed using TMB and an end-point absorbance signal was measured at 450 nm after stopping 
the reaction with 2N sulphuric acid. 
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3.3 RESULTS 
3.3.1 SELECTION OF CAPTURE AND DETECTION ANTIBODY PAIRS 
Characterization of the tandem binding potential of antibody pairs is important for determination of 
their prospective diagnostic utility in an antigen capture assay. The ability of pan-reactive and 
serotype-specific binders to detect DENV NS1 in a sandwich ELISA was therefore evaluated.  
In the first instance, pan-reactive antibodies (including GUS-2) were used in solid-phase capture of 
DENV NS1. HRP-conjugated, serotype-specific antibodies were used for detection of captured 
antigen. The results showed that only GUS-2 was able to bind NS1 from all four dengue serotypes 
for detection by the serotype-specific antibodies (Figure 3.1).  
The assay was also reversed where serotype-specific antibodies were used for capture of DENV 
NS1 and pan-reactive, phage-displayed antibody fragments were used for detection of the captured 
antigen. We previously showed in Chapter 2 that isolated phage-displayed antibody fragments and 
reformatted IgG1 antibodies have matched reactivity with DENV NS1. Murine GUS-2 antibody 
was included in pan-reactive detection as we did not have a phage-displayed antibody fragment that 
corresponded to the hybridoma-derived antibody. The results once again showed that the serotype-
specific antibodies were only able to capture DENV NS1 and bind in-tandem with pan-reactive 
GUS-2 for detection of NS1 capture from all four DENV serotypes (Figure 3.2).  
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Figure 3.1 Tandem binding of pan-reactive antibodies and serotype-specific antibodies to DENV NS1. Fourteen pan-reactive antibodies 
were each immobilized to four wells in a 96-well polystyrene plate. NS1 from each DENV serotype was added to the four wells for each 
pan-reactive antibody. HRP-conjugated, serotype specific antibodies against DENV NS1 were used for detection of binding for the 
corresponding DENV serotype. Binding was determined by measuring the chromogenic signal produced by addition of TMB. 
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Figure 3.2 Tandem binding of serotype-specific antibodies and pan-reactive phage particles to DENV NS1. Five serotype-specific 
antibodies were immobilized to 14 wells each in a 96-well polystyrene plate. DENV NS1 was added to the 14 wells corresponding to the 
relevant serotype-specific antibody. Pan-reactive phage particles displaying scFv (s), Fab (f), VH dAb, or GUS-2 antibody were added to 
the five wells corresponding to each serotype-specific antibody. An HRP-conjugated antibody against M13 bacteriophage was used for 
detection of binding by phage particles. HRP-conjugated antibody against murine Fc γ was used for detection of binding by GUS-2 
antibody. Binding was determined by measuring the chromogenic signal produced by addition of TMB.
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The inability for tandem binding of DENV NS1 by both serotype-specific and pan-reactive 
antibodies raised possibilities of the capture antibodies binding epitopes which sterically hinder the 
binding of the detection antibodies. To investigate this, the pan-reactive antibodies were used to 
capture DENV NS1 and GUS-2 was used for detection of capture. The rationale here was that the 
ability of the serotype-specific antibodies to bind DENV NS1 in tandem with GUS-2 meant that 
they bound spatially disparate epitopes. If the serotype-specific antibodies were sterically hindering 
the binding of the other pan-reactive antibodies, then using GUS-2 as the capture antibody would 
off-set that hindrance. The results of this assay showed that none of the pan-reactive antibodies, 
except D1C2, could bind NS1 from all four serotypes in tandem with GUS-2 (Figure 3.3). The 
ability of D1C2 antibody to bind DENV NS1 in tandem with GUS-2 is a logical finding, as D1C2 
was isolated using a biopanning strategy which involved using Gus-2 to mask the immune-
dominant epitope to isolate a pan-reactive binder from the VH dAb library. D1C2 antibody 
therefore, must be binding a different epitope to GUS-2 but unfortunately binding an epitope which 
spatially competes with all four serotype-specific antibodies. Figure 3.3 also shows that antibodies 
1A1, 3B6, 3E6 and 6H2 were only able to recognize DENV-1 NS1 in a sandwich with GUS-2 but 
not NS1 from the other three DENV serotypes. Because all pan-reactive antibodies except D1C2 
were isolated from biopanning strategies that involved immobilized DENV NS1 it is likely that the 
antibodies recognize cryptic epitopes that are better exposed when the NS1 antigen was adsorbed on 
plastic. 
Taken summatively, the data indicated positive binding reactivity with serotype-specific antibodies 
9H2, 4C11, 7G11, 6A5 and 6A7 as well as pan-reactive antibody D1C2. Because D1C2 could not 
bind DENV NS1 in tandem with the serotype-specific antibodies, only the serotype-specific 
antibodies were taken forward for further characterization. 
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Figure 3.3 Tandem binding of GUS-2 and pan-reactive antibodies to DENV NS1. GUS-2 antibody was immobilized to 52 wells in a 96-
well polystyrene plate. NS1 from each DENV serotype was added to 13 of these wells each. 13 pan-reactive antibodies against DENV 
NS1 were added to the plate. Binding was detected using a HRP-conjugated antibody against human Fc γ. Binding was determined by 
measuring the chromogenic signal produced by addition of TMB. 
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3.3.2 REACTIVITY OF SEROTYPE-SPECIFIC ANTIBODIES WITH NATIVE DENV NS1 
Recombinant antigens often have tags that can be useful for expression and/or purification. One of 
the disadvantages of biopanning using these antigens that have not had the tags removed is that 
binders that recognize antigen-tag junctions can be isolated. DENV NS1 used in this work included 
an N-terminal hepta-histidine tag. To ascertain that the generated serotype-specific antibodies only 
recognized DENV NS1, immunoassays using native DENV NS1 were performed. 
Vero cells were mock ‘infected’ or infected with clinical isolates of each DENV or KUNV. 
Infection with virus leads to accumulation of intracellular, membrane-associated NS1 and 
extracellular accumulation of secreted NS1. Serotype-specific antibodies were used to capture 
secreted NS1 from concentrated culture media in an ELISA format. HRP-conjugated GUS-2 was 
used to detect binding. Antibodies 9H2, 4C11, 7G11 and 6A5 were able to capture DENV NS1 in a 
serotype-specific manner while antibody 6A7 failed to recognize native DENV-4 NS1 (Figure 3.4). 
The Vero cells infected with KUNV were used to test for cross-reactivity with other flaviviral NS1 
and no cross-reactivity was noted. Differences in the observed absorbance values are mainly 
because of differences in NS1 concentration. Dengue viruses are variably virulent resulting in 
production of different amounts of NS1. The amount of NS1 added to the assays was not 
standardized.  
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Figure 3.4 Serotype-specific recognition of native secreted DENV NS1. Each serotype-specific antibody was immobilized to six wells on 
a 96-well polystyrene plate. Concentrated culture supernatants from DENV, mock or Kunjin infected Vero cells were each added to five 
wells corresponding to each serotype-specific antibody. HRP-conjugated GUS-2 was added to detect binding of NS1 to the capture 
antibodies. Binding was determined by measuring the chromogenic signal produced by addition of TMB. 
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The reactivity of the reformatted, serotype-specific antibodies 9H2, 4C11, 7G11 and 6A5 with 
native, membrane-associated DENV NS1 was investigated by immunofluorescence assays using 
DENV, mock and kunjin infected Vero cells. 4G2 is an antibody against flaviviral envelope protein 
and it was used as a positive control to show that the cells were infected with flavivirus. The mock 
‘infected’ Vero cells were used as a negative control. The results as shown in Figure 3.5, indicate 
that all four serotype-specific antibodies were again able to discern NS1 from each DENV serotype 
with no flaviviral cross reactivity noted.  
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Figure 3.5 Serotype-specific recognition of native membrane-associated DENV NS1. 
Immunofluorescence assay micrographs showing binding of serotype-specific anti DENV 
NS1 to DENV, mock and KUNV infected Vero cells. Following 3 days of DENV infection 
or 2 days of KUNV virus infection, cells were paraformaldehyde treated and then 
permeabilised prior to addition of human antibodies against DENV NS1 (9H2, 4C11, 7G11 
and 6A5). A control mouse antibody against flavivirus envelope protein (4G2) was added 
to each well to ensure flaviviral infection of cell. Anti-human IgG-488 (Green) and anti-
9H2 4C11 7G11 6A5 
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mouse IgG-Alexa Fluor546 (Red) were added to all wells in a dual stain to ascertain 
binding of antibodies to native antigen and confirm infection of Vero cells. All wells also 
had a nuclear stain (Hoescht) (Blue) added to them to determine the relative localisation of 
binding. Antibodies against DENV NS1 and the envelope protein showed peri-nuclear 
binding and diffuse cytoplasmic binding respectively.  
 
3.3.3 PREDICTION OF EPITOPES BOUND BY SEROTYPE-SPECIFIC ANTIBODIES 
Sandwich ELISA relies on mutual exclusivity of the epitopes recognized by capture and detection 
antibodies. The epitopes of the serotype-specific antibodies which can be used for either antigen 
capture or antigen detection therefore need to be determined to aid the isolation of a potential pan-
reactive pairing antibody. 
To evaluate whether contiguous or conformational epitopes were recognized by the serotype-
specific antibodies, a Western blot was performed. Denatured DENV NS1 and a control bi-specific 
antibody with a human Fc linker were probed using the serotype-specific antibodies and an HRP-
conjugated antibody against human Fc γ. GUS-2 and an HRP-conjugated antibody against mouse 
Fc γ were used as pan-reactive positive probes for detection of the contiguous immune-dominant 
epitope on NS1 from all four DENV serotypes. Positive control GUS-2 was able to detect 
contiguous epitopes on denatured antigen while serotype-specific antibodies did not bind denatured 
antigen (Figure 3.6). The binding of serotype-specific antibodies therefore, relies on structural 
integrity of the antigen pointing to recognition of conformational epitopes. 
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Figure 3.6 Western blotting of denatured DENV NS1. 5 x 20 μL reactions made up of NS1 from each DENV serotype at concentration of 
5 μg/mL as well as a bi-specific antibody NBF736 with a human Fc γ linker at a concentration of 15 μg/mL were linearized using SDS 
and reducing agent and heated at 90 ˚C for 7 minutes. The 20 μL reactions of reduced proteins were loaded onto a Mini Protean® TGX 
Stain-Free™ Gel. 10 μL of SeeBlus Plus 2 marker was added to lane 1, DENV-1 NS1 + bispecific NBF736 was added to lane 2, DENV-2 
NS1 + bispecific NBF736 was added to lane 3, DENV-3 NS1 + bispecific NBF736 was added to lane 4 and DENV-4 NS1 + bispecific 
NBF736 was added to lane 5. The proteins were  electrophoresed at 200 volts for 30 minutes, turbo-blotted onto a PVDF membrane and 
probed with antibodies GUS-2 (panel A), 9H2 (panel B), 4C11 (panel C), 7G11 (panel D), (panel E) and an HRP-conjugated antibody 
against mouse and/or human Fc γ. The signal was developed with an ECL substrate and exposed to UV light for 3 minutes. Using the 
molecular mass marker (kDa) indicated in panel B, the DENV NS1 band was seen at about 55 kDa with a dimer seen as 110 kDa. Bi-
specific NBF736 an 83 kDa protein was detected at about 95 kDa with a forced dimer detected at >148 kDa. 
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Determination of conformational epitopes requires complex and time consuming techniques which 
were beyond the scope of this project. A small of panel of murine antibodies were used in a 
sandwich ELISA with serotype-specific antibodies to potentially determine the relative epitopes of 
the serotype-specific antibodies. The motivation for this assay was to evaluate if any of the murine 
antibodies hindered binding of the serotype-specific antibodies. The panel of murine antibodies 
included 1G5, 1H7, 3D1 and GUS-2. Antibody 1G5 binds amino acid residues 299-307 on DENV-
2, 3 and 4 NS1, antibody 1H7 binds amino acid residues 25-33 on DENV-2 NS1 and antibody 3D1 
binds amino acid residues 111-119 on DENV-1, 2, 3 and 4 NS1 (6). Antibody GUS-2 also binds 
the same epitope as 3D1 and this was demonstrated in a direct ELISA using a peptide 
corresponding to amino acid residues 111-125 of DENV-1 NS1 in Figure 3.7. In the sandwich 
ELISA, murine antibodies against DENV NS1 were used to capture the antigen and HRP-
conjugated, serotype-specific antibodies were used to detect capture. It was determined as shown in 
Figure 3.8, that the serotype-specific antibodies are unaffected by the binding of 1G5, 1H7 and 
GUS2. 3D1; however, another pan-reactive antibody which binds the same epitope as GUS 2 
perturbed binding of all four serotype-specific antibodies.  
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Figure 3.7 Binding of serotype-specific human antibodies and pan-reactive murine 
antibodies to a DENV NS1 immune-dominant linear peptide. A peptide that includes the 
sequence of the DENV-1 NS1 immune-dominant epitope (DENV-1 NS1_111-125:  
CGGHKYSWKSWGKAKIIG) and an unrelated peptide (AFBP_6:  
CGGSKGTPMYSVDL) were each immobilised to six wells in 96-well maleimide plate 
using the N-terminal cysteines of the peptides. Serotype-specific antibodies (used as 
negative controls) and pan-reactive antibodies were added to wells coated with each 
peptide. The binding of serotype-specific and pan-reactive antibodies to those peptides 
was determined by detection with an HRP-conjugated antibody against mouse or human Fc 
γ. Binding was determined by measuring the chromogenic signal produced by addition of 
TMB. 
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Figure 3.8 Mapping of serotype-specific DENV NS1 epitopes (murine antibody capture). 
Four murine antibodies against DENV NS1 were used as immobilized solid capture of 
DENV NS1 in a sandwich ELISA. NS1 from each DENV serotype was added to 
polystyrene wells coated with each murine antibody.  HRP-conjugated, serotype-specific 
antibodies were used to detect tandem antigen binding for identification of shared epitopes 
between capture and detection antibodies. Binding was determined by measuring the 
chromogenic signal produced by addition of TMB. 
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The perturbation of serotype-specific antibody binding to DENV NS1 that was observed when 
using 3D1 as a capture antibody could have been be due to; (i) 3D1 binding the immune-dominant 
epitope with a footprint that sterically hindered the binding of the serotype-specific antibodies or (ii) 
negative cooperativity and distortion of the epitopes recognized by serotype-specific antibodies 
following binding 3D1. To determine which factor was at play, the sandwich ELISA assay was 
reversed. Capture reversal using human serotype-specific antibody capture and murine antibody 
detection resulted in comparable signals between 3D1 and GUS-2 detection antibodies (Figure 3.9). 
This indicates that pairing of 3D1 and serotype-specific antibodies leads to negative cooperativity 
when 3D1 is used as the capture antibody. 
 
Figure 3.9 Mapping of serotype-specific DENV NS1 epitopes (human antibody capture). 
Four human, serotype-specific antibodies against DENV NS1 were used as immobilized 
solid capture of DENV NS1 in a sandwich ELISA. NS1 from each DENV serotype was 
added to polystyrene wells coated with each human antibody. Murine antibodies and a 
secondary HRP-conjugated antibody against mouse Fc γ were used to detect tandem 
antigen binding for identification of shared epitopes between capture and detection 
antibodies. Binding was determined by measuring the chromogenic signal produced by 
addition of TMB 
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Collectively, the negative cooperativity of 3D1 with all four serotype-specific antibodies and the 
inability of all four serotype-specific antibodies to pair with reformatted antibody D1C2 (VH Fc) 
suggested that the epitopes of the serotype-specific antibodies are spatially clustered on DENV 
NS1. Relative localization of the epitopes however, will require additional experimental work.  
3.3.4 INTERACTION KINETICS OF SEROTYPE-SPECIFIC ANTIBODIES AND DENV NS1 
Quantitative determinations of the interaction kinetics of the serotype-specific antibodies and pan-
reactive GUS-2 with DENV NS1 were performed to evaluate the potential utility of the antibodies 
in a DENV NS1 capture assay.  Association and dissociation phases of the complexes that resulted 
from the interaction of the antibodies with their antigens were investigated using SPR.  
The sensorgrams that are relevant to the ka and kd of GUS-2 with DENV NS1 are shown in Figure 
3.10. The sensorgrams that are relevant to the ka and kd of the serotype-specific antibodies with 
DENV NS1 are shown in Figure 3.11.  The KD were extrapolated from measurements of ka and kd 
as shown in Table 3.1. GUS-2 showed the highest affinity for DENV-1 NS1 (5.4 x 10-9 M) and 
DENV-2 NS1 (1.8 x 10-9 M) constituted by a slower kd and a faster ka respectively, when compared 
to the interactions kinetics of GUS-2 with DENV-3 NS1 and DENV-4 NS1. The KD for the 
serotype-specific antibody interaction with DENV NS1 ranged from 2.9 x 10-7 M between 4C11 
and DENV-2 NS1 to almost 100-fold increased interaction between 6A5 and DENV-4 NS1(3.5 x 
10-9 M) . 4C11 and DENV-2 NS1 in particular had a lower KD because of a faster kd. Figure 3.11 
(panel B) also showed a lower response during the association phase of the kinetics measurements 
with only 20 RU measured when the highest concentration of DENV-2 NS1 (1 μM) was streamed 
over the captured 4C11 antibody surface. Interaction kinetics and affinities between 9H2 and 
DENV-1 NS1 as well as between 7G11 and DENV-3 NS1 were comparable as seen on the 
sensorgrams (Figure 3.11 panel A and B) and the calculated affinities on Table 1. The highest 
affinity of the serotype-specific antibodies was between antibody 6A5 and DENV-4 NS1 (3.5 x 10-9 
M). A two-fold higher association rate and an almost 3-fold slower dissociation rate between 6A5 
and DENV-4 NS1 when compared to 9H2 and DENV-1 NS1 as well as 7G11 and DENV-3 
NS1was responsible for the observed higher affinity.  
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Figure 3.10 SPR sensorgrams for the interaction of GUS-2 antibody and NS1 from each 
DENV serotype. Analysis was performed on the Biacore T100 using single cycle kinetics. 
The antibody was immobilized on a CM5 sensor chip at a density that was measured at 
140 resonance units (RU). Serial two-fold increasing concentrations of antigen from 62.5 
nM to 1 µM were injected over the surface in a single cycle. The association phase 
proceeded for 180 seconds and the dissociation phase proceeded for 600 seconds (900 
seconds for GUS-2 and DENV-2 NS1). The sensorgrams from these injections are shown 
as coloured lines. A 1:1 model of binding was fitted to the data (black lines) and the 
association rate (ka), dissociation rate (kd) and equilibrium dissociation constant (KD) were 
determined for these interactions using the evaluation software. 
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Figure 3.11 SPR sensorgrams for the interaction of 9H2 (A), 4C11 (B), 7G11 (C) and 6A5 (D) antibodies and NS1 from each DENV 
serotype. Analysis was performed on the Biacore T100 using high performance multi cycle kinetics. The antibodies were immobilized on 
a CM5 sensor chip at a density that was measured at 140 resonance units (RU).  Serial two-fold increasing concentrations of antigen 
from 62.5 nM to 1 µM were singly injected over the surface in multiple cycles that included surface regeneration between different 
concentrations of antigen. The association phase proceeded for 180 seconds while the dissociation phase proceeded for 900 seconds 
(only 420 seconds of the dissociation phase is shown). The sensorgrams from these injections are shown as coloured lines. A 1:1 model 
of binding was fitted to the data (black lines) and the association rate (ka), dissociation rate (kd) and equilibrium dissociation constant 
(KD) were determined for these interactions using the evaluation software. 
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Table 3.1 Kinetics and affinities of antibody-antigen interaction. SPR data from single 
cycle and high performance multi-cycle analysis runs indicating association rates (ka) [M-
1 s-1], dissociation rate (kd) [s-1] ± standard error as well as the equilibrium dissociation 
constants (KD) kd/ka [M]. X denotes that no measurable interaction was detected by the 
assay. 
 ANALYTE 
ANTIBODY DENV-1 NS1 DENV-2 NS1 DENV-3 NS1 DENV-4 NS1 
9H2 ka 4.7x104  ± 150 
kd 6.7x10-4 ± 2.9x10-6 
KD 1.4x10-8  
 
 
X 
 
X 
 
X 
4C11  
X 
ka 7.5x103± 140  
kd 2.1x10-3 ± 1.5x10-5 
KD 2.9x10-7  
 
 
X 
 
X 
7G11  
X 
 
X 
ka 4.5x104 ± 89 
kd 7.1x10-4 ± 1.8x10-6 
KD 1.5x10-8  
 
 
X 
6A5  
X 
 
X 
 
X 
ka 7.5x104±57 
kd 2.6 x 10-4 ±2.2x10-7 
KD 3.5 x 10-9  
 
GUS-2 ka 1.2x104± 12  
kd 6.2x10-5 ± 7.9x10-7 
KD 5.4x10-9  
 
ka 1.1x105± 140  
kd 1.9x10-4 ± 5.6x10-7 
KD 1.8x10-9  
 
ka 1.0x104± 11  
kd 2.9x10-4 ± 7.5x10-7 
KD 2.8x10-8  
 
ka 1.1x104± 17  
kd 2.0x10-4 ± 1.1x10-6 
KD 1.9x10-8  
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3.3.5 LIMIT OF DETECTION OF DENV NS1 IN A SEROTYPING SANDWICH ELISA 
 
Knowledge of the affinities of antibodies for their relevant antigen allows for predictions of the 
stability of the antibody pair and sandwiched antigen complex. The stability of that complex 
influences the minimum amount of antigen that can be detected by the antibody sandwich. 
Minimum amounts of antigen that can be detected by a diagnostic assay lend themselves to 
determining the sensitivity of the assay. To be able to ascertain the limits of antigen detection, one 
needs to first establish the optimal concentrations of capture and detection antibodies that are 
required for positive detection of the antigen with minimal noise:signal ratios. Optimized conditions 
yield the best antigen binding and the best precision of antigen detection. 
Checkerboard titrations of the coating antibody and HRP-conjugated detection antibody were 
performed to detect a set amount of DENV NS1 (200 ng/mL) in a sandwich ELISA. 10 μg/mL of 
serotype-specific capture antibodies and 625 ng/mL of HRP-conjugated GUS-2 were shown to 
provide the best signal for detection of 200 ng/mL of DENV NS1 (Figure 3.12). Figure 3.12 also 
shows that the highest concentration of HRP-conjugated GUS-2 (625 ng/mL) had negligible 
background noise when used with the lowest concentration of capture antibody (4.9 ng/mL). When 
GUS-2 was used as the capture antibody for DENV NS1 in a reversal of the assay, 10 μg/mL of 
GUS-2 and 625 ng/mL of HRP-conjugated serotype-specific antibodies again proved to be the 
optimal concentrations required by the assay (Figure 3.13). In this instance however, lower 
concentrations of GUS-2 (down to 2.5 μg/mL) could produce the same signal when paired with 6A5 
anti DENV-4 NS1. 
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Figure 3.12 Antibody titration for serotype-specific antibody capture and GUS-2 antibody 
detection of DENV NS1. Two-fold dilutions of capture antibody were immobilized across 
a 96-well polystyrene plate, starting at 10 μg/mL until 4.9 ng/mL. 200 ng/mL of NS1 from 
a single DENV serotype was added to all the wells. Detection was carried out using a 
range of HRP-conjugated detection antibody that was titrated two-fold down the plate 
starting at a concentration of 625 ng/mL until 4.9 ng/mL. Binding was determined by 
measuring the chromogenic signal produced by addition of TMB. A 3 colour scale heat-
map ranging from blue for lowest absorbance values, orange for mid absorbance values 
and red for the highest absorbance values was used to determine the optimal capture and 
detection antibody concentrations. 
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Figure 3.13 Antibody titration for GUS-2 antibody capture and serotype-specific antibody 
detection of DENV NS1. Two-fold dilutions of capture antibody were immobilized across 
a 96-well polystyrene plate, starting at 10 μg/mL until 4.9 ng/mL. 200 ng/mL of NS1 from 
a single DENV serotype was added to all the wells. Detection was carried out using a 
range of HRP-conjugated detection antibody that was titrated two-fold down the plate 
starting at a concentration of 625 ng/mL until 4.9 ng/mL. Binding was determined by 
measuring the chromogenic signal produced by addition of TMB. A 3 colour scale heat-
map ranging from blue for lowest absorbance values, orange for mid absorbance values 
and red for the highest absorbance values was used to determine the optimal capture and 
detection antibody concentrations. 
  
 123 
 
For ease of standardization, 10 μg/mL of capture antibodies and 625 ng/mL of HRP-conjugated 
detection antibodies were used in sandwich ELISA formats to determine the limit of DENV NS1 
detection. The concentrations of capture and detection antibodies were kept constant while DENV 
NS1 was titrated two-fold from 1.6 μg/mL to 49 pg/mL. The limit of detection was considered as 
the last diluted antigen concentration that gave a value larger than the mean absorbance of negative 
samples plus three standard deviations. The desired level of DENV NS1 detection was 10 ng/mL 
(2). Serotype-specific antibody capture of DENV NS1 with HRP-conjugated GUS-2 antibody 
detection resulted in minimum detection of 2.7, 48.5, 43.4 and 6.0 ng/mL of DENV-1 NS1, DENV-
2 NS1, DENV-3 NS1 and DENV-4 NS1 respectively (Figure 3.14). Meanwhile GUS-2 antibody 
capture of DENV NS1 with HRP-conjugated serotype-specific detection resulted in minimum 
detection of 0.04, 11.5, 12.5 and 0.2 ng/mL of DENV-1 NS1, DENV-2 NS1, DENV-3 NS1 and 
DENV-4 NS1 respectively (Figure 3.15). GUS-2 pan-reactive capture of DENV NS1 therefore 
yielded limits of detection that were closest to fulfilling the minimum desired requirement of 10 
ng/mL when NS1 from all four DENV serotypes was captured in a sandwich assay with HRP-
conjugated serotype-specific antibodies. 
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Figure 3.14 Limit of DENV NS1 detection using serotype-specific antibody capture and 
GUS-2 antibody detection. 10 μg/mL of immobilized antibodies were used to capture 
dilutions of DENV NS1 ranging from 1.6 μg/mL to 49 pg/mL. Detection of captured 
antigen was performed with 625 ng/mL of an HRP-conjugated antibody. Measured 
absorbance values are shown in the curves. The cut-off value was calculated as the mean 
blank value + 3 x SD of negative readings. The limits of detection (LOD) of NS1 from 
each DENV serotype are shown in the figure legend. 
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Figure 3.15 Limit of DENV NS1 detection using GUS-2 antibody capture and serotype-
specific antibody detection. 10 μg/mL of immobilized antibodies were used to capture 
dilutions of DENV NS1 ranging from 1.6 μg/mL to 49 pg/mL. Detection of captured 
antigen was performed with 625 ng/mL of an HRP-conjugated antibody. Measured 
absorbance values are shown in the curves. The cut-off value was calculated as the mean 
blank value + 3 x SD of negative readings. The limits of detection of NS1 from each 
DENV serotype are shown in the figure legend. 
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3.4 DISCUSSION 
Developing a diagnostic sandwich ELISA for capture and detection of antigen can be a difficult 
undertaking. A sufficient number of antibodies that can be used for antigen capture and antigen 
detection have to be trialed for an ability to sandwich the antigen. The formation of an antibody 
sandwich depends on both antibodies binding to spatially distinct sites without impinging each 
other’s individual epitopes. Furthermore, the affinities of each antibody in the sandwich pair are 
required to be high enough to result in a stable sandwich complex that can sensitively detect 
antigen. 
Using a sandwich ELISA format, 13 pan-reactive antibodies that bind DENV NS1 and 5 serotype-
specific antibodies that each bind NS1 from a single DENV serotype were evaluated for their ability 
to capture and detect DENV NS1 in a serotype specific manner. None of the serotype- specific 
antibodies were able to bind DENV NS1 in tandem with the 13 pan-reactive antibodies. Using a 
control pan-reactive murine antibody (GUS-2) however, we found that serotype-specific antibody 
9H2 and GUS-2 could sandwich DENV-1 NS1, serotype-specific antibody 4C11 and GUS-2 could 
sandwich DENV-2 NS1, serotype-specific antibody 7G11 and GUS-2 could sandwich DENV-3 
NS1, serotype-specific antibody 6A5 and GUS-2 could sandwich DENV-4 NS1 and serotype-
specific antibody 6A7 and GUS-2 could sandwich DENV-4 NS1. Furthermore, pan-reactive 
antibody D1C2 and GUS-2 could sandwich NS1 from all four DENV serotypes. In essence, we had 
fulfilled the aims of this project; (i) to isolate immune-reagents that could use NS1 to serotype 
DENV infections and (ii) to isolate a DENV pan-reactive immune-reagent that binds a non 
immune-dominant epitope. However these antibodies could not pair with each other as they bound 
to regions that competitively hindered tandem binding of the antigen.  
In theory, the more antibodies one isolates, especially from animal immunization-driven strategies, 
the greater the chances of finding optimal pairs. When isolating binders using phage display 
technology however, strategies that are used to isolate the binders play a pivotal role in the level of 
success that is achieved. Fewer numbers of isolated clones, especially from biopanning naïve 
human libraries, can limit the ability to assemble a capture assay. The serotype-specificity of the 
isolated antibodies contributes to improvement of diagnostic assay specificity. Pan-reactive 
antibodies that bind a non-immune dominant epitope and are not affected by simultaneous binding 
to the immune-dominant epitope contribute to improvement of diagnostic assay sensitivity. Both of 
these aspects need to be combined to improve the specificity and sensitivity of DENV diagnosis. 
Knowledge of an ability to isolate binders to non immune-dominant regions of DENV NS1, means 
that serotype-specific antibodies could be utilized as DENV NS1 capture reagents in a biopanning 
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strategy to isolate appropriate pan-reactive binders. Equally pan-reactive D1C2 could be used to 
capture DENV NS1 in a biopanning strategy to isolate appropriate serotype-specific binders. The 
likelihood of isolating a single pan-reactive binder however is higher than the likelihood of isolating 
antibodies that recognize NS1 from each DENV serotype. It is for this reason that the serotype-
specific antibodies were taken forward for further characterization. 
The serotype-specific antibodies were found to have a high success rate (4/5) of native antigen 
recognition as all antibodies, with the exception of 6A7 anti DENV-4 NS1, could recognize native, 
secreted DENV NS1 from infected Vero cells. Isolating target-specific binders despite the presence 
of the hepta-histidine purification tag highlights good antigenicity of full length recombinant 
antigen, as has previously been observed in another study (9). 
The epitopes recognized by serotype-specific antibodies as characterized by Western blot and 
ELISA suggested a conformational nature and similar localization on NS1 from all four DENV 
serotypes. The similar localization of serotype-specific binders of DENV NS1 could serendipitously 
be due to the libraries being constructed from donors who have had previous DENV infections of 
all serotypes, or it could suggest the presence of antibodies against NS1 of each DENV serotype in 
the naïve immune repertoire. Computational design of antibody-antigen interfaces may be helpful in 
identifying where the serotype-specific antibodies bind. Exploration of antibody-antigen models 
may even be beneficial in identifying a pairing pan-reactive antibody which could potentially bind 
one of the many linear epitopes which have previously been shown to exist on highly accessible 
regions along the length of DENV NS1 (1, 3, 14). Akey et al (1) identified these epitopes to exist in 
hotspots such as the wing-domain disordered loop and the C-terminal tip of the β-ladder on the 
DENV NS1 hexamer. The immune-dominant epitope of DENV-NS1 exists in the wing-domain 
disordered loop but there are multitudes of other linear epitopes (1) that could potentially be 
targeted by a suitable pan-reactive antibody.  
The KD of an affinity matured antibody derived from the natural immune system is theoretically 
hypothesized to be about 2.3 x 10-9 M (7, 10). Higher affinity antibodies are generally generated by 
way of in vitro affinity maturation. Pan-reactive GUS-2 which was derived from a mouse 
immunization driven strategy was inherently subjected to in vivo affinity maturation and had 
affinities in the expected nanomolar range. Serotype-specific antibody 6A5 which binds DENV-4 
NS1 also had an affinity in the nanomolar range (3.5 x 10-9). Serotype-specific antibodies 9H2 and 
7G11 had approximately 4-fold lower affinity for their targets DENV-1NS1 and DENV-3 NS1 
compared to 6A5 and DENV-4 NS1. More characteristic of the affinity of antibodies isolated from 
naïve libraries, was antibody 4C11 against DENV-2 NS1, which showed the lowest affinity for its 
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target at 2.9x10-7 M. It is evident that the sensorgrams for the interaction between GUS-2 and 
DENV NS1 (Figure 3.10) are different to those of the interaction between the serotype-specific 
antibodies and DENV NS1 (Figure 3.11). The 1:1 binding model is inadequate because the 
interaction of the serotype-specific antibodies does not follow simple reversible mass transport 
kinetics. This means that the reported association and dissociation constants are likely inaccurate. 
The difference in curvature of the association phase of the interaction is indicative of a 
heterogeneity of the serotype-specific antibody affinities for binding sites on DENV NS1 resulting 
in effects of homotropic cooperativity (5). This implies that while low concentrations of a serotype-
specific antibody singly interact with antigen, higher concentrations affect (positively or negatively) 
the affinity of the antibodies to DENV NS1. The net result would be macroscopic and microscopic 
association constants. Employment of techniques such as isothermal titration calorimetry can 
provide information of the valencies of both antigen and antibody and hence analysis of 
cooperativity and stoichiometry of the antibody-antigen interaction to provide more accurate 
equilibrium dissociation rate constants. 
When the serotype-specific antibodies and pan-reactive GUS-2 were used in a limit of detection 
ELISA, it was unsurprising to note that capture with the higher affinity GUS-2 antibody improved 
limits of antigen detection and hence assay sensitivity. This was because higher affinity capture 
antibodies are critical for stabilizing the sandwiched complex. The affinity of the detection antibody 
nonetheless, also plays a complementary role in influencing antigen detection. As these were proof-
of-principle assays, these detection limit assays will need to be repeated with an appropriate pan-
reactive antibody that binds a non immune-dominant epitope using a diagnostically applicable test 
matrix such as serum to determine whether the assay results in improved sensitivity of DENV NS1 
detection. Furthermore, characterized sera of patients who experienced secondary infections with 
DENV would need to be evaluated for an improvement of diagnostic sensitivity when using a pan-
reactive antibody that binds a non immune-dominant epitope is utilized in the assay.  
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To conclude, the current results with GUS-2 capture and serotype-specific antibody detection are 
promising, particularly with antibodies 9H2 and 6A5 that recognize DENV-1 NS1 and DENV-4 
NS1 respectively (Figure 3.15). Comparable detection limits were obtained using 4C11 anti DENV-
2 NS1 and 7G11 anti DENV-3 NS1 as detection antibodies (11.5 and 12.5 ng/mL respectively).  
These detection limits are close to the desired minimum detection threshold of 10 ng/mL. Further 
optimization of the sandwich ELISA conditions could potentially resolve this issue. Although 4C11 
antibody showed exquisite specificity for DENV-2 NS1, the affinity was about 20-fold less than the 
affinity of 7G11 antibody for DENV-3 NS1. An improvement of the affinity of 4C11 was 
conceived to possibly improve the limit of detection of DENV-2 NS1. Affinity maturation of 
antibody 4C11 will therefore be the focus of the next chapter. 
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Chapter 4  
AFFINITY MATURATION OF AN ANTIBODY  
AGAINST DENV-2 NS1  
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4.1 INTRODUCTION 
Primary and secondary responses of B cells to foreign antigens vary in affinity. Higher affinity to 
antigens is developed through a process of combinatorial rearrangement of V gene segments in the 
germline (4), a clonal selection process of some antibodies in the existing repertoire, and somatic 
hypermutation of the antigen binding regions of the antibody (3). In order to improve the affinity of 
antibodies isolated from naive libraries, aspects of in vivo maturation can be  mimicked by  in vitro 
affinity through variations of mutagenesis and variable chain sequence shuffling. Herein, a 
stochastic random mutagenesis strategy and a non-stochastic targeted mutagenesis strategy shall be 
discussed.  
The antigen binding sites of antibodies are made up of selected elements within the variable regions 
known as complementarity determining regions (CDRs). There are three CDRs on each of the 
heavy and light chains and these form contiguous conformations unique to each antibody, varying 
in sequence, size, shape and charge to allow an ability to recognize and bind to different epitopes 
(22).  The number of CDRs that participate in actual antigen recognition vary amongst antibodies 
and are largely influenced by the target antigen (22). Furthermore, not all residues within the CDRs 
participate in antigen recognition as most of them are involved in stabilizing the antibody-antigen 
interaction (14). The leniency in interaction allowed by the residues that determine binding to an 
antigen is what determines cross-reactivity with structurally related antigens. The majority of the 
interaction of antibodies with antigen is enabled by VL CDR3 and VH CDR3 (16). CDR3 of the 
heavy chain however is often considered the most contributory to binding as it is the longest loop 
and is at the centre of the antigen combining site (7).  
 
The aim in affinity maturation is to increase the binding energy between an antibody and an antigen 
to improve their interaction. Because the interaction is predominantly mediated by residues in 
contact with each other on the antibody and antigen, targeted mutagenesis of variable regions of 
antibodies is often the preferred strategy for mutagenesis. The location and the chemistry of the 
amino acid side chains that are substituted during these mutagenesis processes are pivotal in 
optimizing the interaction between the antibody and the antigen.  It is difficult however, to identify 
the exact amino acids that are involved in binding without high resolution structures of the 
antibody-antigen complex. Furthermore amino acid substitutions in the contact regions do not 
necessarily yield improved physicochemical characteristics (5). In general, amino acids with 
hydrophobic properties such as tryptophan for example are known to be integral in mediating 
antibody-antigen interaction (13) and therefore are valued in CDRs and excluded from mutagenesis. 
The substitutions that are desired are inclusions of large aromatic residues that can facilitate van der 
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Waal’s and electrostatic interactions as well as small flexible residues that mediate plasticity of 
interaction. Parallel to, or alternate to targeted mutagenesis, random mutagenesis may be employed. 
Random mutagenesis introduces changes to both the variable and framework regions of the 
antibody fragment. Levels of random mutagenesis that are applied vary, resulting in varying 
mutagenic coverage and therefore variable success in identify synergetic mutations necessary for 
improved interaction. Some success has been had with this strategy but the improvement in binding 
is mainly fortuitous as opposed to rationally attained.  Additional to improvements in binding 
kinetics, random mutagenesis has also been shown to introduce mutations adjunct to regions that 
directly interact with the antigen which can be seemingly neutral, but important in optimizing the 
stability of antibody binding (5, 20).  
4C11 is a parent antibody that was generated from a Fab clone with binding specificity to DENV-2 
NS1. The Fab clone was isolated from a naïve antibody library displayed on M13 phage. 4C11 
binds to DENV-2 NS1 with a low affinity that compromises the potential diagnostic utility of this 
antibody in a DENV NS1 capture assay. Using surface plasmon resonance the equilibrium 
dissociation constant (KD) of the interaction between antibody and antigen was calculated as 5.1 x 
10-7 M. This antibody affinity required improvement to a value approaching 1.0 x 10-9 M in order 
for it to have better value in a diagnostic assay that detects capture of DENV NS1 (2).  The aim of 
this work was to assess the effect of mutagenesis on the kinetics of 4C11 antibody interaction with 
recombinant DENV-2 NS1 and evaluate its impact on the sensitivity of a DENV-2 NS1 capture 
assay. To achieve this, two phage scFv sub-libraries displayed on the gIII protein of filamentous 
phage were constructed. One library used targeted mutagenesis of particular residues within Vh 
CDR3, which were hypothesised to be solvent-exposed based on the known structure of a 
homologous Vh sequence. The selected residues were then targeted for saturation mutagenesis 
(designed to introduce all possible nucleotide substitutions) using nucleotide doping primers to 
produce all possible combinations involving all 20 naturally occurring amino acids. The second 
library was constructed using an error-prone polymerase for moderate global mutagenesis of the 
scFv. Due to a high predominance of the parental sequence that was observed in the random 
mutagenesis library and the low ratio of mutants that actually included amino acid substitutions in 
the CDRs, only the targeted mutagenesis library was carried forward for affinity driven selection. 
Three unique binders A4, C5 and E7 were isolated from the targeted mutagenesis library using a 
selection method based on the equilibrium dissociation of the parental antibody. Bio layer 
interferometry (BLI) with reformatted IgG antibodies demonstrated variations in the interaction 
kinetics of the generated antibodies when compared with the parental antibody. Antibody A4 had a 
single neutral substitution which resulted in slightly improved affinity in comparison to 4C11 
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antibody. Antibodies C5 and E7 had association rate constants that were similar to that of 4C11 but 
unfortunately had higher dissociation rate constants resulting a net loss of affinity.  Despite the 
actual loss of affinity for C5 and E7, all three isolated mAbs showed at least a 2-fold improvement 
in DENV-2 NS1 capture when evaluated in an ELISA format, showing that changes in antibody-
antigen interaction kinetics does not necessarily correlate with assay performance.  
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4.2 MATERIALS AND METHODS 
4.2.1 SYNTHESIS OF 4C11 SCFV FROM 4C11 IGG1 SEQUENCE 
4C11 was synthesized as a scFv by Geneart using both the heavy and light chain variable gene 
sequences. The heavy chain sequence preceded that of the light chain and the sequences were linked 
by a 3 x GGGGS linker. A SpeI restriction site was incorporated into the region immediately 3' of 
the VH-CDR3, by using codons ACA-CTA-GTC to encode amino acid residues TLV. This 
restriction site allows for independent insertion of the PCR products yielded from targeted 
mutagenesis of the variable heavy chain region alone.  
 
 
Figure 4.1 Nucleotide and amino acid sequence of Geneart synthesised 4C11 scFv 
sequence. Variable heavy and light chain sequences of antibody 4C11 are shown with a 
tri-GGGGS linker. The sequence is flanked by cloning restriction endonuclease sites for 
SfiI and NotI. An internal SpeI site (underlined) is also included downstream of the 
variable heavy chain sequence. 
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4.2.2 SUB-CLONING OF 4C11 SCFV INTO PHAGEMID VECTOR PNBF1603 
The 4C11 scFv sequence was sub-cloned into an in-house phagemid vector pNBF1603 by using 
restriction endonucleases SfiI and NotI. 
 
 
Figure 4.2 Phagemid map of expression vector NBF1603. A plasmid with a bacteriophage 
origin of replication (phagemid) is shown. Antibody fragment sequences are cloned in 
downstream of the leader periplasmic signal sequence (pelB) and in between restriction 
sites for SfiI and NotI endonucleases. The antibody fragment sequence is also cloned in 
frame with the gene III protein fusion partner. 
1 µg of reconstituted vector containing  the 4C11 scFv sequence and 1 µg of expression vector 
pNBF1603 were digested using 10 units of  NotI High Fidelity (NEB) endonucleases, 1 x 
CutSmart™ buffer (NEB) and nuclease-free water in a 25 µL total volume reaction. The reaction 
was incubated at 37 ˚C for an hour. 10 units of SfiI (NEB) were then added to the reaction which 
was incubated at 50 ˚C for another hour. 
The products of the restriction endonuclease digest were electrophoresed on a 1% agarose gel with 
Sbyr Safe (Life Technologies) at 90 V for 30 minutes. The DNA product bands were visualized 
using the Safe Imager™ 2.0 (Invitrogen) and the relevant bands excised using a blade. Gel slices 
with the relevant DNA products were purified using the concentrating and desalting protocol of the 
NBF1603  NBF scFv Phagemid
4038 bp
g3p
Amber codon
myc tag
6x His tag
Ribosome binding site
Ampicillin Resistance
M13R primer
P lac
pUC ori
f1 ori
pelB leader sequence
AvaI (100)
ClaI (1295)
EcoRI (1285)
NcoI (92)
PstI (1031)
ApaLI (626)
ApaLI (2118)
ApaLI (3364)
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QiaEXII Gel Extraction Kit (Qiagen) followed by DNA quantification on the NanoDrop 1000 
(Thermo Scientific). 
Ligation of the pNBF1603 vector and 4C11 scFv insert was performed using Rapid DNA Ligation 
Kit (Roche). 
Ligation Conditions 
150 ng Digested insert (4C11 scFv) 
50 ng Digested pNBF1603 
1uL 5x DNA Dilution Buffer 
5uL 2X DNA Ligation Buffer 
0.5uL DNA Ligase 
10 µL total volume reaction was incubated at room temperature for 15 minutes 
XL1-Blue Supercompetent cells (Agilent Technologies) were transformed with the ligation 
reaction. An aliquot of cells was thawed on ice and 50 µL was gently transferred into a pre-chilled 
1.5 mL tube. 0.85uL of β-mercaptoethanol was added to the cells, mixed gently and incubated on 
ice for 10 minutes. 2 µL of the ligation reaction was then added, mixed gently and followed by a 30 
minute incubation on ice. The cells were heat shocked for 45 seconds in a waterbath held at 42 ˚C 
then returned to ice for 2 minutes. 250uL LB was added to the transformation reaction and 
incubated at 37 ˚C, 220 rpm for 1 hour.  100 µL of the culture was spread on a 2YTAG agar plate 
and incubated overnight at 37 ˚C. 
Transformant colonies were screened by colony PCR. 
 
 
pNBF1603_Forward: TCTGCTGTTACTGGCGGCCCAGCCGGCCATGG 
pNBF1603_Reverse:  CCATGATGGTGATGATGATGTGCGGCCGC 
  
Colony PCR 
Bacterial Colony 
Platinum PCR SuperMix High Fidelity 
(Life Technologies) 
pNBF Forward 100 nM 
pNBF Reverse 100 nM 
H2O – Volume to 50 µL 
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PCR Cycling Conditions 
94 ˚C – 2 minutes 
30 cycles of: 
94 ˚C – 30 seconds 
55 ˚C – 30 seconds 
68 ˚C – 1 minute 
68 ˚C – 10 minutes 
4 ˚C – hold 
 
A single clone with the appropriate 4C11 scFv insert was cultured in 5mL 2YTAG broth overnight 
at 37 ˚C, 220 rpm. The culture was used for DNA isolation using the PureLink® Quick Plasmid 
Miniprep Kit (Life Technologies) according to manufacturer’s instructions. 
4.2.3 PCR AMPLIFICATION OF TARGETED MUTAGENESIS INSERTS 
Targeted mutagenesis of 4C11 was performed by randomization of the VH CDR3 as outlined by 
Lou and Marks (11). The PDB database was used to find a homologous VH sequence and model 
exposed regions that would most likely influence interaction with the antigen. The closest VH 
homologue of 4C11 (86.6%) in the PDB database is a human anti-steroid Fab 5F2 in complex with 
testosterone (accession number 3kdm), and UCSF chimera software was used to visualise the model 
Figure 4.3.  The 3D molecular model (SWISS MODEL) shows the surface exposed residues of this 
molecule, and homology with 4C11 was used to predict the exposed residues of the Vh CDR3 of 
4C11.  The sequence for the VH CDR3 in clone 4C11 is ARDTAMVILDY, with the exposed 
residues, highlighted in aqua to be the target residues for mutagenesis were the basis of the 
randomized primers to be used for mutagenesis of VH CDR3.   
Using the 4C11 scFv sequence as template, a library of inserts with mutations in the exposed 
residues was created by using nucleotide doped primers that have a bias to include the wild-type 
nucleotide in 70% of all nucleotide incorporation instances. The forward primer 5'-
TCTGCTGTTACTGGCGGCCCAGCCGGCCATGG-3' incorporates a SfiI restriction site, and 
the reverse primer contains the doped nucleotides and a SpeI site. 5’-
GACGGTGACTAGTGTGCCCTGGCCCCAGTAGTCS13S14S12S14S32S34ATCTCTCGC
ACAGTAATACACAGC-3’, where S is a 50% mix of G and C, 1 is 70%A, 2 is 70% C, 3 is 70% 
G and 4 is 70% T with equal amounts of the remaining nucleotides. 
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Figure 4.3 Hypothetical model of the VH region of 4C11. Shown are three hypervariable 
CDR loops of the heavy chain and anti-parallel β-sheets representative of the conserved 
framework. The complete VH CDR3 is highlighted in orange on the left and the residues 
targeted for mutation are shown using their three letter amino acid code and highlighted in 
aqua on the right. 
Targeted Mutagenesis 
400 ng DNA template 
100 µL Top Taq Master Mix 
(Qiagen) 
pNBF1603 Forward 200 nM 
Doped Reverse Primer 200 nM 
Nuclease-Free Water to 200 µL Volume 
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PCR Cycling Conditions 
94 ˚C – 2 minutes 
25 cycles of: 
94 ˚C – 30 seconds 
55 ˚C – 30 seconds 
72 ˚C – 1 minute 
72 ˚C – 10 minutes 
4 ˚C – hold 
 
4.2.4 PCR AMPLIFICATION OF RANDOM MUTAGENESIS INSERTS 
Moderate global mutagenesis of the entire length of 4C11 scFv was performed using an error prone 
polymerase (Mutazyme II) included in the Genemorph II Random Mutagenesis Kit (Agilent 
Technologies).  The starting amount of DNA and the number of amplifcation cycles, influence 
mutation frequency. The input template amount has an inverse proportionality to error 
accumulation.  
A forward primer 5'-TCTGCTGTTACTGGCGGCCCAGCCGGCCATGG-3' which 
incorporates a SfiI restriction site and a reverse primer 3’-
CCATGATGGTGATGATGATGTGCGGCCGC -5’ which incorporates a NotI restriction site 
were used in the PCR.  
Random Mutagenesis 
400 ng DNA Template 
10 U Mutazyme II DNA Polymerase 
(Agilent Technologies) 
1 x Mutazyme II  Reaction Buffer 
10 nM each dNTP 
pNBF Forward 200 nM 
pNBF Reverse 200 nM 
Nuclease-Free Water to 200 µL Volume 
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PCR Cycling Conditions 
94 ˚C – 2 minutes 
25 cycles of: 
94 ˚C – 30 seconds 
55 ˚C – 30 seconds 
72 ˚C – 1 minute 
72 ˚C – 10 minutes 
4 ˚C – hold 
 
4.2.5 CONSTRUCTION OF 4C11 MUTANT SUB-LIBRARIES 
To construct the mutant libraries, restriction endonuclease digested pNBF1603 vector and 
restriction endonuclease digested PCR inserts derived from random or targeted mutagenesis were 
ligated and used to used to transform TG1 cells (Lucigen). 
Restriction Endonuclease Digest 
Random Mutagenesis Targeted Mutagenesis 
20 µg DNA Vector / 5 µg PCR insert 20 µg DNA Vector / 5 µg PCR insert 
1 x CutSmart™ buffer (NEB) 1 x CutSmart™ buffer (NEB)) 
SfiI (NEB) 30 units/5ug DNA 50 ˚C – 4 hours SfiI (NEB) 30 units/5ug DNA  50 ˚C – 4 hours 
NotI (NEB) 30 units/5ug DNA 37 ˚C – 4 hours SpeI (NEB) 30 units/5ug DNA 37 ˚C – 4 hours 
 
Restriction endonuclease products were analysed on a 1% agarose gel with Sybr® Safe (Life 
Technologies). DNA fragments were electrophoresed at 90 V for 30 minutes. The relevant DNA 
fragments were were visualized using the Safe Imager™ 2.0 (Invitrogen) and excised from the gel 
using a blade. The DNA was purified from the gel slices using the Wizard SV Gel and PCR Clean-
Up System (Promega) according to manufacturer’s instructions. 
pNBF1603 vector backbone and mutant PCR products from both libraries were ligated using 
ElectroLigase (NEB). 1 µg of 4010 bp pNBF1603 backbone and approximately 3 times molar 
excess of insert from each library were ligated according to the reagent protocol. The volume of the 
reaction was concentrated to 5 µL using the Wizard SV Gel and PCR Clean-Up System (Promega). 
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4.2.6 TRANSFORMATION BY ELECTROPORATION AND LIBRARY RESCUE 
A 1.0 mm cuvette was used per reaction in the Biorad Gene Pulser Xcell to apply an exponential 
decay pulse of 1800 volts to 25 µL TG1 phage display electrocompetent cells (Lucigen) to allow 
transformation of the cells with an appropriate amount of pUC 19 positive control DNA (10 pg), 
4C11 digested negative control (100ng) and concentrated ligated library (4 µL) as per Lucigen’s 
transformation protocol. An internal resistance value of 600 ohms and a capacitance value of 10 µF 
were also input into the Gene Pulser’s electroporation parameters. The cells were diluted in 975 µL 
recovery medium (Lucigen) following electroporation. Transformants were plated out at different 
concentrations on YT agar (per litre 5g yeast extract, 8g tryptone, 5g NaCl, 15g agar) supplemented 
with 10 µg/mL ampicillin to determine transformation efficiency, background re-circularized vector 
proportions and library diversity. The rest of the transformation reaction was spread on ten x 150 
mm YT agar plates and incubated overnight at 37 ˚C to prepare glycerol stocks of the library. 
Glycerol stocks were made by scraping transformants with 15 mL total volume of YT broth with 
20% glycerol. The stocks were snap frozen on dry ice and stored at -80 ˚C. 
To rescue the phagemid libraries, 100 mL of 2YTAG broth was inoculated with 100 μL of library 
glycerol stocks and incubated at 37 ˚C, 220 rpm until an OD600 of approximately 0.4 was reached. 
4x1011 particles of M13K07 helper phage were added to the cultures and incubated at 37 °C for 30 
minutes followed by another 30 minutes at 37 ˚C with shaking at 220 rpm. The cultures were then 
spun at 3000 x g for 10 minutes in 50 mL falcon tubes. The supernatant was discarded and the pellet 
resuspended in 100 mL fresh 2YTAK broth. The culture was incubated overnight at 30 ˚C, 220 
rpm. PEG-NaCl (20% polyethylene glycol-6000 and 2.5 NaCl) was used to precipitate the phage as 
detailed in 2.2.3 on page 41 by determination of phage titre as detailed in 2.2.4 on page 41. 
4.2.7 COLONY PCR AND SEQUENCING OF UNPURIFIED PCR PRODUCTS 
To determine appropriate mutagenesis relevant to each sub-library, glycerol stocks were streaked 
out on LBAG agar and incubated overnight at 37 ˚C. Colonies were chosen at random and targeted 
mutagenesis PCR products were amplified with M13 reverse primer (used as the forward primer) 
and g3p reverse primer to yield a 2200 bp fragment. Random mutagenesis PCR products were 
amplified with M13 reverse primer (used as the forward primer) and f1 origin of replication reverse 
primer to yield a 1000 bp fragment.  
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Colony PCR 
Bacterial Colony – DNA Template 
100 nM Forward Primer 
100 nM Reverse Primer 
2 x MyTaq™ Mix (Bioline) 10 µL 
Nuclease-Free Water to 20 µL 
 
PCR Cycling Conditions 
95 ˚C – 1 minute 
25 cycles of: 
95 ˚C – 15 seconds 
55 ˚C – 15 seconds 
72 ˚C – 30 seconds 
72 ˚C – 10 minutes 
4 ˚C – hold 
 
The PCR products were resolved using the E-Gel® 96 agarose gel 2% with SYBR® Safe (Life 
Technologies) on the Mother E-base™ device (Life Technologies). 9 µL of the PCR volume was 
diluted with 11 µL of nuclease-free water and added to the wells of the E-Gel®. The far right wells 
of the E-Gel® had 10 µL of low range quantitative DNA ladder (Life Technologies) diluted in an 
equal volume of nuclease-free water. The electrophoresis system was run on a 12 minute EG 
program and the gel was imaged on the ChemiDoc MP System (Bio-Rad). 
Bidirectional sequencing of unpurified PCR products was performed by the Australian Genome 
Research Facility (Brisbane). 20 µL total volume reactions made up of 11 µL PCR products and 9 
µL nuclease free water were submitted in a plate format along with 200 µL total volume of each 
sequencing primer; pNBF1603_Forward: 5’-
TCTGCTGTTACTGGCGGCCCAGCCGGCCATGG-3’  and gIIIp_Reverse: 3’-
CCTTCATAATTTGCATAGCGATCCAGGG-5’ made up to 3.2 µM concentration. 
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4.2.8 RECOMBINANT DENV-2 NS1 
Recombinant DENV-2 NS1 was generously provided by Professor Paul Young's research group 
(School of Chemistry and Molecular Biosciences, The University of Queensland. The antigen was 
prepared using the NS1 sequence of a clinical isolate from East Timor. The antigen was expressed 
in Schneider 2 cells and has an N-terminal 6 x histidine tag but immuno-affinity chromatography 
was used for its purification. DENV-2 NS1 was provided in PBS. 
4.2.9 BIOTINYLATION OF RECOMBINANT DENV-2 NS1 
Amine biotinylation of DENV-2 NS1 was performed using the EZ-Link Sulfo-NHS LC biotin kit 
(Thermo Scientific) according to instructions. 20 fold excess of 10 mM biotin reagent was added to 
a volume of recombinant DENV-2 NS1 of a known concentration determined by UV 
spectrophotometry at 280 nm. Unbound biotin was removed using a Zeba Spin Desalting Column, 
7K MWCO (Thermo Scientific). 
4.2.10 EQUILIBRIUM BIOPANNING  
The sub-library comprised of mutated antibody scFv fragments displayed on filamentous phage, 
was biopanned against biotinylated recombinant DENV-2 NS1 using the equilibrium selection 
protocol described by Lou and Marks (11). Varying concentrations of biotinylated recombinant 
DENV-2 NS1 were captured  on magnetic beads displaying tetrameric streptavidin (Streptavidin 
Particles Plus-DM. BD Biosciences),  then exposed to the library. In the first round, the molar 
concentration of DENV-2 NS1 that was bound to the magnetic streptavidin beads was equivalent to 
KD/10. This was reduced ten-fold to KD/100 in the second round of biopanning and then KD/1000 in 
the final round of biopanning. Magnetic streptavidin beads were pre-incubated with 1 x PBS with 
2% casein before capture of biotinylated antigen. 1012 transducing units (TU) of the phage library 
were also pre-incubated with 1 x PBS with 2% casein before addition to the first concentration of 
biotinylated recombinant antigen. 1011 TU of the first round binders were used in the second round 
of biopanning while 1010 TU of the second round binders were used the last round of biopanning. 
The IMagnet (BD Biosciences) was used to pull down the fragments that had bound to the 
biotinylated antigen on the streptavidin magnetic beads. This allowed for washing away of non-
binders and weak binders firstly with  1 x PBS  with 2% casein (x2), then 1 x PBS with 0.1% 
Tween-20 (x7) and 1 x PBS (x1). Non-specific elution of phage binders was performed with an 
acidic buffer (200 mM glycine pH 2.7) and neutralised with 1M Tris-HCl pH 7.4. A phage rescue 
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was performed and the titre of the phage was determined (see sections 2.2.3 and 2.2.4 for detailed 
methods on page 41) 
4.2.11 MONOCLONAL PHAGE ELISA 
Method details can be found in section 2.2.5 on page 42. 
4.2.12 REFORMATTING OF ANTIBODY FRAGMENTS  
Unique, antigen specific antibody fragments were reformatted to fully human IgG1. The IgG1 were 
constructed by In-Fusion® cloning (Clontech) of the variable light and heavy chains into  mAb 
expression vectors containing the human IgG1 framework (10) as outlined in section  2.2.9 on page 
46. 
4.2.13 EXPRESSION AND PURIFICATION OF IGG1 
The vectors expressing the introduced variable regions were co-transfected into CHO cells adapted 
for suspension culture using PEIpro (Polyplus transfection) and maintained using the method 
outlined in section 2.2.11 on page 53. The expressed antibodies were secreted into the medium 
enabling harvesting by centrifugation followed by double filtration with Sartobran P300, 0.45/0.2 
µm capsule filters (Sartorium Stedim) on day 10 post-transfection. The antibodies were purified on 
the AKTA Explorer chromatography system (GE Healthcare) using a 5 mL HiTrap mAbSelect 
SuRe column (GE Healthcare). The antibodies were eluted using 0.1 M glycine pH 2.7 and 
neutralized with 1/10 total elution volume of 1 M Tris pH 7.4. The neutralized antibodies were 
desalted and concentrated using Macrosep Advance Centrifugal Devices (Pall). The concentrated 
protein was diluted in 1 x PBS to a concentration of 1 mg/mL and stored at -20 ˚C. 
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4.2.14 BIO LAYER INTERFEROMETRY 
Interaction kinetics were measured using the Octet RED96 System (fortéBIO - Pall). A series of 
hydrated Anti-Human IgG Fc Capture Biosensors (fortéBIO - Pall) were equilibrated for 180 
seconds in 1 x PBS before 200 µL of monoclonal antibody diluted to 25 µg/mL was used to coat the 
biosensors over 3 minutes at a low immobilization level with the response units not exceeding 2.0 
nm. Serial 1 in 2 dilutions of DENV-2 NS1 from 500 nM to 15.6 nM were made. The antibody 
coated sensors were immersed into 200 µL of recombinant antigen diluted to different 
concentrations.  The interaction of each antibody and each antigen dilution proceeded for 3 minutes, 
followed by a 5 minute dissociation phase in 1 x PBS.  Measurements of association and 
dissociation rate constants were used to derive the equilibrium dissociation rate constants. 
4.2.15 LIMIT OF DETECTION ELISA 
Method is as outlined in 3.2.9 on page 100 
Variation – Detection antibody was 100 µL of a pan-reactive, HRP-conjugated antibody from the 
commercial Panbio® Dengue Early ELISA Kit.  
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4.3 RESULTS  
4.3.1 CONSTRUCTION OF THE 4C11 SCFV MUTANT SUB-LIBRARIES 
In this work we sought to mutate residues within the variable regions of the original 4C11 Fab 
binder without any variation to the constant regions. For ease of global mutagenesis in particular, 
the variable regions of 4C11 Fab were synthesised as 4C11 scFv and cloned into an in-house 
phagemid vector (pNBF1603) using restriction endonucleases SfiI and NotI. Targeted mutagenesis 
of the CDR3 regions of the variable heavy domain was performed by PCR using nucleotide doping 
primers. The forward primer for the PCR incorporated a SfiI restriction endonuclease site while the 
reverse nucleotide doping primers incorporated a SpeI restriction endonuclease site. The primer pair 
yielded fragments that were 370 basepairs in length with some proportion of the PCR products 
showing a tendency to produce a non-specific product. Random mutagenesis was performed using 
forward and reverse primers that incorporated an upstream SfiI and downstream NotI restriction 
endonuclease sites that flank the scFv sequence respectively, to yield fragments with a length of 765 
basepairs. Restriction endonuclease treated PCR products of the appropriate fragment size for each 
sub-library construction (Figure 4.4), were gel purified and cloned into a similarly digested and gel 
purified pNBF1603 vector (Figure 4.5). The purified products were treated with an electroligase 
before transformation into TG1 cells. 
 
Figure 4.4 Agarose gel electrophoresis analysis of restriction enzyme treated PCR 
products. Primers for targeted and random mutagenesis yielded PCR fragments of different 
basepair lengths. The fragments were digested with restriction endonuclease pairs SfiI-
SpeI and SfiI-NotI, electrophoresed and the appropriate fragments were ligated with a 
relevantly digested NBF1603 backbone vector. 
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Figure 4.5 Agarose gel electrophoresis analysis of restriction endonuclease treated 
pNBF1603-4C11 scFv. The 4C11 variable heavy sequence (left) and the 4C11 scFv 
sequence (right) were excised from the pNBF1603 vector using restriction endonuclease 
pairs SfiI-SpeI and SfiI-NotI respectively to create a backbone for PCR mutant inserts. 
4.3.2 DNA LIBRARY SIZE 
Phage scFv sub-libraries derived from targeted and random mutagenesis yielded 2.08 x 108 and 3.88 
x 108 transformants as shown in Table 4.1. For the targeted mutagenesis sub-library, maximal 
mutation coverage of the 6 exposed amino acid residues to include substitutions with all 20 natural 
amino acids would require a diversity of 206 (6.4 x 107) individual clones. The library diversity that 
was attained was 2.08 x 108. Cells transformed with digested vector only were used as a negative 
control to determine the background bias of the 4C11 parent vector. The background was 
approximately 9.5 x 105 transformants resulting in the true diversity of the targeted mutagenesis 
sub-library being 2.07 x 108. Each possible mutant combination would have therefore been 
theoretically represented at least once in this library. For the random mutagenesis sub-library, the 
attained library diversity was 3.88 x 108 with a background bias of 1.50 x 106 resulting in a true 
diversity of 3.865 x 108. This diversity brought about by moderate global mutagenesis is important 
as high mutation frequencies are associated with an accumulation of template sequence errors and 
insufficient representation of all generated mutant fragments on a phage display platform. 
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Table 4.1 Summary of library sizes attained from targeted and random mutagenesis. The 
calculated library titre is shown, including the transformation efficiency of the 
electroporation protocol using a control pUC19 vector. Digested parental vector 
(pNBF1603) was also used to transform TG1 cells to quantify the proportion of the library 
that included undigested parental 4C11 scFv. 
 4C11 scFv TM 4C11 scFv RM 
Transformation efficiency 
pUC19 (cfu/µg) 
6.1 x 1010 5.4 x 1010 
Library Titre 2.08 x 108 3.88 x 108 
Negative Control 
Digested Parental Vector 
Only 
9.5 x 105 1.5 x 106 
Ratio of parental : mutants 1: 218 1: 258 
4.3.3 LIBRARY DIVERSITY 
To ascertain the amino acid variation of mutants within the generated sub-libraries and determine 
library quality in terms of redundancy, inclusion of stop codons and out-of frame mutations, 
sequence analysis of random clones from each sub-library was performed. Glycerol stocks of each 
sub-library were streaked out on LB agar supplemented with ampicillin and glucose. Clones chosen 
at random were subjected to colony PCR to amplify DNA segments. The products were resolved by 
E-Gel® electrophoresis (Figure 4.6) and also submitted to the Australian Genome Research Facility 
(Brisbane) for bidirectional Sanger sequencing of unpurified PCR products.  
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Figure 4.6 Agarose gel electrophoresis of colony PCR products. Rows A – C had targeted 
mutagenesis (TM) PCR products amplified with M13 reverse primer (used as the forward 
primer) and gIIIp reverse primer. Rows D – F had random mutagenesis (RM) PCR 
products amplified with M13 reverse primer (used as the forward primer) and f1 origin of 
replication reverse primer. E-Gel low range quantitative DNA ladder shown on the right 
was added to column M. 
Both sub-library sequences were derived from dual sequencing with the pNBF1603 forward and 
gIIIp reverse primers. Contiguous sequences with the primer pair did not cover the upstream 4C11 
scFv sequence up to and including VH CDR1. Good quality sequences from 20 clones in each sub-
library were selected for multiple sequence alignment using the European Bioinformatic Institute’s 
Clustal Omega program to determine appropriate mutagenesis and sequence diversity. For the 
targeted mutagenesis library, the amino acid sequences show that within the 20 clone sample size, 
mutagenesis was confined to the targeted VH CDR3 region. There were no wild type 4C11 VH 
CDR3 sequences that were isolated and each of the 20 clones had unique VH CDR3 sequences 
(Figure 4.7). This indicated a likelihood of a highly diverse library within the region that was 
targeted for mutagenesis. For the random mutagenesis library, amino acid substitutions were noted 
along the length of the 4C11 scFv sequence (Figure 4.8). 10 of the 20 clones that were included in 
the sequence alignment were parental 4C11 scFv. Alignments were made using amino acid 
sequences and not nucleotide sequences thus some mutations which take advantange of the 
redundancy of the genetic code may have resulted in silent mutations. Of the 10 clones that were 
mutated the substitutions were mostly within the framework regions of the scFv. Mutant 6 had a 
single amino acid substitution from an alanine to a threonine at the beginning of VH CDR3 while 
mutant 18 had two changes in VL CDR3 which included glycine to tryptophan and tyrosine to 
phenylalanine amino acid substitutions. Mutant 18 was also the only clone that had an amino acid 
insertion which was seen downstream of VL CDR3. No amino acid deletions or incorporation of 
stop codons were noted. Due to the high representation of parental 4C11 scFv in the random 
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mutagenesis library and limited availability of recombinant DENV-2 NS1 for both biopanning and 
isolated binder characterization, the highly diverse, targeted mutagenesis library was carried 
forward to be interrogated for affinity matured binders.  
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4C11M17      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M11      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M12      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M9       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M4       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M18      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M16      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M15      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M13      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M10      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M7       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M2       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M1       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M3       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M8       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M20      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M19      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M14      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M6       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11O        MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M5       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
             ************************************************************ 
 
4C11M17      YYCARDIMSLRMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M11      YYCARDMEMMKLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M12      YYCARDPAMMRLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M9       YYCARDTWMMHMDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M4       YYCARDKFVDKKDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M18      YYCARDTVLVKYDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M16      YYCARDTAVMNQDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M15      YYCARDTALLIIDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M13      YYCARDTGIVTLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M10      YYCARDMATDILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M7       YYCARDTPVDILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M2       YYCARDSADVNLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M1       YYCARDNAMVLVDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M3       YYCARDTAKVNFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M8       YYCARDTAIVNIDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M20      YYCARDTALAMLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M19      YYCARDTAWVMYDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M14      YYCARDIAMVIHDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M6       YYCARDTAPVMIDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11O        YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M5       YYCARDTATVMLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
             ******      ************************************************ 
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4C11M17      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M11      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M12      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M9       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M4       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M18      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M16      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M15      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M13      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M10      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M7       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M2       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M1       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M3       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M8       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M20      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M19      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M14      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M6       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11O        SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M5       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
             ************************************************************ 
 
4C11M17      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M11      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M12      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M9       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M4       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M18      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M16      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M15      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M13      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M10      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M7       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M2       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M1       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M3       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M8       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M20      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M19      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M14      QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M6       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11O        QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M5       QAEDEADYHCQSYDSSLGGFYVFGPGTSVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
             ********************************************************** 
Figure 4.7 Sequence alignment of targeted mutagenesis clones. Sequences of 20 clones 
chosen at random were compared for diversity in the VH CDR3 regions. In bold and 
underlined are VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 in order of 
appearance.  4C11O is the wildtype 4C11 sequence.  
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4C11M18      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M15      MHWVRLAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M7       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRLTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M6       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M4       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M3       MHWVRQASGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTPYLQMNSLRAEDTAV 
4C11M1       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M20      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDMAV 
4C11M16      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M11      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11O        MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M2       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M5       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M8       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M10      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M12      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M13      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M14      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M17      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M19      MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
4C11M9       MHWVRQAPGKGLEWVSGISGSGGTTSYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV 
             ***** * **************************:********** *********** ** 
 
4C11M18      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M15      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M7       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M6       YYCTRDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M4       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTF 
4C11M3       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M1       YYCARDTAMVILDYWGQDTLVTVSSGGGGSGGGGSGGGGSEAVLTQSSSVSGAPGQTVTI 
4C11M20      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M16      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M11      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11O        YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M2       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M5       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M8       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M10      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M12      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M13      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M14      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M17      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M19      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
4C11M9       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGSEAVLTQPSSVSGAPGQTVTI 
             ***:************* **************************** ************: 
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4C11M18      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M15      SCTGTSSNIGAGHDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M7       SCTGTSSNIGTGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M6       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M4       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M3       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M1       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M20      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M16      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M11      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11O        SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M2       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M5       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M8       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M10      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M12      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M13      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M14      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M17      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M19      SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLTITGL 
4C11M9       SCTGTSSNIGAGYDIHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLTITGL 
             **********:*:********************.************************** 
 
4C11M18      QAEDEADYHCQSYDSSLGWFFMSSDLVPAVSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M15      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M7       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M6       QAEDEADYHCQSYDSSLGGFYVFGPDTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M4       QADDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M3       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M1       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M20      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M16      QAEDEADYHCQSYDSSLGGFYVVGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M11      QAEDEADYHCQSYDSSLGGFYVFRPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11O        QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M2       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M5       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M8       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M10      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M12      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M13      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M14      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M17      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M19      QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
4C11M9       QAEDEADYHCQSYDSSLGGFYVFGPGTS-VSVLAAAHHHHHHGAAEQKLISEEDLNGAA 
             **:*************** *::    .  ****************************** 
Figure 4.8 Sequence alignment of random mutagenesis clones. 20 randomly selected 
clones had their sequences compared for diversity along the length of the scFv. In bold 
and underlined are VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 in order of 
appearance.  4C11O is the wildtype 4C11 sequence.  
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4.3.4 BIOPANNING AND SCREENING OF BINDERS 
The targeted mutagenesis phagemid library was rescued by superinfection with M13K07 helper 
phage. Phage particles were precipitated and enumerated prior to being used for biopanning. A 
soluble-phase based biopanning strategy which employed biotinylated antigen and streptavidin 
magnetic beads was used to select binders with an improved equilibrium dissociation constant KD. 
Three rounds of biopanning were performed in an effort to enrich binders with an improved KD. 
The equilibrium dissociation constant of antibody 4C11 was previously calculated as 5.1 x 10-7 M 
using surface plasmon resonance. 5.0 x 10-8M of biotinylated recombinant antigen (ten-fold less 
than the calculated KD of antibody 4C11) was displayed on streptavidin magnetic beads for 
biopanning. The molar concentration of biotinylated recombinant DENV-2 NS1 displayed on 
magnetic streptavidin beads was decreased ten-fold in subsequent rounds of biopanning; round two 
used KD /100 (5.0 x 10-9 M) and the third round used KD /1000 (5.0 x 10-10 M). The number of 
phage particles that were used input into each round of biopanning were also decreased ten-fold in 
each round, initially starting with 1012 transducing units. After three rounds of biopanning, a 
monoclonal phage ELISA was performed using the output of the third round of biopanning (Figure 
4.9). 
 
 158 
 
 
 
Figure 4.9 Monoclonal phage ELISA of targeted mutagenesis clones. DENV-2 NS1 specific binders were isolated by immobilizing the 
recombinant antigen on a polystyrene 96 well plate and adding phage particles from 90 randomly chosen clones. Wells H7-H12 had no 
phage added to them and acted as negative control wells. Bound phage particles were detected using an HRP-conjugated antibody against 
M13 filamentous phage. 
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90 clones chosen at random were screened for their ability to recognize recombinant DENV-2 NS1. 
Eight clones; A4, B7, C5, E2, E7, E10, H4 and H7 were identified as positive binders.  Considering 
that the targeted mutagenesis sub-library was focused on a single parent clone (4C11 scFv) and the 
biopanning protocol enriches for binders against DENV-2 NS1, it was surprising that the number of 
target-unrelated clones far exceed the number of target-related clones. The eight isolated clones 
were sub-cultured and the phage particles propagated from that culture were used in a confirmatory 
monoclonal phage ELISA (Figure 4.10). All clones except H7 showed binding to DENV-2 NS1. 
This was expected as H7 acted as a negative control in the initial screening and its previous positive 
absorbance reading was likely due to some contaminating crossover. 
 
 
Figure 4.10 Confirmatory monoclonal phage ELISA. To confirm recombinant DENV-2 
NS1 recognition, phage particles corresponding to each clone were propagated and added 
to polystyrene wells coated with recombinant antigen. Binders were detected with HRP-
conjugated antibody against M13 filamentous phage.  
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All seven isolated clones were sequenced to determine their uniqueness (Figure 4.11). Four (B7, E2, 
E10 and H4) of the seven clones were wild type 4C11 scFv which is representative of the bias of 
the library towards 4C11 scFv background. The other three clones (A4, C5 and E7) showed some 
mutations in the targeted VH CDR3 region on positions with high substitution priority as they are on 
the hypervariable loop interface 
 
 
Figure 4.11. Amino acid sequences of post-selection clones. Clones B7, E2, E10 and H4 
have the same VH CDR3 sequence as the parent clone 4C11 scFv. Clone C5 has a single 
amino acid change from methionine to serine while clones E7 and A4 have three of the six 
targeted amino acid residues mutated.  
The three isolated scFv clones were reformatted to full IgG1 in order to characterize alterations of 
the generated antibodies’ kinetic profiles in comparison to the parent antibody. The characterization 
of interaction kinetics was carried out using bio layer interferometry. The net effect of kinetic 
alterations was subsequently characterized by a limit of detection ELISA to evaluate the effect of 
kinetic alterations on solid phase capture of recombinant DENV-2 NS1. Because of changes to the 
assay instrumentation for measuring interaction kinetics from surface plasmon resonance to bio 
layer interferometry and the change in expression hosts for recombinant DENV-2 NS1 expression 
from a mammalian expression system in CHO cells to a baculovirus expression system, a 
comparison of absolute values from previous assays could not be utilised, rather a fold change 
between the parent antibody and mutant variants was used to establish if there have been any 
beneficial gains from VH CDR3 mutagenesis.  
  
E7        YYCARDIGGVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
A4        YYCARDYGRVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
4C11      YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
E10       YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
B7        YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
E2        YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
H4        YYCARDTAMVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
C5        YYCARDTASVILDYWGQGTLVTVSSGGGGSGGGGSGGGGS 
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4.3.5 KINETICS AND AFFINITY CHARACTERIZATION – BIO LAYER 
INTERFEROMETRY 
Antibodies 4C11, A4, C5 and E7 were captured on anti-human IgG Fc capture biosensors. The 
antibody-coated biosensors were dipped in separate two-fold dilutions of DENV-2 NS1 from 500 
nM to 15.6 nM to determine the kinetics of the interaction between the antibodies the antigen 
(Figure 4.12). A molar affinity value was calculated and reported in Table 4.2 using dissociation 
rate constants and association rate constants with responses from concentrations with minimal error 
values. When compared to parental 4C11 antibody, only A4 antibody showed a slight improvement 
in affinity due to a marginal improvement in the dissociation rate constant. Although antibody C5 
showed a similar binding response as antibody A4, antibody C5 like E7 unfortunately had a 
reduction in KD because of an increased off rate (Figure 4.12). 
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Figure 4.12 BLI sensorgrams for the interaction of antibodies 4C11 (A), A4 (B), C5 (C) and E7 (D) with DENV-2 NS1. Anti-human IgG 
Fc capture biosensors were coated with antibody in the first association phase (180 seconds -360 seconds). The interaction was allowed 
to stabilize before the antibody-coated biosensors were dipped in separate two-fold dilutions of DENV-2 NS1 from 500 nM to 15.6 nM. 
The highest concentration as shown on the x-axis is represented the green trace while the lowest concentration is represented by the blue 
trace. The response to the different concentrations of DENV-2 NS1 is measured in nm as shown on the y-axis. 
A B 
C D 
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Table 4.2 Kinetics and affinities of antibody-antigen interaction. Bio layer interferometry 
data indicating association rate constants (ka) [M-1 s-1] ± standard error, dissociation rate 
constants (kd) [s-1] ± standard error as well as the equilibrium dissociation constants (KD) 
kd/ka [M] is shown. Also included is a fold change in KD relative to the interaction of the 
parental 4C11 antibody with DENV-2 NS1 (KD 4C11/ KD mutant antibody). 
Antibody Ka ± SE [M-1 s-1] Kd ± SE [s-1] KD [M] Fold change in KD 
4C11 1.80 x 105 
± 5.30 x 103 
9.82 x 10-4 
± 1.35 x 10-5 
9.34 x 10-9 - 
A4 1.08 x 105 
± 2.13 x 103 
6.87 x 10-4 
± 8.35 x 10-5 
7.41 x 10-9 1.26 
C5 1.78 x 105 
± 4.20 x 103 
1.12 x 10-3 
± 1.54 x 10-5 
1.03 x 10-8 0.91 
E7 2.12 x 105 
± 8.8 x 103 
1.25 x 10-3 
± 1.90 x 10-5 
1.06 x 10-8 0.88 
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4.3.6 EVALUATION OF ANTIBODY PERFORMANCE IN A DENV-2 NS1 CAPTURE 
ELISA 
To evaluate the performance of recombinant DENV-2 NS1 capture by the isolated binders, 
reformatted antibodies were used as capture reagents in a limit of detection ELISA. An HRP-
conjugated, pan-reactive antibody from a Panbio® Dengue Early ELISA Kit was used as the 
detection antibody in all instances. When high affinity binders are isolated, an extended attachment 
to the solid phase capture at low antigen concentration is expected. The results from the limit of 
detection ELISA (Figure 4.13) vary from those obtained by BLI. In a sandwich ELISA format, the 
limit of detection of recombinant DENV-2 NS1 using antibodies 4C11, A4, C5 and E7 was 7.5 
ng/mL, 3.4 ng/mL, 2.4 ng/mL and 3.3 ng/mL respectively. Parental 4C11 antibody showed the 
poorest performance while mutant antibodies A4, C5, and E7 showed at least a 2-fold improvement 
in the amount of recombinant DENV-NS1 that can be accurately detected by absorbance as 
different from the blank.  
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Figure 4.13 Standard curves of recombinant DENV-2 NS1 detection. Antibodies 4C11, 
A4, C5 and E7 were used to capture dilutions of recombinant DENV-2 NS1. Detection of 
captured antigen was performed with a pan-reactive, HRP-conjugated antibody from a 
Panbio® Dengue Early ELISA Kit. Blank subtracted absorbance data indicating the mean 
± SD is shown. The cut-off value for the limit of detection was calculated as the mean 
blank value + 3 x SD of negative readings. The limits of detection of DENV-2 NS1 using 
4C11, A4, C5 and E7 antibodies as capture reagents were 7.5 ng/mL, 3.4 ng/mL, 2.4 
ng/mL and 3.3 ng/mL respectively.  
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4.4 DISCUSSION 
The combination of phage display technology and mutagenesis in affinity maturation strategies has 
had considerable success but is also thwarted by pitfalls. Identifying the ideal regions to mutate to 
attain a significant improvement in affinity is not always straight forward. Furthermore, the creation 
of a phage display library presenting antibody fragments and its subsequent biopanning has multiple 
steps that are inherently riddled with opportunity to lose binders with optimal properties.  
Ideally, an energetic map of the antibody-antigen binding site is useful in identifying the regions 
that need to be targeted in the affinity maturation process. Increasingly, in the absence of antibody – 
antigen structures, computational modeling of protein interfaces is performed to identify the amino 
acids that would participate in the interaction (6). Antigen structures however, such as in this case, 
are not always available. A partial x-ray structure of DENV NS1 was only published in February 
2014 (1). As such, experimental evolution of antibodies, particularly their antigen binding regions is 
performed in an effort to improve affinity. Antigen binding residues do not contribute equally to the 
overall affinity that an antibody has to an antigen. In choosing the amino acid residues to mutate 
within binding regions, some consideration has to be given to the fact that the greater the number of 
residues that are mutated the higher the requirement of the construction of a complex library with 
enormous diversity not adequately feasible with current phage display systems. Generally, six or 
less codons are targeted when using saturated mutagenesis to allow for confident representation of 
all mutants in the constructed sub-library (12). Based on this a low complexity sub-library targeting 
the VH CDR3 was constructed and used to biopan for binders with gain of affinity mutations. 
Parallel to the targeted mutagenesis sub-library, a random mutagenesis sub-library generated by an 
error prone polymerase was also constructed. Random mutagenesis, due to its non-discriminatory 
nature, results in amino acid substitutions in both the framework and CDR egions. Due to this, 
isolation of affinity matured binders using this strategy is often fortuitously instead of rationally 
derived. Unfortunately, the properties introduced by random mutagenesis can also be inadvertently 
detrimental not only in terms of affinity but stability and solubility as well. Based on these 
aforementioned factors, a high representation of parental 4C11 scFv in sequenced clones from the 
random mutagenesis library, and a limitation of available recombinant DENV-2 NS1, the targeted 
mutagenesis sub-library was selected for biopanning and characterization of isolated binders. 
A selection method based on the equilibrium rate constant was chosen to identify higher affinity 
binders. In this method, the molar concentration of biotinylated antigen equivalent to or less than 
the equilibrium rate constant is bound to streptavidin coated magnetic beads and then the sub-
library of mutants is added to identify binders during iterative rounds of biopanning. The premise is 
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that higher affinity binders will competitively displace lower affinity binders to the low 
concentration antigen. Rajpal et al (15) found that this method resulted in moderate improvements 
in affinity as was also discovered in this work. The use of low antigen concentration favours 
moderate to high affinity binders but may not necessarily select for lower dissociation rates. 
Amendments to selection conditions to include more stringent washing steps and longer incubation 
steps could have been considered to remove binders that have an inadequate dissociation rate. The 
limitation of recombinant DENV-2 NS1 antigen availability hindered the use of excess molar non-
biotinylated antigen in a different strategy which relies on dissociation rate constants. In that 
method, low concentrations of biotinylated antigen are similarly oriented on streptavidin coated 
magnetic beads. The sub-library of mutants is again added to allow interaction of binders with the 
antigen. Excess non-biotinylated antigen is then added, the premise there being that low affinity 
binders will dissociate and bind to the non-biotinylated antigen which will be discarded during the 
washing steps. The net result would be higher affinity binders still bound to biotinylated antigen on 
streptavidin magnetic beads being enriched through the rounds of biopanning. 
Three iterative rounds of biopanning yielded seven recombinant DENV-2 NS1 specific binders, 
from 90 randomly selected clones. This number is proportionally low in view of the fact that the 
library is based on a parent antibody which binds DENV-2 NS1. The expectation was that there 
would be a larger number of clones to screen. Since a targeted sub-library focused on DENV-2 NS1 
was used in the biopanning procedure, there was no initial concern about biotinylation or the biotin 
binding pocket on streptavidin diverting selection of binders away from the intended target. It is 
plausible that non-specific binders to streptavidin or biotin-antigen junctions were isolated and 
make up some proportion of the 83 clones that do not recognize DENV-2 NS1. A more likely 
explanation is the low propagation of binders that hinder sufficient phage particles being produced 
to allow for definitive identification of binders by way of absorbance values that conclusively differ 
from non-binders. 
Three unique binders (A4, C5 and E7) were isolated from the biopanning protocol that relied on the 
equilibrium dissociation constant to determine the amount of input antigen. The scFv were 
reformatted to human IgG1 for characterization. In comparison to parental antibody 4C11, antibody 
A4 showed a 1.26-fold improvement in affinity calculated from BLI kinetics measurements and a 2-
fold improvement in antigen capture when used in a detection limit sandwich ELISA. A comparable 
improvement in antigen capture was seen with antibodies C5 and E7, but these antibodies had 
decreased affinity due to faster off rates. Antibody A4 had three amino acid substitutions in the 
targeted VH CDR3 region from T-A-M to Y-G-R. Similarly antibody E7 had three amino acid 
substitutions involving a change from residues T-A-M to I-G-G. Antibody C5 meanwhile had a 
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single amino acid substitution from T-A-M to T-A-S. The inclusion of tyrosine (Y) and glycine (G) 
in VH CDR3 in high affinity binders is common and this bias has been shown to be consequent of 
reading frame 1 of the heavy chain diversity gene segment (17). Glycine residues are known to 
mediate turns in the CDR loops which can improve antibody-antigen interaction while tyrosine 
residues have been found to specifically interact with antigen in a non-specific manner assisted by 
the interaction between the aromatic rings and positively charged residues (13). Charged arginine 
(R) and non-polar isoleucine (I) residues have limited utility when substituted in CDRs because 
they lack an ability to establish substantial non-bonded forces required to mediate an interaction 
with the antigen. Serine (S) on the other hand is ampipathic and has moderate hydrogen potential 
values that contribute to interaction with antigen in a topology-dependent manner. Summatively, the 
tyrosine-glycine-arginine substitution resulted in the marginal improvement in affinity of antibody 
A4. 
On reflection, the residues that were mutated were modeled off a paratope which represents a 
hypothetical structure based on the most closely related existing homologue.  As this structure has 
not been fully validated, the mutagenic changes that are introduced may not be fully maximised. 
Furthermore, literature has previously focused on VH CDR3 being the main binding energy 
contributor in interactions with antigen (18, 23). It has been found however, that where CDR3 of 
both heavy and light chains are targeted, a greater number of beneficial mutations are identified in 
the light chain (15). This indicates an in vivo propensity for fine tuning in the heavy chain, mediated 
by VDJ recombination that is lacking in the light chain. Further iterations of this work could 
perhaps investigate the effect of VL CDR3 mutagenesis on affinity maturation as it undergoes fewer 
in vivo recombination events. A strategy that involves parallel mutagenesis of heavy and light 
variable regions and then combining the low complexity libraries has been shown to result in the 
isolation of high affinity binders (21). In that strategy, identifying and targeting consensus 
sequences that are known to accumulate mutations on variable regions of antibodies such as A/G-G-
C/T-A/T or A-G-C/T (8, 9, 19) could be explored. 
The success of affinity maturation strategies can be fortuitous but the design of high quality 
mutagenesis libraries is also pivotal for improving the odds of isolating binders with improved 
properties. Furthermore, when opting for targeted mutagenesis, particularly of a single limited 
region such as VH CDR3, the original properties of the parent clone and the epitope to which is 
binds, places constraints on the level of success that can be achieved in terms of fine tuning the 
interaction between the antibody and the antigenic determinant. In terms of antibody 4C11, this 
could suggest that the VH CDR3 residues chosen for mutagenesis are in fact very important to 
binding, and relatively intolerant to amino acid substitutions.  This is supported by the fact that 4 
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out of the 7 sequences were wildtype even though no wild type clones were detected in 20 
randomly sequenced library clones.    
Only antibody A4 showed an improvement in comparison to the parental antibody by both BLI 
characterization and limit of detection ELISA. The improvement in affinity that was attained 
however lacks a considerable improvement to the dissociation rate. Despite this the improvement is 
sufficient to stabilize the interaction with DENV-2 NS1 and translate to comparable performance in 
a serotyping DENV NS1 capture assay using serotype-specific antibodies 9H2 anti DENV-1 NS1, 
7G11 anti DENV-3 NS1 and 6A5 anti DENV-4 NS1 which were characterized in Chapter 3. To 
conclude, this affinity maturation exercise has highlighted the difficulties in truly capturing the 
nuances associated with sequence and function as well as their subsequent influence in determining 
affinity. 
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Chapter 5  
REFLECTIONS 
PROSPECTIVE WORK 
AND  
CONCLUSIONS  
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5.1 PROJECT CONTEXTUALIZATION 
 
The project described in this thesis endeavored to improve the specificity and sensitivity of the 
diagnosis of DENV infections. DENV NS1 was chosen as the antigenic target for diagnosis because 
of its ability to act as a proxy for the presence of virus (32) and also for its ability to be pre-emptive 
for the development of severe disease (Dengue Hemorrhagic Fever/Dengue Shock Syndrome) (19). 
Many commercial antibody-based assays that capture and detect DENV NS1 are available but have 
consistently been shown to have deficits in specificity and even more so in sensitivity (3, 5, 11, 14, 
17, 18, 20, 21, 23, 29, 33). Diminution of specificity is driven by cross-reactivity with NS1 from 
other flaviviruses which have high homology with DENV NS1. Compromised sensitivity 
meanwhile, which is mainly seen in secondary infections with DENV, is thought to be due to the 
formation of immune complexes made up of antibodies that target the immune-dominant epitope on 
DENV NS1 and DENV NS1 itself (13). The formation of the immune complexes conceivably leads 
to altered binding of anti-NS1 assay antibodies through steric hindrance and compromises the 
ability of the assay antibodies to either capture or detect DENV NS1.  
Progressive nanoparticle-based assays for the capture DENV NS1 have been reported in recent 
research literature. One example is an SPR-based assay that detects binding of DENV NS1 to gold 
nanoparticles that have anti DENV NS1 immobilized to the nanoparticle (8). Another example 
involves immobilization of antibodies against DENV NS1 onto gold nanoparticles that are coated 
onto screen-printed electrodes (25). Binding of DENV NS1 to the immobilized antibodies is 
measured by amperometric responses. Despite these elaborate assays, the inherent deficits of the 
diagnostic assays unfortunately still remain. We chose to improve DENV diagnostic sensitivity by 
focusing on the actual immune reagents used in the diagnostic assays. Additionally, a serotyping 
capability of the DENV NS1 assay would increase its cost-benefit ratio. 
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5.2 HYPOTHESIS, METHODS & MAIN FINDINGS 
We hypothesized that serotype-specific antibodies against DENV NS1 could maintain specificity of 
detection while pan-reactive binders against non immune-dominant epitopes on DENV NS1 could 
improve sensitivity of detection. This thesis describes the first study that explicitly explores the use 
of naive immune repertoires to isolate antibodies against DENV NS1 in an effort to use serotype-
specificity to improve DENV diagnostic sensitivity. 
To investigate our hypothesis, we interrogated three naive phage libraries displaying human 
antibody fragments. Different biopanning strategies illustrated in Figure 5.1 were used to isolate 
binders against DENV NS1.  
To isolate serotype-specific binders, a subtractive biopanning strategy was used. This strategy 
yielded binders against NS1 from each DENV serotype. To isolate pan-reactive binders that 
recognize non immune-dominant epitopes on DENV NS1, only the strategy that involved the 
masking of the immune-dominant epitope with an immobilized antibody (tandem binding 
biopanning) was successful, isolating a single pan-reactive antibody. Unfortunately, pairing of the 
serotype-specific antibodies against DENV NS1 with the pan-reactive antibody that binds a non 
immune-dominant epitope on DENV NS1 was unsuccessful because the antibodies did not bind 
mutually exclusive epitopes on the antigen. Binding of any of the serotype-specific antibodies 
therefore sterically hindered binding of the pan-reactive antibody and vice-versa, indicating that the 
epitopes for serotype-specificity are spatially clustered with each other and with the pan-reactive 
non-immune dominant epitope.  
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Figure 5.1 Biopanning strategies for isolation of binders against DENV NS1.Antigen that 
was adsorbed on a polystyrene immunotube was used to isolate pan-reactive binders from 
a phage-displayed antibody fragment library in a direct biopanning strategy. Pan-reactive 
binders were also isolated using a tandem-binding biopanning strategy in which 
polystyrene-immobilized GUS-2 (a pan-reactive antibody against the immune-dominant 
epitope on DENV NS1) was used to capture the antigen. The captured antigen was 
exposed to the phage-displayed library to isolate target-specific binders. Serotype-specific 
binders were isolated using a subtractive biopanning strategy in which adsorbed NS1 from 
three other DENV serotypes were used as negative controls to deplete binders against high 
homology regions from the phage-displayed antibody fragment library. The library was 
finally exposed to the target antigen and the binders were eluted. 
  
 177 
 
Characterisation of serotype-specific antibodies revealed that one of the serotype-specific 
antibodies, (4C11, which recognizes DENV-2 NS1) had low affinity for its target. Targeted 
mutagenesis of the VH CDR3, a region known to influence antibody-antigen interactions, and 
random mutagenesis of the entire phage-displayed antibody fragment was carried out using 
nucleotide doping primers and error-prone polymerase respectively. Diffuse mutagenesis along the 
lengths of the antibody fragments in the random mutagenesis 4C11 sub-library tended to also 
involve framework regions which should ideally remain conserved. The targeted mutagenesis 4C11 
sub-library was therefore the only library taken forward for biopanning for a higher affinity binder. 
A new single binder, with a single amino-acid substitution from a serine to a methionine was 
isolated and it showed only a two-fold improvement in affinity. These findings indicated that VH 
CDR3 in antibody 4C11 is tolerant of only small changes and these changes do not significantly 
affect affinity. 
5.3 IMPLICATIONS OF FINDINGS & LIMITATIONS OF THE RESEARCH 
Our initial hypothesis was that we could increase both the specificity and sensitivity of DENV 
diagnosis by adding serotyping capability, and by targeting non immune-dominant epitopes on 
DENV respectively. Unfortunately, we could not accept or reject this hypothesis because the 
serotype-specific antibodies and the pan-reactive antibody binding a non-immune dominant epitope 
on DENV NS1 could not simultaneously bind DENV NS1 in a sandwich ELISA. To isolate a pan-
reactive antibody against DENV NS1 that can simultaneously bind the serotype-specific antibodies 
and be unaffected by binding of endogenous antibodies against the immune-dominant epitope of 
DENV NS1 requires an inventive biopanning strategy. Immobilized serotype-specific antibodies 
can be used as DENV NS1 capture reagents in a tandem-binding biopanning strategy as shown in 
Figure 5.1. The fact that the serotype-specific antibodies seem to bind spatially clustered epitopes 
and orient the NS1 in the same direction gives plausibility that this strategy will be capable of 
isolating a single pan-reactive antibody. To avoid the immune dominant epitope however, an 
additional antibody masking this epitope will also need to be used as an immobilized DENV NS1 
capture reagent between iterations of serotype-specific driven biopanning. Isolation of an 
appropriate pan-reactive binder would then allow testing of the hypothesis that serotype-specific 
antibodies against DENV NS1 when paired with a pan-reactive binder against a non immune-
dominant DENV NS1 epitope can improve diagnostic specificity and diagnostic sensitivity of 
DENV infections. The hypothesis would need to be tested using characterised sera from healthy 
individuals, individuals with acute primary and secondary DENV infections and individuals with 
acute and primary and secondary flaviviral infections. The mere conception of such a complex 
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biopanning strategy underscores the versatility of phage display in condition-controlled antibody 
discovery. 
Isolation of the serotype-specific antibodies is the highlight of the research reported in this thesis. 
The DENV NS1 serotyping assay that is being proposed has superior attributes compared to 
competing assays in published literature. A serotyping assay that uses polyclonal human anti-
DENV NS1 and serotype-specific phage-displayed scFvs from a human naive library, both 
targeting virus particles (presumably the E protein of DENV) have been described by Cabezas et al. 
(6, 7). Ding et al. (10) describe a serotyping assay that incorporates hybridoma-derived, serotype-
specific antibodies and a hybridoma-derived pan-reactive antibody against DENV NS1. Meanwhile, 
Qiu (24) and Xu (31) both from the same group, describe serotyping assays for DENV-1 NS1 and 
DENV-2 NS1 using hybridoma-derived serotype-specific antibodies and hybridoma-derived pairing 
antibodies for each serotype-specific antibody. The aforementioned studies are a sampling of the 
serotyping assays that have been developed. These assays have inherent weaknesses. Targeting the 
envelope protein reduces the window of DENV diagnosis due to the limited duration of virus 
detection (16). The immunization-driven strategy for isolation of both serotype-specific and pan-
reactive antibodies against DENV NS1 resulted in an expected high specificity but variable 
sensitivity. Also, using different pairing antibodies for each serotype-specific antibody will 
invariably lead to a highly complex assay unless the serotyping aspect is abandoned.  
Another limitation of this work is that assumptions were made about the regions that were most 
likely to contribute to the interaction of low affinity antibody 4C11 and DENV-2 NS1. This led to 
very limited success in improving the affinity of that interaction. Firstly, only VH CDR3 was 
targeted for mutagenesis undermining the possible influence of Vλ CDR3 on antibody-antigen 
interaction. Only one mutant was isolated with a single amino acid change in VH and this change 
made only a marginal change in affinity, so changes in VH seem not to be tolerated; possibly more 
variants could be isolated by mutagenesis of the light chain.  A random mutagenesis library was 
also created, but the frequency of mutation in framework regions in randomly sequenced clones 
meant this library was not interrogated further.  However, it is possible that high affinity binders to 
DENV-2 NS1 could have been fortuitously isolated from this library. Biopanning of the 4C11 
random mutagenesis library could therefore be undertaken to evaluate if a higher affinity antibody 
against DENV-2 NS1 can be isolated before new mutagenesis strategies are explored. It would be 
important however to confirm that random mutagenesis does not shift the current epitope.  
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5.4 RECOMMENDATIONS FOR FUTURE WORK 
The research presented in this thesis opens up exciting possibilities for other associated projects. 
A full antibody complement for a serotyping DENV NS1 assay, i.e serotype-specific antibodies and 
a pairing pan-reactive antibody against a non immune-dominant epitope, would be useful for 
inclusion in a multiplexed assay for the development of a DENV blood screening assay. 
Multiplexing using technologies such as lab on chip or Luminex-based platforms can facilitate 
further improvement of diagnostic sensitivity (ultra-sensitivity) by incorporating assays that detect 
several markers of DENV infection. A point of consideration however, is the fact that DENV 
infections are mostly prevalent in countries with developing economies and assays should be 
restricted to formats that are compatible with currently existing laboratory capabilities. 
There is currently no approved vaccine for DENV infections. Phase III trials of a recently 
successful tetravalent DENV vaccine by Sanofi Pasteur were very encouraging with regard to 
seroconversion rates to all four DENV serotypes (26). The Envelope protein of DENV is the target 
of the Sanofi Pasteur vaccine which is made up of a genetically modified recombinant virus vaccine 
called ChimeriVax Dengue. The vaccine employs the use of the 17D yellow fever vaccine as a 
scaffold in which Envelope protein genes corresponding to neutralizing determinants of the virion 
from the yellow fever 17D strain were substituted with those of the dengue virion. Protective 
immune responses can be elicited from vaccination with DENV NS1 (2). The serotype-specific 
antibodies that were isolated in this work target conformational epitopes. To evaluate the utility of 
those epitopes in inducing a protective immune response as a vaccine would involve a laborious 
undertaking to firstly identify the exact epitopes bound by the antibodies and then manipulate linear 
polypeptides to form those exact conformations when displayed on a suitable display scaffold. The 
recently resolved structure of NS1 (1) nonetheless opens up possibilities for more informed epitope 
mapping research for possible vaccine development. 
Diagnostic antibodies do not need to be of human origin, and since serotype-specific antibodies 
isolated in this work are of human origin, it allows for their possible use in other applications. As an 
alternative to vaccine development, the use of therapeutic antibodies against DENV NS1 could be 
explored. Passive immunity can be achieved by inoculation with antibodies against NS1 following a 
challenge with DENV (28). Mortality-associated DHF is associated with increased levels of NS1 
(19) and therefore accumulated levels of NS1 in circulation could be modulated using therapeutic 
antibodies. Because NS1 is not part of the virion, the effector function of the antibodies would not 
be in virus neutralization but rather in complement activation or increased phagocytosis to mop up 
excess NS1. Some antibodies against NS1 that map to the conserved wing peptide on DENV NS1 
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(22) and the conserved tip of the DENV NS1 β-ladder (9) have been implicated in auto-reactivity 
with cellular components such as platelets and endothelial cells and therefore have to be avoided as 
they can actually accelerate disease pathogenesis.  It would be interesting to see if antibodies 
derived from naïve, human antibody fragment libraries would target epitopes that can elicit a 
therapeutic response. 
 
The mechanisms through which DENV NS1 contributes to disease pathogenesis are not fully 
elucidated. It has been hypothesized that DENV NS1 contributes to endothelial dysfunction by 
mimicking lipid metabolic pathways (15). The isolated serotype-specific antibodies could be used 
as research tools to investigate pathogenesis and the immunological pathways that are inhibited by 
antibodies against DENV NS1. 
 
In the presence of an appropriate pairing, pan-reactive antibody that binds a non immune-dominant 
epitope, the serotype-specific antibodies that have been isolated from this work could therefore lend 
themselves to DENV NS1 quantitation. There have been reports on the possibility of clinically 
exploiting the correlation of high DENV NS1 levels with the likelihood of severe disease 
presentation (4, 12, 19, 27). This would be a more DHF/DSS-specific predictive marker than 
measuring non-specific level of cytokines. Murine research by Watanabe et al. (30) however, 
suggests that presentation with DHF/DSS is dependent on the infective serotype. To conclusively 
tell if there is an association between high DENV NS1 levels and presentation with DHF/DSS, there 
is a requirement for the use of standardized monoclonal antibodies with homotypic reactivities in 
the quantitation assays as opposed to the pooled polyclonal antibodies with heterotypic reactivities 
which have been used in the cited literature. 
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5.5 CONCLUSION 
To conclude, this thesis investigated the use of naive immune repertoires to isolate antibodies 
against DENV NS1 in an effort to particularly improve DENV diagnostic sensitivity. We 
successfully isolated serotype-specific antibodies against DENV NS1 that lend themselves to 
precise DENV diagnostic specificity. These antibodies are crucial for future iterations of 
biopanning to isolate pan-reactive, non immune-dominant epitope binders that can improve DENV 
diagnostic sensitivity. Furthermore we developed biopanning strategies that incorporated 
combinations of positive and negative biopanning utilizing NS1 derived from the four DENV 
serotypes.  These strategies were designed to probe subtle variations in the three dimensional 
space/shape relationships of the serotype-specific DENV NS1 surface and this successfully 
translated to the isolation of antibodies against DENV NS1 with exquisite specificity for each 
serotype where serotype-specificity was verified by binding to both soluble, recombinant DENV 
NS1 and DENV NS1 expressed on membranes of DENV infected Vero cells.  The techniques and 
methodologies developed during the course of this research could be applied to antibody isolation 
against other viruses and virus families, where it may be of value to generate antibodies to common 
viral subunits with high homology within a viral family. 
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